Starbreeze AB (publ) interim report January-March 2024

First quarter 2024 · Net sales amounted to SEK 56.6 million (26.7). · PAYDAY 2 accounted for SEK 10.9 million (26.4). · PAYDAY 3 accounted for SEK 23.3 million (0). · Third-party publishing accounted for SEK 17.4 million (0). · EBITDA* amounted to SEK 48.5 million (4.1), including items affecting comparability of 19.9 million. · Cash flow from operating activities amounted to SEK 78.4 million (20.7). · Depreciation, amortization and impairment amounted to SEK 71.8 million (15.6). · Profit/loss before taxes amounted to SEK -21.0 million (-24.7). · Basic and diluted earnings per share amounted toSEK -0.01 (-0.03). · Cash and cash equivalents amounted to SEK 387.2 million (78.0). Significant events during and after the quarter · January 9, Starbreeze announced changes in Group management. · January 10, the Starbreeze Nomination Committee announced the proposal to appoint Jürgen Goeldner as the new Chairperson of the Board of Directors at the 2024 Annual General Meeting. · February 15, “Operation Medic Bag” was launched – a focused project to meet the expectations of the player community and improve PAYDAY 3. The game has seen three major updates since February 15. · February 22, The Tribe Must Survive was released in Early Access on Steam. · March 12, Board member Jürgen Goeldner was appointed interim CEO of Starbreeze. A process to recruit a permanent CEO is ongoing. · April 15, a content update was released for Roboquest with new content, new functionality, and improvements. CEO’s message PAYDAY™ 3 evolves with 'Operation Medic Bag' Starbreeze has been a force in the global games industry for more than 25 years and will continue to be so by developing and publishing games globally and leverage the strength of both the organization and the IP portfolio.During my months as interim CEO my focus has been on PAYDAY 3 as well as business development aspects, for example our presence at the Game Developers Conference (GDC) in March, where we among other things met industry peers and new potential partners. We also showed a playable tech demo of Project Baxter and received high interest. RESULTS AND FINANCIAL POSITION Our cash position at the end of the quarter was SEK 387m, with a balance sheet light on debt. The underlying result for the quarter, adjusted for items affecting comparability, was strong thanks to revenues from multiple titles as well as cost control measures. The revenue streams show that we are no longer a one product company. Together with our co-publisher we are running a concerted effort to improve on PAYDAY 3 by reprioritizing and focusing the development based on players’ feedback with only a minor impact on planned investments. PAYDAY 3 PAYDAY 3’s ‘Operation Medic Bag’ is a comprehensive initiative that covers both smaller initiatives as well as improvements to the games’ progression system. On top also matchmaking and server infrastructure and a solo/offline mode. We are going to increase both the cadence and scope of the patches, with several larger milestone releases planned, the first of which will launch in June. The team is working from feedback from our players and community, identifying the changes that we believe are the most impactful ones from a player perspective. We can already see the sentiment shift confirming that we are on the right track. “Operation Medic Bag” has meant that we’ve pushed some content DLCs in favor of adding new features. So, our pipeline for the summer months is very strong. Consequently, we expect to see an impact on sales from the third quarter onwards. The PAYDAY IP is strong, and the potential for the IP remains high, evident not only from our conversations in the industry. PROJECT BAXTER As previously mentioned, Starbreeze’ presence at GDC was in large part to talk to future partners about Baxter. While we will be the publisher of the game, we will enter partnerships where it makes sense. This will be for marketing, distribution in both the digital and physical sense or other support that increases the quality and potential of the project while at the same time lowering the project risk. THIRD PARTY PUBLISHING Roboquest continues to perform strongly, and we continue to work with the developer to expand the game. Roboquest follows a Games as a Service-model with four targeted updates slated for 2024, the first of which was published here in April. The game continues to enjoy a very high rating from both players and media.During the quarter, The Tribe Must Survive launched in Early Access on Steam. The purpose of Early Access is to foster a collaborative relationship with the player community, gathering valuable feedback on all aspects of the game. The 1.0 version of the full game will launch on May 23rd, 2024. ORGANIZATION During the quarter, the number of employees decreased slightly. We continue to hire specific competency for positions on Project Baxter while keeping the organization efficient for all our projects. CLOSING WORDS The search for a permanent CEO is coming to an end. For that position many candidates were identified, interviewed and assessed.With a “vertical slice” of Project Baxter as the next step of the project, interested parties will be invited to submit their offers and we will select the best partner and deal for the product, the brand and ultimately for the company. JÜRGEN GOELDNER, interim CEO Webcast Time: 10.00 CESTParticipation: To connect to the webcast– click here . For more information, please contact: Jürgen Goeldner, interim CEOMats Juhl, CFOTel: +46 0(8) - 209 229Email: ir@starbreeze.com This information is information that Starbreeze AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, via the contact persons set out above, at 6:45 am CEST on May 14, 2024. About StarbreezeStarbreeze is an independent developer, publisher, and distributor of PC and consoles targeting the global market, with studios in Stockholm, Barcelona, Paris and London. Housing the smash hit IP PAYDAY™, Starbreeze develops games based on proprietary and third-party rights, both in- house and in partnership with external game developers. Starbreeze shares are listed on Nasdaq Stockholm under the tickers STAR A and STAR B. Read more at www.starbreeze.com and corporate.starbreeze.com.

OssDsign AB (publ) publishes Q1 2024 interim report

OssDsign AB (publ) announces that the interim report for Q1 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q1 2024 results will also be presented at an investor webcast today May 14th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q1-2024/  or via the OssDsign website. The first quarter in figures · Net sales amounted to TSEK 27,029 (21,466), now with all sales coming from orthobiologics in the U.S., which corresponds to a sales growth of 207% vs comparable numbers in Q1 2023. · The U.S. business continued its strong underlying growth, quarter on quarter, and has now demonstrated eight consecutive quarters of triple-digit growth. · Gross margin of 93.7% vs a blended margin of 70.4% in the same quarter in the previous year. · Operating loss of TSEK 12,034 (23,696). Sales variable costs increased whereas non-sales variable costs decreased compared to the previous year. Total operating expenses decreased vs the previous year. Continued trend of improved operating leverage in the business, albeit somewhat exaggerated in Q1, as a result of positive gross margin development and lower start of year operating expenses, as the company is transitioning more functions to the U.S. · Loss after taxes amounted to TSEK 11,148 (23,252). · Earnings per share were SEK -0.1 (-0.3). · Cash flow from current operations was TSEK -28,203 (-26,701), showing solid underlying improvement but, as previously stated, was expected to be adversely impacted by the outflow from high 2023 year-end bonus and non-recurring accruals. Important events during the first quarter · OssDsign reports compelling data from the clinical study TOP FUSION. · 12-month data from the clinical study of OssDsign Catalyst published in Biomedical Journal of Scientific & Technical Research. · OssDsign appoints Tom Buckland as Chief Technical Officer. Important events after the end of the first quarter · OssDsign awarded long-term agreement with Premier, Inc. · OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals.

Norse Atlantic ASA: Q1 2024 demonstrating substantial year-on-year improvements while preparing for growth into busy summer season

• Revenue increased by 97% to USD 78.2 million in Q1 2024 compared to Q1 2023 • 201,462 passengers carried in Q1 2024, up 83% compared to Q1 2023 • ASK up by 72% in Q1 2024 compared to Q1 2023 • Load factor increased by 19 percentage points to 73% in Q1 2024 compared to Q1 2023 • Strong operational performance as 100% of planned flights were completed during the quarter • Record high number of ACMI and charter operations, totalling 107 flights during the quarter • CASK numbers improving, CASK ex fuel being down by 28% in Q1 2024 compared to Q1 2023 • Total cash held at end of quarter at USD 33.2 million • Subsequent to the quarter end, a USD 20 million revolving credit facility was secured from Norse’s two largest shareholders for the purpose of providing a liquidity buffer prior to moving into the more cash generative summer season • Strategic options continue to be developed and explored in collaboration with advisors Seabury Securities “The first quarter has shown major improvement on all metrics compared to the first quarter of the previous year. ASK was up about 72% year-on-year, and load factors increased by 19 percentage points with improved revenues per passenger. Norse Atlantic continued to demonstrate robust operational excellence as 100 % of the quarter’s scheduled planned flights were completed as planned. This winter we have developed seasonal strategies, with more emphasis on holiday destinations and charters. Norse Atlantic managed a record high of 107 charter flights during the quarter. We will refine this strategy further for next winter, with several longer-term contracts secured or under negotiation. We are looking forward to the busiest summer season so far in Norse Atlantic´s short history. During the summer the fleet of aircraft operated in Norse’s own network increases from 10 to 12 aircraft, representing a capacity growth of 20%. Norse will continue to focus on careful and profitable growth. We are happy to see that our footprint in the market has increased as the network expands to include Athens this summer, Las Vegas from the fall, and a new continent as Cape Town joins the network in the winter. Our goal is to see CASK continuously decreasing year-on- year for each quarter. Norse remains steadfast in its commitment to achieve the lowest CASK in the Transatlantic market. Norse is on a path towards year-round profitability, and a successful summer 2024 is the next important stepping-stone on that journey,” said Bjorn Tore Larsen, CEO and Founder Norse Atlantic Airways. For further information please see attached Q1 2024 report and Q1 2024 presentation. A video presentation of the Q1 2024 results can be found here:  https://norse.videosync.fi/2024-q1-results Contacts: Investor contacts: Anders Hall Jomaas, CFO, Anders.Jomaas@flynorse.com Media contacts: Philip Allport, Senior Vice President Communications, media@flynorse.com This information is subject to the disclosure requirements pursuant to Section 5 -12 the Norwegian Securities Trading Act and the Euronext Growth Rule Book part II. Norse Atlantic Airways is an airline that offers affordable fares on long-haul flights, primarily between Europe and the United States. The company was founded by CEO and major shareholder Bjørn Tore Larsen in March 2021. Norse has a fleet of 15 modern, fuel-efficient and more environmentally friendly Boeing 787 Dreamliners that serve destinations including New York, Los Angeles, Orlando, Las Vegas, Cape Town, Bangkok, Miami, Oslo, Athens, London, Berlin, Rome and Paris. The company's first flight took off from Oslo to New York on June 14, 2022.

Corporate cost-cutting at a four-year high despite growing economic optimism

Two in five (41%) businesses across Europe plan to cut costs in 2024, the highest level since 2021 according to the annual European Payment Report  from Intrum , the credit management services provider which operates across 20 European markets.The 27th edition of Intrum’s annual study assesses the fortunes of 9,255 companies across 25 European countries. It sheds light on the myriad of challenges they face after an unrelenting 18 months of economic headwinds.After a recent period dominated by economic instability and the cost-of living crisis, economic conditions are improving in Europe, with inflation in March 2024 falling to 3.2% in the UK and 2.4% in the Eurozone. The brighter outlook is starting to feed through to business confidence. Intrum’s research shows 31% of executives say their business has strengthened over the past 12 months, up from 24% in 2022. More than half (55%) even say their business has the opportunity to expand over the coming years.Still, macroeconomic conditions continue to cast a long shadow. Three in five (61%) respondents do not expect interest rate reductions for at least another year, despite suggestions that the ECB may be ready to cut rates sooner.To navigate this testing outlook, the percentage of firms planning cost-cutting measures has increased for a third successive year, from a low of 28% in 2021 to 41% now. More than one in three (34%) businesses are more likely to request longer payment terms from suppliers, or pay later than agreed. A further 15% of businesses say they will begin extending payment terms in 2024 to navigate the economic disruption and downturns.At the same time, almost one in ten (8%) are looking to reduce the payment terms they offer their own clients or customers to help manage cashflow.Table 1: New corporate actions planned for 2024 to manage economic disruption and downturns 2020 2021 2022 2023 2024We plan to cut costs 38% 28% 33% 37% 41%We plan to be more cautious about taking on 34% 22% 23% 22% 20%financial debtWe plan to cut down on recruitment 29% 16% 16% 14% 15%We plan to sell-off part of the company 18% 9% 9% 7% 8%We plan to grow by conducting Mergers & 15% 9% 8% 7% 8%AcquisitionsWe plan to increase our investment in product - 7% 10% 11% 10%innovation and development to become morecompetitiveWe will ask suppliers for longer payment terms - - - 13% 15%than in the pastWe will reduce the payment terms we offer - - - 8% 8%clients/customersWe will offer employees voluntary redundancy - - - 7% 8%We will make compulsory redundancies in our - - - 6% 6%workforce Across Europe, businesses in Spain (20%) are the most likely to ask suppliers for longer payment terms, closely followed by Italy (19%), Portugal (18%), France (17%) and Denmark (17%).However, Intrum’s research highlights the negative impact of longer payment terms, or debtors simply not paying, as businesses spend significant time chasing down late payments.Across Europe, the average business is losing more than a quarter of the working year– 73 working days – a year chasing late payments, channelling valuable time away from focusing on their core business, including growth and innovation.Table 2: Countries where businesses are most likely to request longer payment terms from suppliers Country PercentageSpain 20%Italy 19%Denmark 17%France 17%Norway 16%Hungary 16%United Kingdom 15%Slovenia 15%Bulgaria 14%The Netherlands 13%Belgium 13%Finland 12%Ireland 8% European businesses are currently owed €10.5 trillion – 30% of total GDP and equivalent to the combined GDP of France, Germany and the UK– in outstanding payments from customers and creditors. Large businesses are owed €5.1m on average, while SMEs are each waiting on €448,000.Looking at amounts owed by sector, organisations in government and the public sector have the biggest outstanding amounts (€5,135 million), followed by banking and financial services (€3,782 million) and insurance (€2,813 million ).Andrés Rubio, President & CEO of Intrum, comments:“It’s troubling to see that cost-saving challenges are piling up for thousands of businesses in 2024, to a greater extent than at any time in the last five years. Businesses having to cut costs and ask for longer payment terms from suppliers while insolvencies are increasing is a concerning trend.It is understandable that executives are nervous in the aftermath of recent years’ challenging economic environment. We must help businesses to manage and recoup the money they are owed and encourage suppliers and customers to pay on time, to avoid putting growth on hold and necessitating cost cutting measures to survive the current headwinds.Governments and industry alike must take steps to make sure that businesses are being supported and on time payments encouraged in order to avoid disrupting businesses’ cash flow and their ability to pay their debts. Without doing so, the problem only escalates and creates a cycle of unresolved credit commitments.” ENDS Notes to Editors*10.15 (hours a week) x 52 weeks = 527.8 hours a year. This divided by the average number of working hours in a day (7.28) = 72.5 days, rounded to 73 days.The full report is available as of 14 May 2024 on intrum.com About The European Payment Report 2024The European Payment Report 2024 is an instrument for gaining insight into the payment behaviours of European businesses and examines trends related to late payments, invoice payment practices and overall financial risk. The report is based on an external survey conducted by FT Longitude in 25 countries in Europe. In total, 9,255 small, medium and large companies across 15 industry sectors participated in the research. Respondents were CFOs or other persons with financial knowledge of the company they work for and the companies have been selected randomly from a B2B database. The fieldwork for the study was conducted between 5 December 2023 and 12 March 2024.For more information, please contact:Kristin Andersson, Global Media Relations Director+46 70 585 78 18kristin.andersson@intrum.com

Essity invests in new R&D center in France

Essity is continuously developing new methods to provide the market with sustainable and user-friendly products. The company’s current R&D center in Kunheim, France, has filed 25 patents in recent years for ground-breaking innovations such as Lotus Aqua Tube (flushable toilet roll core), Lotus and Okay Sans Tube (coreless toilet paper), Tork SmartOne (dispenses one sheet at a time) and paper hygiene products based on alternative fibers.  “Essity's research and development is re-shaping paper making to contribute to a more sustainable and circular society, while improving people’s hygiene and health. The new global R&D center in France, will enable us to continue to develop innovative new paper hygiene products and solutions that meet the needs and high expectations of customers and consumers,” says Magnus Groth, President and CEO of Essity. The new R&D center, strategically located near the current facility, ensures the retention of Essity’s more than 80 experts and engineers working there today. Essity aims to create a larger, more efficient center equipped to address future challenges. In addition to France, Essity has R&D centers in Mexico, Sweden, Germany and in the USA, led by the company’s global unit focusing on brands, innovation and sustainability. In 2023, Essity invested SEK 1.7bn (approximately 1.2% of net sales) in research and development. Essity is the world’s largest supplier of hygiene solutions in Professional Hygiene with the globally leading Tork brand. Essity is also the world’s third largest supplier of consumer tissue, with a presence primarily in Europe and Latin America. Essity’s brands such as Lotus, Tempo, Zewa, Cushelle, Plenty and retailer brands lead the European market, while Regio and Familia are key players in Latin America.  

Change in Group Management Team of Lindex Group plc

LINDEX GROUP plc, Changes board/management/auditors, 14.5.2024 at 9:00 EEST Change in Group Management Team of Lindex Group plc Chief Operating Officer (COO) of Lindex Group plc’s Stockmann division and member of the Group Management Team Tove Westermarck will join a new employer. She will continue in her role in the Lindex Group until autumn 2024. The recruitment process for a new COO has been initiated. “Tove has played a significant role in the development of Stockmann's department store and online business during her long Stockmann career. She has held demanding leadership positions in many different areas of our business and has worked alongside our people through many phases of change. Last November, the Stockmann division’s strategy was updated, and its implementation was started under Tove’s leadership with a focus on the development of offering, loyalty programme and omnichannel experience as well as cost efficiency improvement,” says the CEO Susanne Ehnbåge. “I would like to thank Tove already at this stage for her dedicated work to improve the profitability of Stockmann's business and to develop the Stockmann brand and customer experience,” Ehnbåge adds. “Stockmann is a work community, with a strong merchant mindset – a desire to provide the best quality and service in the city – and a love for our iconic brand. I have been privileged to develop Stockmann in a broad and international way and work with such great people throughout my career so far. My warm relationship with the company will continue, now that I'm moving on to a new job. I’m convinced that our committed team will drive the implementation of our strategy with determination, further strengthening the customer experience and building a good foundation for Stockmann's future growth,” says Tove Westermarck. LINDEX GROUP plc Susanne EhnbågeCEO Further information:Group Communications & Investor RelationsMediaDesk tel. +358 50 389 0011info@stockmann.comorinvestor.relations@stockmann.com Distribution:Nasdaq HelsinkiPrincipal media

Cell Impact Q1 2024: Laying the groundwork for large-volume deliveries

During the quarter, Cell Impact continued to deepen the cooperation with F.C.C. which after the end of the quarter led to two formal agreements. The first is a formal extension of the current cooperation agreement in the form of a leasing agreement and the other is a framework agreement that regulates the conditions for continued cooperation between the companies. In March, the company announced its first deal in the area of electrolysis. The agreement extends over 30 months and was signed with a new European customer. It includes an initial delivery of flow plates, tooling and fixtures worth just over SEK 18 million. One proof that customers need the company’s expertise and offerings is evident in the large number of concrete test tools being requested. We are seeing great interest from existing, new and prospective customers in the production lines which among other things include forming, high-precision punching and laser welding. “The great interest gives me great confidence in the company’s future development. Our secured financing for 2024 and into 2025 gives us the platform we need to translate some of these projects into new revenues, “ said Daniel Vallin, interim CEO of Cell Impact. Financial summary · Net sales totaled SEK 5.8 million (20.0). · Operating loss (EBIT) was SEK –22.0 million (–29.9). · The Group’s result after financial items was SEK –22.8 million (–30.5). · Earnings per share attributable to the Parent Company’s shareholders before and after dilution totaled SEK –0.04 (–0.40). · Debt/equity ratio was 81 percent (79) on the balance sheet date. · Cash flows from operating activities amounted to SEK –43.2 million (–29.6). · On the balance sheet date, the Group’s cash and cash equivalents totaled SEK 47.6 million (117.7). This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.

Greenbridge Announces Investment in EpinovaTech

Greenbridge Sàrl (Greenbridge), is pleased to announce an agreement to acquire over 50% of the share capital of EpinovaTech AB (EpinovaTech) through a direct investment in the company and the acquisition of shares from existing shareholders. The completion of the transaction is subject to regulatory approvals and is expected to be finalized during Q2 2024. EpinovaTech was founded in 2019 and is headquartered in Lund, Sweden. A producer of epiwafers, the company has patented a technology called NovaGaN®, which allows the widespread adoption of Gallium Nitride (GaN) into industries such as automotive, 5G and renewable energy, where there is need for high efficiency and power-handling capabilities. The NovaGaN® technology enables faster and smaller electronics with reduced energy consumption, while also offering compatibility with existing chip factories, thus providing economies of scale, industrial scalability, and short time-to-market. This investment underscores Greenbridge's commitment to fostering innovation and growth of companies that are disrupting their industries and have the potential to become the market leader. Greenbridge will take an active ownership role and work closely with the board and management team of EpinovaTech to refine and develop the long-term strategy. “I firmly believe EpinovaTech holds the potential to completely revolutionise the EV industry and the larger electronic and renewable energy industries. Greenbridge will work relentlessly to ensure that happens.” -  Ola Rollén, Greenbridge founder and Chairman. “I am very pleased with this investment and for the interest from Greenbridge in the company's pioneering NovaGaN® technology. I am convinced that this is the beginning of something big.” - Martin Olsson, EpinovaTech AB founder and Inventor. “EpinovaTech has set out to revolutionise the semiconductor industry at its core. We see a perfect match with Greenbridge - a visionary investor with an industrial heart - that shares our belief that strong partnerships are key for success. We are very much looking forward to a close relationship with Greenbridge as an active and long-term owner. “- Victoria Woyland, CEO of EpinovaTech AB For further information, please contact: Alan Hennebery, Chief Financial Officer, Greenbridgealan.hennebery@greenbridge.luJozephine Saers, Investor Relations Manager, Greenbridgejozephine.saers@greenbridge.lu Cecilia Rollén, Market Analyst and Communications, Greenbridgececilia.rollen@greenbridge.lu Martin Olsson, Founder and Inventor, EpinovaTechmartin.olsson@epinovatech.com Victoria Woyland, CEO, EpinovaTechvictoria.woyland@epinovatech.com About Greenbridge Greenbridge is a future-focused, long-term investment company with a mission to identify the trends, technologies and companies that will drive the next industrial revolution. Since 2016, Greenbridge has discovered and supported visionary founders and helped them to redefine their industries and disrupt the present for a greater future. About EpinovaTech AB EpinovaTech is a nano-technology company founded in 2019 looking to make the next generation power-chips based on Gallium Nitride (GaN) offering the highest power density at lowest weight and cost. EpinovaTech’s patented technology, NovaGaN® allows for the adoption of GaN in automotive, currently dominated by Silicon Carbide (SiC), as well as other high-demanding sectors such as 5G and renewable energy, while not only reducing energy waste but also making applications faster and smaller. NovaGaN® is compatible with existing chip manufacturing infrastructure providing economies of scale, industrial scalability, and short time-to-market.

Interim Report January - March 2024

CEO comment On May 1st I started my tenure as President and CEO of Nobia. We are still operating under difficult market conditions, but I am excited, humbled and very energized to take on the responsibility to this great company. The market remains difficult for both our consumer and project businesses. We anticipate that the combination of high interest rates and a decline in housing starts will continue to weigh on our project market throughout the remainder of the year. In the consumer market, we see modest improvements in consumer confidence and an increase in design appointments across all countries, albeit starting from a low base. The challenging market is reflected in our organic net sales that declined 20% in the quarter. Despite improved gross margin and cost out activities the operating income was slightly negative. Together with the Nobia team, I am committed to take all actions necessary to take us through the current headwinds. As we press forward with the execution of our strategy, including transformation of our operations in the UK and unlocking the full potential in the Nordics, in part from the full commissioning of the Jönköping factory, we also need to further reduce our fixed cost base. In the first quarter, we successfully undertook  significant actions to improve our balance sheet. This included divesting non-core assets ewe and Bribus, entering a sale and leaseback agreement for our Jönköping site, conducting a share rights issue, and securing extended credit facilities with our banks. I want to put on record my appreciation to all our shareholders for their support and participation. The transformation of the UK business is progressing  at pace. George Dymond has now assumed my former responsibilities as the Head of our UK operations. Since the beginning of the year, we have taken significant steps towards adopting a more asset-light operational model by closing nine underperforming stores and consolidating our UK manufacturing operations. Magnet has also successfully improved average order values in the consumer channel and entered new partnerships to distribute kitchens, including the signing of Magnet’s first franchisee agreement. Completion of the Nordic factory in Jönköping is also progressing well. I recently visited the factory together with one of our largest customers and it is impressive to witness the progress the team has made and how it will step-change our competitiveness in multiple ways. We produced over 30,000 cabinets from Jönköping in the quarter, this is modest volume but ahead of our plan and an important step toward the full commissioning of the factory. The work is, however, far from complete and the next step is to deliver full kitchen manufacturing and then ramp up volume. The cost program executed in 2023 has rendered savings well ahead of plan. However, as the market continues to be challenging we plan to reduce our fixed cost base further. This includes the transitioning to a more asset light model in the UK, harmonization of processes in the Nordics and supply chain consolidation. I will provide an update on the further actions we are taking in the second quarter. Having encountered numerous challenges in recent years including a material downturn in new house building activity, as a result there is pent-up demand in our markets. While we anticipate facing further challenging conditions for the remainder of 2024 we are making progress across all aspects of our business and these changes will position us well for growth and market share gains. I recognize the significant work ahead but I want to thank our teams for the hard work they do everyday across all our markets and especially so in these challenging times.  Kristoffer LjungfeltPresident & CEO

Swedbank Robur Corporate Governance & Engagement Report 2023

The 2023 report states, among other things, that Swedbank Robur:•    Voted at 968 meetings, in more than 40 different markets•    Evaluated more than 500 shareholder proposals•    Voted for 91% of the equity holdings •    Participated in 100 nomination committees, which is more than any other investor in Sweden•    Contacted 1418 companies in sustainability issues, with focus on, among other things, climate, biodiversity, and children’s rights ”We can both handle sustainability risks effectively and find good investment opportunities through our work with sustainability and corporate governance. We continue to work systematically to create long term and sustainable return to our savers”, says Pia Gisgård, Head of Sustainability and Corporate Governance at Swedbank Robur. All decisions regarding voting are made internally by Swedbank Robur. To not outsource the voting is a conscious strategic choice. Proposals to general meetings are evaluated internally according to Swedbank Robur’s Principles for Shareholder Engagement.”As active owners we believe that it is important to take the opportunity to vote on general meetings. Our senior corporate governance specialists evaluate the proposals. Then we decide how to vote. Our decision is based on what we determine is best for our savers”, says Pia Gisgård.  Swedbank Robur has four themes for its sustainability dialogues, climate, nature, human rights and corporate governance. Swedbank Robur have dialogues directly with companies, but also use engagement service from ISS Ethix and Sustainalytics 360 and is a member of several international investor collaborations.  ”Collaboration through investor initiatives are important since they increase our possibility to impact companies and give us access to exchange of experience. In addition, it is also resource effective, both for us as an investor and for the companies”, says Pia Gisgård. During 2023, Swedbank Robur became a member of the network Farm Animal Investment Risk & Return (FAIRR), which works for a sustainable food industry. They were also founding participants of Nature Action 100, which has the ambition to address nature loss and biodiversity decline and participated in the engagement initiative ”Human Rights in Big Tech”, which was administered by the Council on Ethics of the Swedish National Pension Funds. More information:Swedbank Robur Corporate Governance & Engagement Report 2024 (eng, pdf ) Contact:Carina Sesser Nylund, Head of information, Swedbank Robur, +46 72 230 52 64

Bigger Is Not Always Better – How Small-Scale Geothermal Projects Benefit The Energy Transition

The World's urgent need for cleaner and secure energy has become clearer than ever. While fighting climate change has been the main catalyst for renewable energy projects, energy security and energy independence also became a clear priority in Europe after the Russian full-scale invasion of Ukraine in 2022. Geothermal energy is a key technology to utilize locally available energy resources and decarbonize energy production not the least within heating and cooling, where 70% still comes from fossil fuels. Geothermal projects, however big or small, can contribute greatly to the overall goal of increasing renewables and energy security at the same time. Marta Rós Karlsdóttir, PhD, Managing Director of Baseload Power Iceland, is a speaker at the upcoming Iceland Geothermal Conference on this theme. The title of her speech is “Unlocking Underutilized Geothermal Potential with Small-Scale Combined Heat and Power Plants through Low-Medium Enthalpy Geothermal Resources: A Success Story from Baseload Power Iceland”. Marta Rós Karlsdóttir will showcase Baseload Power Iceland’s pioneering approach to exploring low and medium-temperature resources, revisiting old datasets and underutilized wells with the aim of optimizing energy efficiency and supporting local energy grids by producing both electricity and heat in small- and medium-scale projects. The Iceland Geothermal Conference, one of the most well attended events in the geothermal world, will take place on May 28-30 in Reykjavik, Iceland. The themes of the event include geothermal energy as a catalyst for change, cutting-edge innovation and geothermal business models. Marta Rós holds a PhD and a MSc degree in mechanical engineering from the University of Iceland. Before joining Baseload, she held management positions at Iceland’s National Energy Authority and the Icelandic Power company ON Power, as well as a leadership position in sustainability consulting at Verkís Consulting Engineers. Read more about conference here Iceland Geothermal Conference 2024 

Audientes A/S: The board of directors resolves on a rights issue of shares of approx. DKK 4.9 million in total

Background Audientes is positioned to capitalize on a significant growth opportunity in the hearing health sector, particularly within expanding middle-income markets such as India and China, where the demand for affordable hearing solutions remains largely unmet. As projected by the WHO , the number of individuals with disabling hearing loss is expected to reach 630 million by 2030 and 900 million by 2050, driven by demographic shifts and environmental factors. Unlike traditional vendors that target high-income markets with premium products, Audientes has broadened its market reach by offering competitively priced, high-quality hearing aids since mid-2022. Additionally, the Company has during the last year introduced the Companion by Audientes product aiming at addressing the needs of aging populations in developed nations, including Japan, the USA, and the EU. This strategic expansion into the consumer electronics segment positions Audientes uniquely in the market, enhancing its portfolio and reinforcing its commitment to accessible hearing health solutions available across a broad variety of sales channels. Audientes recently diversified its business model in early 2024 by launching a software platform for licensing to OEMs and other brands. This initiative allows third parties to develop and sell innovative products, further extending Audientes' market influence and leveraging its software assets developed since its IPO. Use of proceeds The Rights Issue can initially provide Audientes with approx. DKK 4.9 million (if fully subscribed) before transaction related costs of approx. DKK 0.8 million. The maximum net proceeds of approx. DKK 4.1 million from the initial part of the Rights Issue (after amortization of interest and loan) are intended to finance the following activities (arranged by priority): · Sales, marketing, and operations of the Companion by Audientes product in Japan, China and Europe – approx. 30 percent of the issue proceeds. · Sales, marketing, and operations of Ven and in India, Nepal, and surrounding countries – approx. 20 percent of the issue proceeds. · New product development and certifications for RIC-style (Receiver in Canal) hearing aid product for China, India, and other regulated markets with medical device rules – approx. 20 percent of issue proceeds. · Products already made or to be manufactured at OSM Group – approx. 10 percent of the issue proceeds. · General and administrative costs (incl. financial compliance) – approx. 20 percent of the issue proceeds. Terms for the Rights Issue The Board of Directors of Audientes has today, with the support of existing authorizations, resolved on the Rights Issue of a maximum of 138,768,644 new shares. The Rights Issue can initially provide the Company with a maximum amount of approx. DKK 4.9 million before deduction of transaction related costs. Audientes existing shareholders will receive pre-emptive rights to subscribe for New shares in relation to existing shareholdings. Those who are registered as shareholders in Audientes on the record date of 21 May 2024 will be allocated pre-emptive rights to subscribe for New shares in the Rights Issue. The subscription price in the Rights Issue is DKK 0.035 per share. For each existing share, two (2) pre-emptive subscription rights are allocated (so-called share right). One (1) pre-emptive right entitles the holder to subscribe for one (1) New share. Shares must be subscribed during the subscription period starting from 22 May 2024 up to and including 4 June 2024. The public also has the possibility to subscribe for shares in the Rights Issue. Last day of trading in Audientes’ shares including the right to receive share rights in the Rights Issue is May 16 2024. First day for trading in Audientes’ shares excluding the right to receive share rights is May 17 2024. Trading in subscription rights takes place from 17 May 2024 and including 31 May 2024. The the Rights Issue will result in a share capital increase of a maximum of nominal DKK 1,387,686, from 693,843.22 to a maximum of DKK 2,081,530, through the issue of a maximum of 138,768,644 new shares. The number of shares in Audientes after the Rights Issue will, upon full subscription, amount to 208,152,967 shares. Existing shareholders who choose not to participate in the Rights Issue will be subject to a dilution effect corresponding to approx. 67 percent of the total number of shares and votes in the Company after the Rights Issue, calculated on the number of shares in the Company after the Rights Issue, upon full subscription. Shareholders who choose not to participate in the Rights Issue have the opportunity to compensate for the financial dilution effect by selling their subscription rights no later than 31 May 2024. Complete terms and conditions for the Rights Issue as well as more information about Audientes will be presented in the issuer memorandum which is expected to be published on the Company’s and Spotlight Stock Markets websites around 16 May 2024. Commitments in relation to the Rights Issue In total, approx. 26 percent of the initial part of the Rights Issue, corresponding to approx. DKK 1.3 million, is agreed upon in writing by pre-subscription commitments including Audientes CEO Steen Thygesen, Audientes founder and CTO Hossein Jelveh and other existing shareholders including Michael Ole Fehrn, Johan Jacob Trap Friis, Per Lindström, and Shenzhen Hengtong Partner Company Ltd. Existing providers of the Company’s convertible loans have also undertaken pre-subscription commitments (Gerhard Dal, Selandia Alpha Invest A/S and Renewable Ventures Nordic AB). Audientes will continue to evaluate and take advantage of potential investment interest from professional investors in connection with the Rights Issue during the course of the capital raising. Indicative timetable for the Rights Issue · Board decision and company announcement of the planned rights issue: 14 May 2024 · Issuer memorandum published via Cision (as a company announcement) on Audientes and Spotlights website: 16 May 2024. · Record date for participation in the Rights Issue: 21 May 2024. · Last day of trading in shares including the right to receive subscription rights: 16 May 2024. · First day of trading in shares excluding the right to receive subscription rights: 17 May 2024. · Trading in subscription rights: 17 May 2024 – 31 May 2024 (the last day of trading in subscription rights will be announced through a separate press release). · Subscription period: 22 May 2024 – 4 June 2024 · Publication of the final outcome of the Rights Issue: around 10 June 2024 For more information about the Rights Issue, please contact: Bjørn Wennerlund, Villand Capital Phone: +45 60 13 77 86 or +46730 - 93 96 30 Email: info@villandcapital.com Steen Thygesen,CEO, Audientes A/S Phone: +45 53 17 26 10 Email:st@audientes.com    About Audientes A/S Audientes A/S is a Danish hearing health company specializing in smart, self-fitting and affordable hearing aids and advanced hearables. Audientes’ unique hearing aid solution, Ven™ by Audientes, is available for purchase in the Indian and Nepalese markets and will be introduced in other markets in the coming years. Companion by Audientes is an advanced hearable, a consumer electronics product, that is commercially available in Europe and later in 2024 in Japan, China, and other markets. Audientes’ mission is to make high-quality hearing aids and hearables for hearing improvement or hearing enhancement accessible to everyone who needs them globally. Audientes is listed on Spotlight Stock Market Denmark (AUDNTS) and headquartered in Copenhagen, Denmark with subsidiaries in Hyderabad, India and in Tokyo, Japan. For additional information please refer to the company’s websites, www.audientes.com, www.audientes.eu, or www.audientes.in.

Dedicare Implements Management Changes in Sweden and Initiates Cost-Saving Program

Dedicare is undergoing a management change in Sweden, where Bård Kristiansen, CEO of Dedicare Norway since 2017, will take over as interim CEO for Dedicare Sweden. Bård will continue as CEO for Dedicare Norway, while Lene Langås, operational manager within nurse staffing since 2013, will be appointed as interim operational manager for the Norwegian operations. The process of recruiting a new CEO for Dedicare Sweden will commence immediately. Eva Brunnberg is leaving the company, at her own request, and thereby vacating the position of CEO for Dedicare Sweden. "Bård has successfully built up and developed the Norwegian operations, where turnover has more than quadrupled under his leadership, with significantly increased profitability, while simultaneously meeting the qualitative goals," says Krister Widström. "I want to thank Eva for her great commitment, hard work, and good cooperation during a challenging period in Sweden," says Krister Widström. As a result of current market conditions within Swedish healthcare staffing and to some extent increased competition in the Norwegian market, as previously reported by Dedicare, the management together with the board has decided on a cost-saving program. The program is expected to generate annual savings of approximately SEK 15 million, with full effect from the fourth quarter of 2024. The measures taken aim to streamline operations and enable continued investments in future growth in markets and segments with strong demand. Dedicare's long-term strategy and financial goals of achieving annual revenue growth of at least 10 percent with an EBITA margin exceeding 7.0 percent over time remain unchanged. For more information, please contact:  Krister Widström, Group CEO, krister.widstrom@dedicaregroup.com, +46 70 526 7991  Anette Sandsjö, CFO, anette.sandsjo@dedicaregroup.com, +46 73 343 4468

Tranter and Hexxcell forge strategic partnership to revolutionize industrial heat exchanger maintenance.

Combining Tranter's extensive global expertise in the heat exchanger and maintenance services market with Hexxcell's cutting-edge digital solutions, the partnership is positioned to elevate service standards by providing unparalleled insights into effective maintenance strategies. Leveraging Hexxcell’s groundbreaking hybrid-AI digital twin models, plant operators will gain comprehensive insights into heat exchanger performance and identify operational improvements, optimal maintenance actions, and redesign options. Through advanced monitoring, predictive analytics, and prescriptive maintenance, the innovative solution provides actionable recommendations to improve efficiency, reduce downtime, and ensure sustainable operations. “At Tranter, we are dedicated to driving innovation and sustainability in the heat exchanger industry. Our partnership with Hexxcell demonstrates our commitment to delivering cutting-edge solutions that promote sustainable outcomes for both our customers and the environment.” Jan Debruyn, President and CEO, Tranter, Inc. “Hexxcell is at the forefront of digital innovation in heat transfer systems. We are excited about the possibilities our partnership with Tranter brings to customers. By integrating our technologies and services, we enable operators to reduce costs, emissions, and downtime, while ensuring their heat exchangers receive best-in-class service” Francesco Coletti, CEO of Hexxcell Ltd. Tranter is a leading global provider of heat exchanger solutions and maintenance services, and offers a wide range of products and services, through their innovative FullServ® service concept. Regardless of the heat exchanger brand, Tranter provides comprehensive support, ensuring a seamless customer experience. Hexxcell is an industry leader of advanced monitoring and predictive maintenance software for the process industry. Hexxcell Studio™’s Hybrid-AI Digital Twins combine Artificial Intelligence (AI) with rigorous physics-based models and deep domain knowledge to monitoring, design and maintenance of industrial thermal systems. The collaboration between Tranter and Hexxcell unlocks new growth opportunities and paves the way for a new era of predictive maintenance and design optimization in the heat exchanger industry.  For more information, contact: Jamey MarlingGlobal director- Service segmentJamey.Marling@tranter.com Niccolo Le BrunHead of Digital InnovationN.Le-Brun@hexxcell.com 

Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China

China, which is estimated to have up to 5 million patients suffering from the progressive autoimmune disease, IgA nephropathy (IgAN), has the highest prevalence of primary glomerular diseases in the world, with IgAN accounting for about 35% to 50% of cases with a biopsy proven incidence of over 100,000 patients per year. There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian countries. “This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO. Results from the Chinese subpopulation analysis of the Phase 3 NefIgArd trial, presented at the American Society of Nephrology (ASN) Kidney Week in 2023, provided evidence that the treatment effect of Nefecon in the Chinese cohort was greater than in the global data set with regards to kidney function, proteinuria and microhaematuria. In the Chinese cohort, the mean absolute change from baseline in estimated glomerular filtration rate (eGFR) at 24 months showed an approximately 66% reduction in loss of kidney function with Nefecon over the period, compared with a 50% reduction in loss of eGFR in the global data set. Nefecon® was awarded conditional approval in IgAN by China’s National Medical Products Administration (NMPA) in November 2023. In addition to being approved and commercially launched in Mainland China, Nefecon® has also received approval in Macau, Hong Kong and Singapore, and was successfully commercially launched and first prescribed in Macau at the end of last year.  New Drug Applications (NDA) for Nefecon® were also successfully accepted for review in Taiwan and South Korea at the end of 2023.

Finnair considers issuance of new notes and announces a voluntary tender offer of its outstanding notes maturing in 2025

Finnair Plc               Stock Exchange Release                14 May 2024 at 3:20 p.m. EEST NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES") OR IN OR INTO OR TO ANY PERSON RESIDENT OR LOCATED IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. Finnair Plc (the “Company”) is considering the issuance of new inaugural rated euro-denominated notes (the “New Notes”). The potential issue is expected to take place in the near future subject to market conditions. At the same time, the Company announces that it invites the holders of its 4.250 per cent, unrated notes due 19 May 2025 with an initial nominal amount of EUR 400 million (ISIN: FI4000507132) (the “Notes”) (the "Noteholders") to tender the Notes for cash on the terms and conditions set out in the Tender Offer Memorandum dated 14 May 2024 (the "Tender Offer Memorandum") (the “Tender Offer”). Noteholders are advised to read carefully the Tender Offer Memorandum for full details of, and information on the procedures for participating in, the Tender Offer. Details of the Tender Offer The Company proposes to initially accept for purchase any and all of the Notes validly tendered, although the Company reserves the right, in its sole discretion, to decide on acceptance of the Notes for purchase, including not to accept any Notes for purchase.  Whether the Company will accept for purchase any Notes validly tendered is subject to, without limitation, the pricing of the issue of the New Notes (the “New Issue Condition”). The purchase price of the Notes is EUR 1,005 per EUR 1,000 in principal amount of the Notes. Accrued and unpaid interest will be paid in respect of all Notes accepted for purchase. When considering the allocation of the New Notes, the Company will take into consideration the Notes tendered and may give priority to those Noteholders who, prior to such allocation, have validly tendered or have given a firm intention to the Company or any Dealer Manager that they intend to tender their Notes for purchase pursuant to the Tender Offer. Therefore, a Noteholder that wishes to subscribe for New Notes in addition to tendering its existing Notes for purchase pursuant to the Tender Offer will be eligible to receive, at the sole and absolute discretion of the Company, potential priority in the allocation of the New Notes, subject to satisfaction of the New Issue Condition, the selling restrictions contained in the prospectus for the New Notes and such Noteholder making a separate application for the subscription of such New Notes to a Dealer Manager (in its capacity as a bookrunner of the issue of the New Notes) in accordance with the standard new issue procedures of such Dealer Manager. However, the Company is not obliged to allocate the New Notes to a Noteholder who has validly tendered or indicated a firm intention to tender its Notes for purchase pursuant to the Tender Offer. Any such allocation will also, among other factors, take into account the minimum denomination of the New Notes (being EUR 100,000) and the minimum subscription amount, (being EUR 100,000). Expected Transaction Timeline Unless extended, re-opened or terminated as provided in the Tender Offer Memorandum, the offer period closes at 4:00 p.m. Finnish time (EEST) on 22 May 2024. The final outcome of the Tender Offer will be announced as soon as practicable after the expiry of the offer period. Subject to satisfaction of the New Issue Condition, the settlement date for the Tender Offer and the New Notes is expected to be 24 May 2024. Rationale for the Tender Offer The Company intends to use the proceeds of the New Notes, less costs and expenses incurred by the Company in connection with the issue of the New Notes, to fund the purchase of Notes accepted for purchase in the Tender Offer and refinancing and other general corporate purposes of the group. The rationale of the Tender Offer is, thus, to proactively manage the debt portfolio of the Company. Danske Bank A/S and Nordea Bank Abp act as the Dealer Managers (the "Dealer Managers") and Nordea Bank Abp acts as the Tender Agent (the "Tender Agent") for the Tender Offer. Information in respect of the Tender Offer and the Tender Offer Memorandum may be obtained from the Dealer Managers. Danske Bank A/S, Deutsche Bank Aktiengesellschaft, Nordea Bank Abp, OP Corporate Bank plc and Skandinaviska Enskilda Banken AB (publ) act as Bookrunners for the issue of the New Notes (the "Bookrunners"). Dealer Managers: Danske Bank A/S Telephone: +45 33 64 88 51 Attention: Debt Capital Markets Email: liabilitymanagement@danskebank.dk Nordea Bank Abp Telephone: +45 6136 0379 Attention: Nordea Liability Management Email: NordeaLiabilityManagement@nordea.com For further information: Mikko Hepokari, Group Treasurer, tel. +358 40 745 4292, mikko.hepokari@finnair.com Kristian Pullola, CFO, tel. +358 9 818 4960, kristian.pullola@finnair.com FINNAIR PLC Distribution: NASDAQ OMX Helsinki Principal media Finnair is a network airline, specialising in connecting passenger and cargo traffic between Asia, the Middle East, North America and Europe. Finnair is the only airline with year-round direct flights to Lapland. Sustainability is at the heart of everything we do – Finnair intends to reach carbon neutrality latest by the end of 2045. Customers have chosen Finnair as the Best Airline in Northern Europe in the Skytrax Awards for 13 times in a row. Finnair is a member of the oneworld alliance. Finnair Plc’s shares are quoted on the Nasdaq Helsinki stock exchange. IMPORTANT NOTICE Neither this release nor the Tender Offer Memorandum constitutes a recommendation by Finnair, the Dealer Managers, the Tender Agent, the Bookrunners, or any of their respective directors, officers, employees, agents or affiliates regarding the Tender Offer or a recommendation as to whether the Noteholders should tender any Notes in the Tender Offer or a recommendation to subscribe for any notes potentially issued by the Company. The Noteholders should consult their own tax, accounting, financial and legal advisers and make an independent decision as to whether to tender any Notes held by them for purchase pursuant to the Tender Offer or to invest in any notes potentially issued by the Company. Distribution restrictions The distribution of this release and the invitation to tender the outstanding Notes is prohibited by law in certain countries. The Tender Offer is not made to the public either inside or outside of Finland. Persons resident outside of Finland may receive this release, the Tender Offer Memorandum and any other information and materials relating to the Tender Offer only in compliance with applicable exemptions or restrictions. Persons into whose possession this release, the Tender Offer Memorandum and any other such information and materials may come are required to inform themselves about and comply with such restrictions. This release, the Tender Offer Memorandum and any other such information or materials may not be distributed or published in any country or jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of a state or jurisdiction other than Finland, including the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore and South Africa. The information contained in this release shall not constitute an offer to sell or tender, or a solicitation of an offer to buy or sell the Notes to any persons in any jurisdiction in which such offer, solicitation or sale or tender would be unlawful. None of Finnair, the Dealer Managers or the Tender Agent or any of their respective affiliates and representatives assume any legal responsibility for such violations, regardless of whether the parties contemplating investing in or divesting the Notes are aware of these restrictions or not. United States The Tender Offer is not being made, and will not be made, directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of or of any facilities of a national securities exchange of, the United States or to any U.S. Person (as defined in Regulation S of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) (each, a “U.S. Person”)). This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Notes may not be tendered in the Tender Offer by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States or by, or by any person acting for the account or benefit of, a U.S. Person. Accordingly, copies of this release, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to any persons located or resident in the United States or to any U.S. Person. Any purported tender of the Notes in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of Notes made by, or by any person acting for the account or benefit of, a U.S. Person or by a person located in the United States or any agent, fiduciary or other intermediary acting on a nondiscretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted. Each Noteholder participating in the Tender Offer will represent that it is not a U.S. Person, it is not located in the United States and it is not participating in the Tender Offer from the United States, or it is acting on a non-discretionary basis for a principal located outside the United States that is not giving an order to participate in the Tender Offer from the United States and is not a U.S. Person. For the purposes of this paragraph, United States means the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia. United Kingdom The communication of this release, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer is not being made and such documents and/or materials have not been, and will not be, approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. This release, the Tender Offer Memorandum and any such other offer material relating to the Tender Offer may only be distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, (iv) persons who are within Article 43 of the Order and (v) other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) to (v) above together being referred to as “relevant persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this release, the Tender Offer Memorandum or any of its contents. France The communication of this release and the Tender Offer is not being made, directly or indirectly, to the public in France. Neither the Tender Offer Memorandum nor any other documents or offering materials relating to the Tender Offer have been or shall be distributed to the public in France and only qualified investors (investisseurs qualifiés) within the meaning of Article 2(e) of Regulation (EU) 2017/1129 are eligible to participate in the Tender Offer. The Tender Offer Memorandum has not been and will not be submitted to the clearance procedures (visa) of the Autorité des marchés financiers. Republic of Italy None of the Tender Offer Memorandum nor any other documents or materials relating to the Tender Offer have been or will be submitted to the clearance procedure of the Commissione Nazionale per le Società e la Borsa (“CONSOB”) pursuant to Italian laws and regulations. In the Republic of Italy, the Tender Offer is being carried out as an exempted offer pursuant to Article 101 bis, paragraph 3 bis of Legislative Decree no. 58 of February 24, 1998, as amended (the “Financial Services Act”) and article 35 bis, paragraphs 3 and 4 of CONSOB Regulation No. 11971 of May 14, 1999, as amended (the “CONSOB Regulation”). Noteholders or beneficial owners of the Notes that are located in Italy can tender Notes for purchase through authorized persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in the Republic of Italy in accordance with the Financial Services Act, CONSOB Regulation No. 16190 of 29 October 2007, as amended from time to time, and Legislative Decree No. 385 of 1 September 1993, as amended from time to time) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority. General This release or the Tender Offer Memorandum do not constitute an offer to buy or the solicitation of an offer to sell any Notes (and tenders of the Notes in the Tender Offer will not be accepted from any Noteholders thereof) in any circumstances in which such offer or solicitation would be considered unlawful. In those jurisdictions where the securities, investor protection or other laws require the Tender Offer to be made by a licensed broker or dealer and the Dealer Managers or any of the Dealer Managers' affiliates is such a licensed broker or dealer in any such jurisdiction, the Tender Offer shall be deemed to be made by the Dealer Managers or such affiliate, as the case may be, on behalf of Finnair in such jurisdiction. In addition to the representations referred to above in respect of the United States, each Noteholder participating in the Tender Offer will also be deemed to give certain representations in respect of the other jurisdictions referred to above and generally as set out in the Tender Offer Memorandum. Any tender of the Notes for purchase pursuant to the Tender Offer from any Noteholder that is unable to make these representations will not be accepted. Each of Finnair, the Dealer Managers and the Tender Agent reserves the right, in its absolute discretion, to investigate, in relation to any tender of the Notes for purchase pursuant to the Tender Offer, whether any such representation given by any Noteholder thereof is correct and, if such investigation is undertaken and as a result Finnair determines (for any reason) that such representation is not correct, such tender shall not be accepted. Disclaimer This release is for information purposes only and is not to be construed as an offer to sell any securities of Finnair. No actions have been taken to register or qualify the New Notes, or otherwise to permit a public offering of the New Notes, in any jurisdiction. If Finnair decides to proceed with the issue of the New Notes, any offering material or documentation related to the New Notes may be received only in compliance with applicable exemptions or restrictions. None of Finnair, the Dealer Managers, the Tender Agent nor the Bookrunners or their representatives accept any legal responsibility for any violation by any person, whether or not the persons contemplating investing in or divesting Finnair’s securities, including the New Notes, are aware of such restrictions. The New Notes have not been and will not be registered under the U.S. Securities Act, or under the securities laws of any state or other jurisdiction of the United States. The New Notes may not be offered, sold, pledged or otherwise transferred directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act.

Water in Communications Workshops

Water has never been a more pressing and relevant issue. Which is why it’s never been more important to communicate about water. Since the Water in Communications programme launched in 2021, more than 1,000 journalists and communicators have participated in the series of training workshops that serve as a prelude to, and integral part of, World Water Week .  The free online workshops seek to improve the accuracy, intensity, and quality of reporting and storytelling on water, thereby broadening awareness about water issues and climate change. They provide inspirational keynote presentations and discussions to give participants the knowledge and skills needed to broaden their reach and empower people to make better decisions about water.  This year’s programme highlights include: • A deep dive into the theme of World Water Week 2024: Bridging Borders: Water for a Peaceful and Sustainable Future including sessions on human security and water diplomacy. • Interactive masterclass session with Anders Sahlman, Science Communicator, and Presentation Coach. • Several sessions on representation, how to decolonize visual communications, and strengthen the voice of women.  For the first time, all sessions will be simultaneously translated into Spanish.  All workshop sessions are recorded to ensure everyone can watch (or re-watch) the training programme when convenient.   The 2024 Water in Communications programme will run on selected dates from 4 to 27 June 2024, starting at CEST 2pm, with sessions held on Zoom.  More information as well registration under this link .

Eevia Health Plc makes adjustments to the Financial calendar

For practical reasons and due to the timing of public holidays during the month of May, Eevia is adjusting its financial calendar, and is announcing the following: The publication of the Interim Report for Q1-2024 will be changed from May 20 to May 22, 2024, due to public holidays in Finland and Norway. Eevia will publish its statutory financial statements and the auditor’s report on June 7, 2024. Eevia will hold its Annual General Meeting of the Shareholders (AGM) on Friday, June 28, 2024. The notice for the AGM will be published on June 7, 2024. For further information, please contact: Stein Ulve, CEO, Eevia Health Plc Email: stein.ulve@eeviahealth.comor investor@eeviahealth.com Telephone: +358400 22 5967 INFORMATION ABOUT EEVIA HEALTH PLC Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forestsnearor above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brandsglobally. These global brands utilize the ingredients in their consumer product formulas. Eevia Health is a manufacturer of 100% organically certified plant extracts.Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such asbilberry,lingonberry,chaga-mushroom, and pine bark, are wild-harvested sustainably. Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA . To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn@EeviaHealth.

Neste enables Signature Aviation transition to offering only blended sustainable aviation fuel for all business aviation customers at its Los Angeles International Airport terminal

Neste Corporation, News, 14 May 2024 Photo: Signature Aviation Enabled by its partnership with Neste, Signature Aviation, who operates the world’s largest network of business aviation terminals, is now providing only blended Neste MY Sustainable Aviation Fuel™  to all aircraft refueling at its terminal at Los Angeles International Airport (LAX).  Since April 1, Signature’s LAX terminal has become the second business aviation terminal worldwide, joining Signature’s terminal at San Francisco International Airport, to offer only blended SAF to business aviation customers. The blended fuel provided by Signature to their customers at LAX consists of 30% SAF and 70% conventional jet fuel. This enables customers using the blended fuel to achieve up to a 24%* reduction in greenhouse gas (GHG) emissions from their air travel compared to flights powered by conventional fossil jet fuel.  "We are proud to continue to expand our collaboration with committed partners like Signature Aviation, who recognize the key role sustainable aviation fuel can play in reducing GHG emissions from air travel. Offering blended Neste MY Sustainable Aviation Fuel to all of its customers at LAX is a shining example of how the business aviation community can work together with fuel producers to accelerate SAF adoption and emission reductions," says Carrie Song, Senior Vice President Commercial, Renewable Products at Neste.  "This is a transformative time for Signature, and our partnership with Neste is helping us take another significant step towards net zero by providing a 100% supply of blended SAF at our Los Angeles location," said Derek DeCross, Chief Commercial Officer at Signature Aviation. "This collaboration exemplifies how we're working together with both our guests and our partners to accelerate the adoption of environmentally friendly practices and paving the way for a more sustainable future in aviation." Today’s announcement builds on the partnership between Signature and Neste to accelerate SAF adoption that dates back to 2020. In October 2022, Signature expanded the availability of Neste MY SAF to all of its locations in California enabled by Neste’s growing SAF production and supply capabilities. Neste will increase its global SAF production capability to 515 million gallons of SAF (1.5 million metric tons) per annum in 2024 and has been working with industry partners to expand the availability of its renewable products. In 2023, Neste commissioned terminal capacity at Vopak’s Los Angeles terminal in California for storing SAF and renewable diesel, enabling GHG emission reductions in the transportation sector and supporting the energy transition in the region.  Sustainable Aviation FuelSustainable aviation fuel is a renewable aviation fuel providing a more sustainable alternative to conventional, fossil-based jet fuel. Neste’s SAF is made from sustainably sourced, 100% renewable waste and residue raw materials, such as used cooking oil and animal fat waste. Using Neste MY Sustainable Aviation Fuel reduces greenhouse gas emissions by up to 80%* over the fuel’s life cycle, compared to using conventional jet fuel. SAF is currently approved for use blended up to 50% with conventional jet fuel. It is blended with conventional jet fuel before use and works seamlessly with existing aircraft engines and fueling infrastructure.  *) Estimated based on an up to 80% emission reduction for the SAF when used in neat form (i.e. unblended). It is calculated with established life cycle assessment (LCA) methodologies, such as CORSIA methodology. 

Bulletin from Sobi’s Annual General Meeting (AGM)

Adoption of the profit and loss statements and balance sheet and discharge of liability The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits. The Board members and the chief executive officer were discharged from liability for the financial year 2023. Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor The ordinary Board members Christophe Bourdon, Annette Clancy, Helena Saxon, StaffanSchüberg, Filippa Stenberg and Anders Ullman were re-elected as Board members and Zlatko Rihter was elected as new Board member for the period until the end of the next AGM. Annette Clancy was re‑elected as chair of the Board of Directors. Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM. The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal. Remuneration report, guidelines for executive remuneration, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares The AGM resolved to approve the Board of Directors’ remuneration report. The AGM resolved to approve the Board of Directors’ proposal for guidelines for executive remuneration. The AGM resolved to approve the Board of Directors’ proposal to implement long-term incentive programmes, consisting of hedging arrangements in respect of the programmes by way of directed issues of no more than 1,641,103 series C shares in the aggregate, authorisation for the Board of Directors to resolve on a repurchase of all issued series C shares and transfer of no more than 3,156,277 own common shares in the aggregate to participants of the programmes. The AGM approved the Board of Directors’ proposal regarding the authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 39,370,000 shares in total. The Board of Directors’ proposal regarding transfer of no more than 1,006,742 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the incentive programmes 2020 and 2021, was also approved by the AGM. For full details on each proposal adopted by the AGM, please refer to sobi.com. Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn . Contacts For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media contacts, click here . Gerard Tobin Head of Investor Relations

Report from Epiroc’s Annual General Meeting 2024

The income statements and the balance sheets of the parent company and the Group were approved. The Directors of the Board and the President and CEO were discharged from liability for the financial year 2023.  The proposed dividend of SEK 3.80 per share, to be paid in two equal instalments of SEK 1.90, was approved. The record date for the first instalment is May 16, 2024, and for the second instalment October 22, 2024. The first instalment is expected to be distributed by Euroclear on May 21, 2024, and the second instalment on October 25, 2024. The Annual General Meeting approved the remuneration report. The following nine Board members were re-elected: Anthea Bath, Lennart Evrell, Johan Forssell, Helena Hedblom, Jeane Hull, Ronnie Leten, Ulla Litzén, Sigurd Mareels and Astrid Skarheim Onsum. Ronnie Leten was re-elected Chair of the Board.  The Annual General Meeting approved the fees to the Board members elected by the meeting and not employed by the company as follows: Remuneration of SEK 2,710,000 to the Chair of the Board and SEK 850,000 each to the other Board members. To the Chair of the Audit Committee SEK 360,000 and SEK 235,000 each to the other members. To the Chair of the Remuneration Committee SEK 165,000 and SEK 120,000 each to the other members, and remuneration of SEK 80,000 to each Board member who, in addition to the above, participates in a committee in accordance with a decision of the Board of Directors. The Annual General Meeting approved the proposal allowing Board members to choose between receiving 50% of the Board remuneration in the form of synthetic shares and the rest in cash or to receive the whole remuneration in cash. The Annual General Meeting also approved that the obligation of Epiroc AB to pay an amount corresponding to the synthetic shares shall be hedged through the purchase of own series A shares.  The Annual General Meeting re-elected Ernst & Young as Epiroc AB’s auditor. The remuneration to the auditor shall be as per approved invoice. The Annual General Meeting approved the proposal of the Board of Directors regarding a performance-based personnel option plan for 2024. The Annual General Meeting authorized the Board to decide on the purchase and transfer of own series A shares, in order to fulfill obligations related to the performance stock option plan for 2024, and to the part of the Board fee that consists of synthetic shares. The Board was authorized to sell shares in order to fulfill obligations related to the performance stock option plans for 2018, 2019, 2020 and 2021, and to cover costs related to synthetic shares to the Board of Directors.  The Annual General Meeting approved the proposed instruction for the Nomination Committee. A speech by President and CEO Helena Hedblom will be available on Epiroc’s webpage www.epirocgroup.com/agm, where the minutes from the Annual General Meeting will also be published. For more information please contact:Karin Larsson, VP Investor Relations and Media+46 10 755 0106ir@epiroc.comOla Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.com Epiroc is a global productivity partner for mining and construction customers, and accelerates the transformation toward a sustainable society. With ground-breaking technology, Epiroc develops and provides innovative and safe equipment, such as drill rigs, rock excavation and construction equipment and tools for surface and underground applications. The company also offers world-class service and other aftermarket support as well as solutions for automation, digitalization and electrification. Epiroc is based in Stockholm, Sweden, had revenues of more than SEK 60 billion in 2023, and has around 18 200 passionate employees supporting and collaborating with customers in around 150 countries. Learn more at www.epirocgroup.com.

Epiroc to utilize mandates to repurchase and sell shares

The mandates cover: 1) The acquisition of not more than 1,950,000 series A shares, whereof a maximum of 1,900,000 may be transferred to option holders under the performance-based personnel option plan 2024.2) The acquisition of not more than 20,000 series A shares, later to be sold on the market in connection with payment to Board members who have opted to receive synthetic shares as part of their remuneration.3) The sale of not more than 60,000 series A shares to cover costs related to previously issued synthetic shares to Board members.4) The sale of a maximum 4,000,000 series A shares currently held by the company, for the purpose of covering costs of fulfilling obligations related to the performance-based personnel option plans 2018, 2019, 2020 and 2021. Repurchases and sales are subject to market conditions, regulatory restrictions and the capital structure at any given time. The number of issued shares is presently 1,213,738,703 whereof 823,765,854 series A shares and 389,972,849 series B shares.  For more information please contact:Karin Larsson, VP Investor Relations and Media+46 10 755 0106ir@epiroc.comOla Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.com Epiroc is a global productivity partner for mining and construction customers, and accelerates the transformation toward a sustainable society. With ground-breaking technology, Epiroc develops and provides innovative and safe equipment, such as drill rigs, rock excavation and construction equipment and tools for surface and underground applications. The company also offers world-class service and other aftermarket support as well as solutions for automation, digitalization and electrification. Epiroc is based in Stockholm, Sweden, had revenues of more than SEK 60 billion in 2023, and has around 18 200 passionate employees supporting and collaborating with customers in around 150 countries. Learn more at www.epirocgroup.com.

Resolutions at the Annual General Meeting in K-Fast Holding AB 2024

The Annual General Meeting (“AGM”) of the shareholders in K-Fast Holding AB (publ) was held on Tuesday 14[th] of May 2024. The AGM approved the following main resolutions in accordance with the presented proposals. Adoption of the Income Statement and Balance SheetThe AGM adopted the Income Statement and Balance Sheet of the Parent Company and Consolidated Income Statement, Consolidated Balance Sheet for the Group for the period 1 January 2023 – 31 December 2023. Allocation of profit or lossThe AGM approved the Board’s proposal to carry forward retained profit of SEK 2,225,629,526 at the disposal of the AGM. The BoardThe AGM discharged the Board members and CEO from liability for the previous financial year. The AGM resolved that the Board of Directors should comprise six members without deputies.  The following members were re-elected to the Board: Ulf Johansson, Christian Karlsson, Sara Mindus, Jesper Mårtensson, Erik Selin and Jacob Karlsson. The AGM appointed Erik Selin as Chairman. Directors’ feesThe AGM approved Directors’ fees in accordance with the Nomination Committee’s proposal of SEK 200,000 for the period up until the next AGM for each Board member not employed by the company, except for Erik Selin. The proposed fees also include remuneration for committee work. Auditor and feesErnst & Young AB (“EY”) were re-elected as company Auditor for the period until the end of the next AGM. EY will appoint Peter von Knorring as Auditor in Charge. Fees to the company’s Auditors are payable in accordance with approved invoice. Approval of Remuneration ReportThe AGM approved the Board’s Remuneration Report for senior management members. Guidelines for remuneration to executive managementThe AGM approved the Board’s proposed guidelines for remuneration to executive management. Resolution on authorizing the Board to resolve to issue new sharesThe AGM authorized the Board to decide, on one or several occasions, in the period up until the 2025 AGM, with or without departing from shareholders’ pre-emptive rights, to issue new shares. Authorization includes the right to pay for newly issued shares in cash, through offset or in the form of non-cash consideration. Based on the authorization, the number of shares can be increased, within the framework of the authorization, to a maximum of 25,000,000 (twenty-five million) new Class B shares. The purpose of the authorization, and the reason for any departure from shareholders’ pre-emptive rights, is to enable timely and cost-efficient new share issues, with the aim of financing the acquisition of properties or businesses by the company, or to carry out other investments. New share issues under this authorization, departing from shareholders’ pre-emptive rights, shall be based on a market-based subscription price that reflects market conditions at the time of issue. The CEO, or the person appointed by the Board of Directors, shall have the right to make such minor adjustments to the decision as may prove necessary in connection with the registration thereof. Resolution on authorizing the Board to repurchase treasury sharesThe AGM authorized the Board, in the period until the 2025 AGM, to decide, on one or several occasions, to repurchase and transfer Class B shares held in treasury. Repurchase may only occur on a regulated market place where the company’s shares are listed and at a price per share within the registered share price interval as applicable from time to time, corresponding to the interval between highest bid price and lowest offer price. Within the framework of the authorization, the company is permitted to repurchase a maximum number of shares corresponding to one tenth of the total number of shares issued in the company. The purpose of the authorization is to create the right conditions for the Board to reach expedient decisions regarding the effective utilization of the company’s capital and liquidity. Authorization permits the Board, if it is considered appropriate, to utilize potential surplus liquidity to effect reversals to shareholders without necessitating more administratively complex procedures such as customary dividend and/or cancellation of shares. The authorizations also aim to give the company greater flexibility to make acquisitions of properties, companies or other investments. _________________________ Hässleholm, Sweden, May 2024 K-Fast Holding ABThe Board For more information, please contact:Johan Hammarqvist, Head of Investor Relations and Communicationse-mail: johan.hammarqvist@k-fastigheter.se, telephone: +46 (0)10-167 60 99  K-Fastigheter is much more than a property company. Through an integrated process, we build our business in the two business segments Construction and Property Management. In business segment Construction the objective is to deliver completed housing units based on the Group’s concept houses, developed in-house, as well as high-quality frame solutions. Our prefab operations is organized in the subsidiary K-Prefab. To enhance cost efficiency and cut construction times, K-Fastigheter has chosen to work with three concept houses for housing, developed in-house. Business segment Property Management manages the Groups property portfolio with focus on housing. K-Fastigheter offers more than 5,000 homes from Copenhagen in the south to Gävle in the north and is continuously assessing new markets. K-Fastigheter strive to create attractive homes with a high comfort factor. The Group’s property portfolio has a book value SEK 15,3 billion. Annual rental value in invest properties under management amounts to SEK 686 million. Since November 2019, the company’s Class B shares have been traded on Nasdaq Stockholm (under the ticker: KFAST B). Read more at k-fastigheter.com

Resolutions at GARO Aktiebolag’s Annual General Meeting 2024

The Annual General Meeting approved the presented income statements and balance sheets and remuneration report and approved discharge from liability for board members and the managing director. In addition, the following decisions were made. Election of Board of DirectorsAs board members Rickard Blomqvist (Chairperson), Martin Althén, Susanna Hilleskog, Mari-Katharina Jonsson Kadowaki, Johan Paulsson and Lars Kongstad were re-elected. Fees to the Board of DirectorsIt was resolved that Board fees shall be unchanged and paid by SEK 725,000 to the Chairperson of the Board and SEK 300,000 to each of the other Board members elected by the Annual General Meeting who are not employed by the group. It was further resolved that fees for assignment in the Audit Committee shall be unchanged and paid by SEK 100,000 to the Chairperson and SEK 50,000 to each of the other members of the Audit Committee. Fees for assignment in the Renumeration Committee shall be unchanged and paid by SEK 50,000 to the Chairperson and SEK 25,000 to each of the other members of the Renumeration Committee. Election of auditorErnst & Young AB was re-elected as the company’s auditor for a period of mandate of one year. Ernst & Young AB has informed the company that authorized public accountant Carolina Timén will be auditor in charge. It was resolved that auditor fees shall be paid in accordance with approved invoice. DividendIn accordance with the proposal of the Board of Directors, the Annual General Meeting resolved that no dividend shall be distributed for the financial year 2023 and the company’s funds available for distribution shall be carried forward. Authorisation for the Board of Directors to resolve on new issues of shares in connection with acquisitionsThe Meeting resolved to authorise the Board of Directors to, on one or several occasions up to the next Annual General Meeting, with or without deviation from the shareholders’ preferential right, resolve on new issues of shares in connection with acquisitions. The total number of shares that may be issued, by virtue of the authorisation shall be within the limits of the Articles of Association and not exceed ten (10) percent of the total number of shares in GARO at the time of the Board of Directors’ resolution. The authorisation includes a right to resolve on new issues by contribution in kind or payment by set-off in connection with acquisitions. The purpose of the authorisation, and the reason for deviation from the shareholders’ preferential right, is to enable the company to acquire companies, businesses or parts thereof. Authorisation for the Board of Directors to resolve on repurchase and transfer of own sharesThe Meeting resolved to authorise the Board of Directors to resolve on repurchase and transfer of own shares with the purpose to enable financing of acquisitions by using own shares and to enable the Board of Directors to continuously adapt GARO’s capital structure to the company's capital requirements. Acquisition may be made of such number of shares that GARO’s holding of own shares does not at any time exceed five (5) percent of the total number of shares in the company. Transfer may take place on Nasdaq Stockholm and/or outside of Nasdaq Stockholm in connection with acquisition of companies or businesses, on one or more occasions prior to the next Annual General Meeting. For more information, please contact:Helena Claesson, CFO: +46 (0)70 676 07 50 GARO AB (publ) Corp. Reg. No. 556071–7772 is a company that develops, manufactures and markets innovative products and systems for the electrical installations market under its own brand. GARO’s customer offering is to provide complete solutions in the product areas of Electrical distribution products, E-mobility, Project business & Temporary Power with a focus on electrical safety, user-friendliness and sustainability. GARO was founded in 1939, has its head office in Gnosjö and is today an international company with operations in seven countries. The company’s production units in Sweden are located in Gnosjö and Hillerstorp in Sweden and in Szczecin in Poland. GARO is listed on Nasdaq Stockholm under the ticker name GARO. For more information, see www.garo.se

Getinge's financial target 2024-2028: Adjusted EPS growth of above 12% on average

In the letter from the U.S. FDA, there are no new field actions referred to, but healthcare providers are advised to transition from Getinge’s Cardiosave Intra-Aortic Balloon Pump (IABP), Cardiohelp System, and HLS Sets Advanced to alternative products, and to continue using Getinge’s products only if no other alternatives are available. Getinge is estimated to have a market share in the U.S. of over 60% for the mentioned products, which includes both hardware and consumables.  “We take this very seriously and as a result of the U.S. FDA’s letter, we have decided to immediately pause promotional activities of the Cardiohelp System and Cardiosave IABP in the U.S. until outstanding actions related to quality improvements have been addressed and approved. The sale of these hardware products will be limited to customers who have no available alternatives. We will also inform all customers about the regulatory requirements for the use of the Cardiohelp System. Regarding Intra-Aortic Balloon catheters and HLS sets, we will continue to supply and service the installed base”, says Mattias Perjos, President & CEO of Getinge. For markets outside the U.S., Getinge has implemented product improvements, and will continue to sell Cardiosave IABP and the Cardiohelp System as well as continue to provide intra-aortic balloon catheters and HLS sets in markets where they are permitted and approved for use. In recent years, Getinge has taken important steps to correct quality-related deficiencies, focusing on product upgrades. For example, Getinge has developed a new packaging for HLS sets, which was recently submitted for approval in CE markets. At the same time, Getinge has accelerated the development of the next generation of the Cardiohelp System and Cardiosave IABP hardware, where the company expects to submit applications for clearance in the U.S. end of H1 to end of H2 2025 followed by an update and submission for clearance of the HLS set. The mentioned decisions are likely to have a negative financial impact until the new products are approved and launched. However, it is too early to have a firm opinion on the exact extent, which is why Getinge does not have stated targets for organic net sales growth and adjusted EBITA margin for the period. Structurally, however, Getinge assesses the justified organic net sales CAGR during the period to be in the area of 3-6% and the EBITA margin in the area of 16-19% at the end of the period, after taking today's decision into account. All in all, this contributes to the following financial target for 2024-2028: Adjusted EPS growth above 12% on average. Getinge’s dividend policy remains unchanged and amounts to 30-50% of the company’s net profit. For 2024, Getinge repeats its guidance of 2-5% organic growth in net sales and 3-5% growth from acquired units. Getinge does not provide any annual guidance for adjusted EBITA margin. Getinge also updates its sustainability targets as follows. These are not tied to the period 2024-2028. Socially • Employee engagement: >70% • Compliance in quality, audit results/inspection: <1.5 deviation Environment • Reduce Scope 1 and 2 emissions by 90% by 2030[2)] • Reduce Scope 3 emissions by 25% by 2030 and by 90% by 2050[2)] Governance • Percentage of employees who have completed training in business ethics: >90% 1) Base year: 2023. 2) Base year: 2021. Contact informationLars Mattsson, SVP Corporate DevelopmentCorporate Strategy | M&A | Investor RelationsPhone:  +46(0)10 335 0043E-mail:  lars.mattsson@getinge.com  This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20.15 pm CEST on May 14, 2024. About GetingeWith a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in 135 countries.

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Leqembi is approved for biweekly intravenous (IV) treatment, which is normally done at medical facilities. Subcutaneous administration with an autoinjector simplifies home treatment and the injection process requires less time than the IV formulation. This makes the treatment easier for patients and their care partners and may reduce the need for hospital visits and nursing care compared to IV administration, in addition to being more convenient for patients to continue the treatment. Alzheimer’s disease is an ongoing neurotoxic process that begins before and continues after amyloid-beta (Aβ) plaque deposition, which is a hallmark of the disease. Data suggests that early and continued treatment may prolong the benefit even after Aβ plaque is cleared from the brain. If approved by the FDA, patients who have completed the biweekly IV initiation phase could transfer to the subcutaneous autoinjector 360 mg weekly maintenance regimen, currently under review. This would maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils[i] which can continue to cause neuronal injury even after the Aβ plaque has been cleared from the brain. The BLA is based on data from the Phase 3 Clarity AD open-label extension (OLE) study, and modeling of observed data. Leqembi is now approved in the U.S., Japan and China, and applications have been submitted for review in the European Union, Australia, Brazil, Canada, Hong Kong, Great Britain, India, Israel, Russia, Saudi Arabia, South Korea, Taiwan, Singapore and Switzerland. In March 2024, Eisai submitted to the FDA a Supplemental Biologics License Application (sBLA) for less frequent monthly IV maintenance dosing of Leqembi. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on May 15, 2024, at 01.30 a.m. CET. For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  oskar.bosson@bioarctic.sePhone: +46 70 410 71 80 Jiang Millington, Director Corporate Communication and Social MediaE-mail: jiang.millington@bioarctic.sePhone: +46 79 33 99 166About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)Lecanemab (Leqembi) is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, and China with the following indications:  · U.S.: For the treatment of Alzheimer’s disease (AD). It should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. See full US prescribing information  including boxed waring. · Japan: For slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD. · China: For the treatment of MCI due to AD and mild AD dementia. Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 14 countries and regions, including the European Union (EU). Eisai has completed a lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD (Study 301) open-label extension (OLE) study. A maintenance dosing regimen has been evaluated as part of the Phase 2b study (Study 201). Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se. [i] Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.[ii] Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.[iii] [ii] Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z [iii] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)

Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and Eisai and BioArctic are currently preparing for a joint commercialization in the region. BioArctic's report for the first quarter 2024 will be published on May 17 at 08.00 a.m. CET. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on May 15, 2024, at 05.45 a.m. CET.              For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  oskar.bosson@bioarctic.sePhone: +46 70 410 71 80 Jiang Millington, Director Corporate Communication and Social MediaE-mail: jiang.millington@bioarctic.sePhone: +46 79 33 99 166About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)Lecanemab (Leqembi) is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, and China with the following indications:  · U.S.: For the treatment of Alzheimer’s disease (AD). It should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. See full US prescribing information . · Japan: For slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD. · China: For the treatment of MCI due to AD and mild AD dementia. Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 14 countries and regions, including the European Union (EU). Eisai has completed a lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD (Study 301) open-label extension (OLE) study. A maintenance dosing regimen has been evaluated as part of the Phase 2b study (Study 201). Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.

Techstep partners with Nordic mobile operator to advance product offerings

Techstep has recently entered into a partner agreement with a Nordic mobile operator to introduce Own software and managed services to their customers.   Under the agreement, Techstep will work closely with the mobile operator to adapt their services to an evolving market landscape. The collaboration, which represents a new market segment for Techstep, aims to optimise value chains and tailor solutions for a mutually beneficial product partnership.   "Earlier this year, Techstep launched a refocused commercial strategy, emphasising partner sales as a key channel for standardised and scalable solutions to facilitate broader market penetration and customer reach. This partnership marks a significant step forward in Techstep's growth strategy to become the leading mobile technology company in Europe", says Morten Meier, CEO of Techstep ASA.  The agreement is currently in a planning phase on how to commercialise offerings and services through their channel.     Further information from:  Morten Meier, CEO, Techstep ASA, tel: +47 970 57 717  About Techstep ASA  Techstep is a mobile technology company, enabling organisations to perform smartly, securely, and sustainably by combining mobile devices, software and expertise to meet customers’ business and ESG goals. We are a leading provider of managed mobility services in Europe, serving more than 2 100 customers in Europe with an annual revenue of NOK 1.1 billion in 2023. The company is listed on the Oslo Stock Exchange under the ticker TECH. To learn more, please visit www.techstep.io. 

Everfuel – Q1 2024: Focus on HySynergy 1 completion and execution of realigned strategy

Herning, Denmark, 15 May 2024 – Everfuel A/S today published its first quarter 2024 financial results. Key events Q1 2024: · HySynergy 1 start-up moved to second half 2024 due to failed commissioning tests of certain sub-systems provided by the supplier postponing internal Everfuel and supplier software validation  · LOI with undisclosed industrial offtaker of green hydrogen in Germany · Political agreement in Denmark for financing of the hydrogen pipeline infrastructure · Five trailers in operation, serving the Heinenoord bus station and upcoming bus depots in Germany · Q1 EBITDA of EUR -2.6. million (EUR -5 million Q1 2023) · Cash position of EUR 25.4 million at end of March 2024  · Significant cost reduction in downstream business activities · Current liquidity position expected to fund investment and operation plans well into 2025 · Updated long-term ambition of >2 GW installed capacity, EUR >1 billion revenue by end-2035 with an EBITDA margin of 30-35% Everfuel’s ambition is to make green hydrogen for zero emission industrial activity and mobility commercially available across Europe. Everfuel primarily focus on the development of large-scale green hydrogen production capacities starting in Denmark and providing green hydrogen for industrial and mobility users in Europe. The Company is engaging with partners, customers and authorities across the entire value chain, from production to distribution and fuelling, when executing its long-term strategy for value creation as a leading European green hydrogen company.   On May 8, Everfuel announced a Letter of Intent (LoI) with a large industrial offtaker in Germany for the supply of up to 10,000 tons of green hydrogen per year from 2028. Industrial-scale green hydrogen production, distribution and fuelling networks are required for Europe to meet stated climate targets. Everfuel’s activities support these targets and maintains the ambition of being one of the first green hydrogen companies to reach over EUR 1 billion in revenue from hydrogen sales to industry and mobility customers. “Everfuel continues the implementation of our realigned strategy, prioritising the development of large-scale electrolysers supplying industry and heavy-duty mobility, while at the same time reducing cash burn and adding financial flexibility. Today, we present our updated long-term ambitions as a leading European independent hydrogen producer, enabling hard-to-abate industries to decarbonise, as reflected in the recent LOI signed with a new partner in Germany. Execution of our strategy is supported by the Hy24 JV, which positions us to accelerate the deployment of green hydrogen production to meet strong European demand growth driven by the urgent need for zero-emission energy and transport systems,” said Jacob Krogsgaard, the founder and CEO of Everfuel. Following the strategy realignment, Everfuel has updated the company’s financial model and set new long-term ambitions based on the development of the hydrogen backbone infrastructure in line with agreements announced Danish and German Governments. Everfuel targets to have more than 2 GW of green hydrogen production capacity installed by end-of 2035 based on the execution of three electrolyser projects in Denmark, supporting the above-mentioned revenue target and an expected EBITDA margin of 30-35%. Total investments are forecast to around EUR 2 billion, of which EUR  300 million is expected externally raised equity financing and the remainder being expected cashflow from operations, debt at group and SPV level and various grants. Of the EUR 300 million equity requirement, approximately one-third has already been raised. Everfuel recognises, that as an early mover in a new industry, the Company is breaking new ground and continuously contribute to constructive maturation of technology together with suppliers and stakeholders, exposing the Company to protracted political progress, immature technology, supply chain challenges, cost inflation and scarce resources including access to competence. Key financials Total revenue, representing the sale of hydrogen, projects and other operating income, was EUR 1.2 million in the first quarter of 2024, up from EUR 0.6 million in the same period of 2023. Total revenue included EUR 0.4 million in proceeds from sales of legacy assets related to the downstream business. EBITDA was negative EUR 2.5 million (negative EUR 5.0 million in first quarter 2023). The improvement is driven by high-grading of the downstream project portfolio and optimised downstream operations as well as savings in group cost. Total Group assets at 31 March 2024 were EUR 107.6 million, compared with EUR 111.2 million at year-end 2023. The increase in non-current assets reflects that the construction phase of HySynergy 1 is close to completion. The decrease in current assets reflects that accrued grants have been received and a reduction in in cash and cash equivalents. At period end, the cash position was EUR 25.4 million, compared to EUR 28.6 million at year-end 2023. The decrease reflects investments made during the period. Total equity amounted to EUR 67.5 million (EUR 70.3 million). Changes from year-end reflects the net loss in the period. HySynergy 1 update On 24 April 2024, Everfuel provided an update on the commissioning of the 20 MW HySynergy 1 electrolyser with focus on sub-systems required to start production and delivery of green hydrogen. The main electrolyser facility is ready for start-up, while some sub-systems experience delays following commissioning tests. This is impacting the planned start-up of the HySynergy 1 facility with production now expected to commence in the second half of 2024. Testing, verification and certification is being executed in close cooperation with the electrolyser supplier, Nel, and other sub-suppliers with focus on the following areas; Gas holder rebuild, high-pressure systems, compressors and finalisation of software and automation, documentation and certifications. Everfuel and sub-suppliers have committed highest attention and priority for completing the remaining commissioning steps which are strongly interdependent with certain steps subject to specific time windows for external expertise to undertake testing and verification. As a consequence of the mentioned activities, commissioning of the main compressor, final validation of the high -pressure system and completion of the automation and software system are affected. Outlook Everfuel maintains a high level of activity related to multiple business development projects. For 2024, the completion of the HySynergy 1 commissioning and start of hydrogen deliveries will be the first major milestone. Everfuel continues to progress HySynergy 2 towards FID and are maturing the other large-scale electrolyser projects to be executed as SPVs under the strategic collaboration with Hy24. The JV with Hy24 and the cooperation with ITOCHU and Osaka Gas are part of Everfuel’s strategy to systematically build a strong foundation for capitalisation of large-scale electrolyser projects under development. In 2024, the Company will continue to strengthen this foundation as part the ongoing engagement with existing and potential new strategic partners which support execution of Everfuel’s green hydrogen growth ambitions. The financial results for the first quarter of 2024 reflect that the company is still in the initial stages of commercialising the green hydrogen value chain. HySynergy 1 is expected to have material positive impact on revenue generation when it is in operation. The delayed start-up will impact cash flow from hydrogen sales, however, Everfuel expects to have liquidity to finance the current approved investments well into 2025 before requiring additional equity. Longer-term, the combination of increased green hydrogen production, distribution and end-user deliveries are expected to drive revenue growth and cash generation. For 2024, Everfuel maintains the expectation to report a negative financial result, in the range of EUR 15 to EUR 11 million, with a significant improvement in cash flow compared to 2023. Webcast CEO Jacob Krogsgaard and CFO Jesper Ejlersen will present the company's results today at 09:00 CEST and invite investors, analysts, and media to join the live webcast presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast. Join the results webcast on Teams via the following link: Q1 2024 results presentation     Questions can be submitted through the online webcast during the presentation. A recorded version of the presentation will be made available at www.everfuel.com after the presentation has concluded. For further information, please contact: Jesper Ejlersen, CFO, Everfuel, jej@everfuel.comMads Tirsgaard Mortensen, Investor Relations Director, Everfuel, mm@everfuel.com, +45 7730 4727 About Everfuel | www.everfuel.com Everfuel own and operate green hydrogen infrastructure and partner with industry and vehicle OEMs to connect the entire hydrogen value chain and seamlessly provide hydrogen fuel to enterprise customers under long-term contracts. Green hydrogen is a 100% clean energy carrier made from renewable solar and wind power and key to decarbonising industry and transportation in Europe. We are an ambitious, rapidly growing company, headquartered in Herning, Denmark, and with activities in Denmark, Germany and The Netherlands, and a plan to grow across Europe. Everfuel is listed on Euronext Growth in Oslo under EFUEL. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Key highlights Lundbeck’s revenue increased by 7% CER[1] (+5% DKK) to DKK 5,288 million in the first quarter of 2024, mainly driven by growth in the U.S. and Europe · United States: DKK 2,498 million (+9% CER; +7% DKK) · Europe: DKK 1,248 million (+9% CER; +6% DKK) · International Markets: DKK 1,481 million (+4% CER; -1% DKK) The revenue of Lundbeck’s strategic brands increased by 17% CER (+15% DKK), reaching DKK 3,759 million, representing 71% of total revenue · Brintellix[®]/Trintellix[®]: DKK 1,168 million (+11% CER; +8% DKK) · Rexulti[®]: DKK 1,115 million (+7% CER; +5% DKK) · Abilify Maintena[®]/Asimtufii: DKK 859 million (+10% CER; +9% DKK) · Vyepti[®]: DKK 617 million (+79% CER; +76% DKK) Adjusted EBITDA[2] decreased to DKK 1,746 million (-2% CER; -5% DKK) as a result of a lower adjusted gross margin, following quarterly fluctuations in stock valuation. In addition, the first quarter of 2024 reflects higher R&D costs to support the pipeline in progress and targeted investments in sales and promotion mainly for Rexulti[®] and Vyepti[® ]in the U.S. Adjusted EBITDA margin reached 33.0% equivalent to a decrease of 3.6 percentage points. Adjusted earnings per share (EPS) reached DKK 1.38 (+1%). Excluding the effect from quarterly fluctuations in stock valuation, the underlying growth in the adjusted EBITDA was 6% CER, constituting an adjusted EBITDA margin decrease of 0.6 percentage points. In connection with the corporate release, Lundbeck’s President and CEO, Charl van Zyl said: “I am pleased to present another solid quarter for Lundbeck with a robust operational performance and a 7% revenue growth driven by the continued strong performance of our strategic brands. In line with our Focused Innovator strategy, we are driving forward promising scientific innovations such as our potential first-in-class therapy for migraine prevention, anti-PACAP, and a possible first treatment option targeting the rare neurological condition, Multiple System Atrophy.”  Key figures []DKK million Q1 2024 Q1 2023 Change Change(DKK) (CER)[1]Revenue 5,288 5,044 7% 5%EBITDA 1,746 1,744 4% 0%Adjusted EBITDA 1,746 1,845 (2%) (5%)EPS (DKK) 1.01 0.89 13%Adjusted EPS (DKK) 1.38 1.36 1% Recent events On 30 April 2024, U.S. Food and Drug Administration (FDA) communicated to Lundbeck that Lu AF82422 orphan drug designation request has been granted for treatment of Multiple System Atrophy (MSA). On 9 April 2024, Lundbeck and Otsuka Pharmaceutical Co., Ltd. submitted a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults. The sNDA submission is based on previously disclosed results, including data from the two clinical phase III trials and the clinical phase II trial. All three trials investigated the treatment of PTSD in adults treated with brexpiprazole in combination with sertraline versus sertraline plus placebo. On 27 March 2024, Lundbeck and Otsuka Pharmaceutical Europe Ltd. announced that the European Commission (EC) has approved Abilify Maintena[®] 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole. The EC decision applies to all European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. On 15 March 2024, Lundbeck announced the advancement of the clinical development of Lu AG09222 for migraine prevention with the initiation of PROCEED, a randomized, double-blind, phase IIb, dose-finding trial to assess efficacy and safety of multiple subcutaneously administered doses. The PROCEED trial builds on the positive results of the HOPE phase IIa Proof-of-Concept trial demonstrating efficacy of intravenously administered Lu AG09222 in migraine prevention. On 5 March 2024, Lundbeck announced clinical data from the AMULET phase II, double-blind, randomized trial of Lu AF82422 in MSA at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024). Based on the encouraging AMULET trial outcomes, Lundbeck plans to initiate a phase III study, following further dialogue with health authorities. Lundbeck announced key leadership changes on 23 February 2024. Michala Fischer-Hansen joined as Executive Vice President and Head of Europe & International Markets. Additionally, Tine Østergaard Hansen and Dianne Hol were appointed Senior Vice President of Corporate Communication & Public Affairs and Executive Vice President of People & Organization, respectively. Furthermore, on 13 May 2024, Lundbeck announced the appointment of Maria Alfaiate as Executive Vice President Commercial and Corporate Strategy. Financial guidance 2024 maintained On 7 February 2024, Lundbeck communicated the financial guidance for 2024 focusing on revenue performance and adjusted EBITDA at CER. The revenue growth is expected to be 7% to 10% at CER when compared to revenue of the prior year excluding the effect from hedging. The adjusted EBITDA growth is expected to be 10% to 16% at CER when compared to adjusted EBITDA of the prior year excluding effects from hedging. Further details are available in section 2.7 Outlook. [1] Change at CER (Constant Exchange Rates) does not include effects from hedging. [2] EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization. Adjusted EBITDA is defined as EBITDA adjusted by certain items, for details see section 4 Notes, note 3 Adjusted EBITDA.

Photocure ASA: Results for the first quarter of 2024

“Photocure delivered positive results in the first quarter of 2024 with Hexvix/Cysview revenue growth of 10% year-over-year and EBITDA of NOK 7.9 million. Both our North American and European business segments had positive contributions in the quarter as we continue to grow revenues and contain expenses,“ says Dan Schneider, President & Chief Executive Officer of Photocure. Photocure reported total group revenues of NOK 118.0 million in the first quarter of 2024 (NOK 106.2 million) and EBITDA* of NOK 7.9 million (NOK -1.2 million), driven by a combination of unit volume and price increases and a benefit from foreign exchange. Hexvix[®]/Cysview[®] revenues ended at NOK 116.8 million in the quarter (Q1 2023: NOK 105.9 million). EBIT was NOK 0.7 million (NOK -7.7 million) and the cash balance at the end of the period was NOK 258.3 million. At the end of Q1 2024, the installed base of rigid BLC systems in the U.S. was 364, up 14% since Q1 2023. This includes 6 mobile towers owned by ForTec Medical. In the U.S., 27 flexible BLC towers remain active. “ForTec has decided to pursue a mobile BLC strategy, expanding on a pilot program that began in 2021. In addition to the 6 Saphira™ towers that it currently owns, ForTec intends to expand its portfolio of equipment and launch a mobile BLC program throughout the U.S. later this year. A national roll-out by ForTec’s sales force would significantly increase the number of field-based account managers selling BLC with Cysview, and would also open the market to hospitals that currently do not have access to BLC equipment, particularly those in ForTec’s vast customer network,“  Schneider adds. Photocure reiterates its business and financial guidance for 2024: The company anticipates new and upgraded Saphira™ blue light tower installations in the U.S. in the range of 40 to 70, consolidated product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding business development expenses. “Our first quarter results underscore that 2024 is off to a strong start as we remain focused on maximizing the growth and profitability of our Hexvix/Cysview franchise. We expect momentum to continue with the strong Saphira placements in the U.S., increasing penetration in Europe leveraging the recent image quality upgrades, the anticipated commercial expansion of Fortec’s mobile tower strategy, and building upon the growing awareness of the benefits of blue light cystoscopy in light of the many new bladder cancer treatments coming to the market,” Schneider says, and concludes: “Additionally, there are several initiatives and events that have potential to create a step change in the future growth of our business including potential reclassification of BLC equipment in the U.S., which is anticipated to open the market to multiple tower manufacturers, our plan to reintroduce a new flexible BLC solution globally through a partnership, and the anticipated market approvals of Asieris’s candidates; Cevira and Hexvix in China. Given the many initiatives and activities in progress, we believe that 2024 is setting up to be an exciting year for the Company.” Please find the full financial report and presentation enclosed. EBITDA* and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the first quarter 2024 financial report on page 23. The quarterly report and presentation will be published at 08:00 CEST and will be publicly available at www.photocure.com. Dan Schneider, CEO and Erik Dahl, CFO, will host a live webcast at 14:00 CEST. The presentation will be held in English and questions can be submitted throughout the event. The streaming event is available through https://channel.royalcast.com/landingpage/hegnarmedia/20240515_13/ The presentation is scheduled to conclude at 14:45 CEST. For further information, please contact:  Dan SchneiderPresident and CEOPhotocure ASATel: + 1-609 759-6515Email: ds@photocure.com Erik DahlChief Financial OfficerTel: +47 450 55 000Email: ed@photocure.no David MoskowitzVice President of Investor RelationsTel: +1 202 280 0888Email: david.moskowitz@photocure.com Media and IR enquiries:Geir BjørloCorporate Communications (Norway)Tel: +47 91540000Email: geir.bjorlo@corpcom.no About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Tolv Hillestad, Group Controller, Photocure ASA, on 15 May 2024 at 08:00 CEST.

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On May 13, 2024, BlackRock's holding in Metso’s shares fell below the 5 percent threshold and amounted to 40,869,435 shares or 4.93 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 904,576 shares, which corresponds to 0.10 percent of the total amount of Metso’s shares. On May 13, 2024, BlackRock's total position amounted to 41,774,011 or 5.03 percent of Metso’s shares and votes. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through financial instruments in % (7.A + and (total of 7.B) 7.B) voting rights (total of 7.A)Resulting 4.93% 0.10% 5.03%situation on thedate onwhich thresholdwas crossed orreachedPosition of 5.02% 0.07% 5.10%previousnotification A: Shares and votingrightsClass/type of Number of % ofshares shares and shares and voting voting rights rightsISIN code Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA 9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)FI0009014575 40,869,435 4.93%SUBTOTAL A 40,869,435 4.93%B: FinancialInstruments accordingto SMA 9:6aType of financial Expiration Exercise/ Physical or Number % of sharesinstrument date Conversion cash of and voting Period settlement shares rights and voting rightsAmerican Depositary N/A N/A Physical 9,005 0.00%Receipt(US5926721094)Securities Lent N/A N/A Physical 895,571 0.10% SUBTOTAL B 904,576 0.10% Metso Corporation  Distribution:  Nasdaq Helsinki Ltd Main media www.metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

Stora Enso raises its guidance for the full year 2024 adjusted EBIT (Inside information)

Stora Enso estimates that the previous full year 2024 adjusted EBIT guidance will be exceeded, thanks to successful implementation of profit improvement actions and more favourable market conditions. The Company has therefore revised its full year 2024 adjusted EBIT guidance to be significantly higher (+50% and above) than the full year 2023 of EUR 342 million. The previous guidance for the full year 2024 was the adjusted EBIT to be higher (more than +15%, but less than +50%) than full year 2023.In the outlook comment in its Q1 2024 report, published on 25 April, Stora Enso stated that it anticipates a gradual recovery in market conditions in 2024, with increased demand for consumer board, higher pulp demand and prices. These market trends are continuing with improved volume and pricing. The Group’s profit improvement actions are becoming visible in the result development. Consequently, Stora Enso has revised its internal forecasts for the full year 2024 to a higher level than previously estimated.The outlook has improved due to increasing orderbooks and volumes for consumer board, as well as improved pricing outlook for the containerboard and consumer board businesses. Pulp prices continue to increase, and the outlook for the rest of this year is stronger than previously estimated. Challenging market conditions still continue in the Wood Products and Packaging Solutions divisions.Market uncertainties such as a continued high inflationary environment, strikes, demand and price development, and other external disruptions which may impact the Group’s profits, are still expected to persist towards the end of 2024. Stora Enso Oyj will publish its Half-year Report for January–June 2024 on Wednesday 24 July 2024 at approximately 8:30 EEST (7:30 CEST).Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors    STORA ENSO OYJ

FX-rate and dividend amount in SEK for the first redemption procedure 2024 in Betsson AB (publ)

The Annual General Meeting 2024 of Betsson AB (publ) decided on two separate redemption procedures, totaling EUR 0.645 per share, to take place during 2024. The first redemption procedure is taking place between 21 May and 12 June 2024. The redemption amount of EUR 0.3225 per share will be paid to shareholders in SEK. The FX rate for the first redemption procedure has been determined at EUR/SEK: 11.6815 and the payout amount per share is SEK 3.77. Summary of the first redemption procedure: In the redemption procedure, each Betsson share is split into two shares (share split 2:1) of which one will be named redemption share. Trading in the redemption shares can take place between 21 May and 3 June 2024. After this, the redemption shares are automatically redeemed for a redemption amount which requires no action from the shareholders. Payout: Payment to shareholders is made at EUR 0.3225 per redemption share and occasion. The cash payment of the redemption amount will be carried out in SEK. The exchange rate for the first cash payout will be EUR/SEK: 11.6815, which corresponds to an amount per share of SEK 3.77. Timeline: First day of trading in Betsson shares excluding the right to redemption shares:16May 2024 Record date for share split: 17 May 2024 Trading in redemption shares: 21 May through 3 June 2024 Record date for redemption of redemption shares: 7 June 2024 Cash amount paid to holders of redemption shares: 12 June 2024 Trading information: Series A shares: New ISIN-code for Betsson series A share: SE0021626769 Ticker for redemption share of series A: BETS IL A ISIN-code for Betsson redemption share of series A: SE0021626785 Trading venue for Betsson redemption share of series A: Spotlight Stock Market Series B shares: New ISIN-code for Betsson series B share: SE0021626777 Ticker for redemption share of series B: BETS IL B ISIN-code for Betsson redemption share of series B: SE0021626793 Trading venue for Betsson redemption share of series B: Nasdaq Stockholm For more information about the redemption procedure, see Betsson AB's website under the section Investor relations – The share – Dividend information.For further information, please contact: Roland Glasfors, Vice President Communications & Investor Relationsir@betssonab.comAbout Betsson ABBetsson AB (publ) is a holding company that invests in and manages fast-growing companies within online gaming. The Company is one of the largest in online gaming in Europe and has the ambition to outgrow the market, organically and through acquisitions. This should be done in a profitable and sustainable manner, and with local adaptations. Betsson AB is listed on Nasdaq Stockholm Large Cap (BETS-B).

Nel ASA: The potential new fueling company will be named Cavendish Hydrogen

The purpose of the spin-off is to create two independent pure-play companies aiming to become market leaders in their respective fields. Furthermore, Nel is pleased to announce that the following have been elected as members of the board of directors of Cavendish Hydrogen  – Jon André Løkke (Chair)  – Mimi K. Berdal (Board Member)  – Vibeke Strømme (Board Member)  – Allan Bødskov Andersen (Board Member)  – Kim Søgård Kristensen (Board Member) Robert Borin will act as CEO, and Marcus Halland will act as CFO of Cavendish Hydrogen. Nel has also completed an internal reorganization whereby Nel’s assets, rights, and liabilities related to the Fueling division and shares in the relevant Fueling subsidiaries have been transferred from Nel to Cavendish Hydrogen. Subject to Nel’s decision to complete the spin-off and pursue the separate listing of Cavendish Hydrogen, the shares in Cavendish Hydrogen are intended to be distributed to the shareholders of Nel as dividend in kind. The decision to spin off and separately list Cavendish Hydrogen has not yet been concluded, and no assurances can be given that it will be completed. However, if such a decision is made, the company plans to conduct the spin-off by the end of the second quarter of 2024. If completed, the shares of Nel (comprising its Electrolyser division) will remain listed on the OSE under the ticker "NEL". Carnegie AS is acting as global coordinator, and Arctic Securities AS and Fearnley Securities AS as joint lead managers (together the “Managers”) to Nel and Cavendish Hydrogen, and Wikborg Rein Advokatfirma AS is acting as Nel and Cavendish Hydrogen's legal counsel. Advokatfirmaet Thommessen AS is acting as legal counsel to the Managers. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. ENDS For additional information, please contact: Kjell Christian Bjørnsen, CFO, +47 917 02 097 Lars Nermoen, Head of Communications, +47 902 40 153 About Nel ASA | www.nelhydrogen.com Nel has a history tracing back to 1927 and is today a leading pure play hydrogen technology company with a global presence. The company specializes in electrolyser technology for production of renewable hydrogen, and hydrogen fueling equipment for road-going vehicles. Nel's product offerings are key enablers for a green hydrogen economy, making it possible to decarbonize various industries such as transportation, refining, steel, and ammonia. Forward-looking statements: This announcement contains certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

TORM plc capital increase in connection with exercise of Restricted Share Units as part of TORM’s incentive program

TORM plc has increased its share capital by 48,985 A-shares (corresponding to a nominal value of USD 489.85) as a result of the exercise of a corresponding number of Restricted Share Units. All new shares are subscribed for in cash. 571 shares are subscribed for at DKK 0.08 per A-share and 48,414 shares are subscribed for at DKK 180.8 per A-share. Transfer restrictions may apply in certain jurisdictions outside Denmark, including applicable US securities laws. The capital increase is carried out without any pre-emption rights for existing shareholders or others. The new shares (i) are ordinary shares without any special rights and are negotiable instruments, (ii) give right to dividends and other rights in relation to TORM as of the date of issuance and (iii) are expected to be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible. After the capital increase, TORM’s share capital amounts to USD 944,483.17 divided into 94,448,315 A-shares of USD 0.01 each, one B-share of USD 0.01 and one C-share of USD 0.01. A total of 94,448,315 votes are attached to the A-shares. The B-share and the C-share have specific voting rights. Further, the Board of Directors has as part of a long-term incentive program decided to grant certain employees (“Participants”) adjustment RSUs following exercise of 28,356 original RSUs granted in 2021 and 2022 to reflect the payment of dividend since the relevant grant date. The Participants will be granted a total of 954 RSUs in the form of restricted stock options. These adjustment RSUs will not be subject to further dividend adjustment and will have to be exercised within the same exercise window as they were issued. They will have a strike price of one US cent. In addition, the Board of Directors has as part of a long-term incentive program decided to grant Executive Director Jacob Meldgaard adjustment RSUs following exercise of 170,134 original RSUs granted in 2021 and 2022 to reflect the payment of dividend since the relevant grant date. Executive Director Jacob Meldgaard will be granted a total of 5,563 RSUs in the form of restricted stock options. Contact Christopher Everard, General Manager Tel.: +44 (0) 7920 494 853 About TORM TORM is one of the world’s leading carriers of refined oil products. TORM operates a fleet of approximately 90 product tanker vessels with a strong commitment to safety. environmental responsibility and customer service. TORM was founded in 1889 and conducts business worldwide. TORM’s shares are listed on Nasdaq in Copenhagen and on Nasdaq in New York (ticker: TRMD A and TRMD. ISIN: GB00BZ3CNK81). For further information. please visit www.torm.com. Safe harbor statements as to the future Matters discussed in this release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. Words such as, but not limited to, “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “targets,” “projects,” “forecasts,” “potential,” “continue,” “possible,” “likely,” “may,” “could,” “should” and similar expressions or phrases may identify forward-looking statements. The forward-looking statements in this release are based upon various assumptions, many of which are, in turn, based upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, the Company cannot guarantee that it will achieve or accomplish these expectations, beliefs, or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, our future operating or financial results; changes in governmental rules and regulations or actions taken by regulatory authorities; the central bank policies intended to combat overall inflation and rising interest rates and foreign exchange rates; inflationary pressure; increased cost of capital or limited access to funding due to EU Taxonomy or relevant territorial taxonomy regulations; the length and severity of epidemics and pandemics and their impact on the demand for seaborne transportation of petroleum products; general domestic and international political conditions or events, including “trade wars”, and the conflict between Russia and Ukraine, the developments in the Middle East, including the conflicts in Israel and the Gaza Strip, and the conflict regarding the Houthi attacks in the Red Sea; changes in economic and competitive conditions affecting our business, including market fluctuations in charter rates and charterers’ abilities to perform under existing time charters; changes in the supply and demand for vessels comparable to ours and the number of newbuildings under construction; the highly cyclical nature of the industry that we operate in; the loss of a large customer or significant business relationship; changes in worldwide oil production and consumption and storage; risks associated with any future vessel construction; our expectations regarding the availability of vessel acquisitions and our ability to complete acquisition transactions planned; availability of skilled crew members other employees and the related labor costs; work stoppages or other labor disruptions by our employees or the employees of other companies in related industries; the impact of increasing scrutiny and changing expectations from investors, lenders and other market participants with respect to our ESG policies; Foreign Corrupt Practices Act of 1977 or other applicable regulations relating to bribery; effects of new products and new technology in our industry, including the potential for technological innovation to reduce the value of our vessels and charter income derived therefrom; new environmental regulations and restrictions, whether at a global level stipulated by the International Maritime Organization, and/or imposed by regional or national authorities such as the European Union or individual countries; the impact of an interruption in or failure of our information technology and communications systems, including the impact of cyber-attacks, upon our ability to operate; potential conflicts of interest involving members of our board of directors and senior management; the failure of counterparties to fully perform their contracts with us; changes in credit risk with respect to our counterparties on contracts; our dependence on key personnel and our ability to attract, retain and motivate key employees; adequacy of insurance coverage; our ability to obtain indemnities from customers; changes in laws, treaties or regulations; our incorporation under the laws of England and Wales and the different rights to relief that may be available compared to other countries, including the United States; government requisition of our vessels during a period of war or emergency; the arrest of our vessels by maritime claimants; any further changes in U.S. trade policy that could trigger retaliatory actions by the affected countries; potential disruption of shipping routes due to accidents, climate-related incidents, environmental factors, political events, public health threats, acts by terrorists or acts of piracy on ocean-going vessels; the impact of adverse weather and natural disasters; damage to storage and receiving facilities; potential liability from future litigation and potential costs due to environmental damage and vessel collisions; and the length and number of off-hire periods and dependence on third-party managers. In the light of these risks and uncertainties, undue reliance should not be placed on forward-looking statements contained in this release because they are statements about events that are not certain to occur as described or at all. These forward-looking statements are not guarantees of our future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements. Except to the extent required by applicable law or regulation, the Company undertakes no obligation to release publicly any revisions or updates to these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Please see TORM’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of certain of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

Dolphin Drilling AS – Update on Blackford Dolphin

(Oslo, 15 May 2024) Dolphin Drilling AS (Dolphin Drilling, OSE:DDRIL) refers to the 10 May 2024 announcement regarding the termination of the drilling contract with General Hydrocarbons Limited (GHL), and the request for arbitration to pursue the recovery of sums remaining due by GHL. The termination of the contract is disputed by GHL, which also made an application to the Nigerian courts for an interim injunction seeking to maintain status quo, pending the appointment of an arbitrator. GHL is portraited in Nigerian media to have been granted a permanent restraining order for the rig, which is inaccurate. This has been brought to the court’s attention, whereupon the court has directed GHL’s counsel to take steps to prevent any such further pre-emptive or prejudicial communications from being instigated by GHL, with counsel also undertaking to do so. The company wishes to clarify that no new decision has been made by the Nigerian court in relation to restraining of the Blackford Dolphin. The situation is that the court has today appointed a mutually acceptable sole arbitrator and will hear arguments on 20 May 2024 on the discharge of the status quo orders earlier granted. The company will continue to update the market on any material developments in the arbitration and court processes as they occur. For further information, please contact: Ingolf Gillesdal, Corporate Finance and Investor Relations, tel: +47 920 45 320 Stephen Cox, CFO, tel: +44 7800 612 130

Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm

Data presentations will include an efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) in primary immunoglobulin A nephropathy (IgAN) as well as a real-world analysis of the challenges associated with the use of systemic glucocorticoids (SGC) in IgAN. “We are delighted to participate in ERA and look forward to engaging with the leaders in the renal space,” said Richard Philipson, Chief Medical Officer at Calliditas. “We are especially excited to be in Stockholm, where Calliditas is headquartered and where we developed the first treatment specifically designed for IgA nephropathy, to present analyses that highlight the continued opportunity for our treatment to address the significant unmet need in this rare disease.” The presentation and symposium details are below. Following the meeting, they will be available on the Presentations and Publications page  on Calliditas’ corporate website. Presentation Details: Title: “Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan” Oral Poster Presentation: 501129 Date and Time: May 25 3:15-4:30 CET Location: Focused Oral Room 3 Title: “Real-world challenges associated with the use of systemic glucocorticoids in a US IgAN cohort” Poster Number: 2533 Date and Time: May 26 8:54-9:06 CET Location: A5 Symposium Details: Title: Clinical Markers in IgA Nephropathy: Is All Proteinuria the Same? Date and Time: Saturday, May 25: 10:15 - 11:15 am (Room A2+A3) Moderator: Prof. Jonathan Barratt, Renal Medicine at Leicester University. Panel: Shikha Wadhwani, MD, MS, FASN Northwestern University; Richard Lafayette, M.D., F.A.C.P., Stanford Healthcare For more information, visit the ERA 2024 website here . Indication TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Important Safety Information Contraindications: TARPEYO is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of TARPEYO. Serious hypersensitivity reactions, including anaphylaxis, have occurred with other budesonide formulations. Warnings and Precautions Hypercorticism and adrenal axis suppression: When corticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may occur. Corticosteroids can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where patients are subject to surgery or other stress situations, supplementation with a systemic corticosteroid is recommended. When discontinuing therapy or switching between corticosteroids, monitor for signs of adrenal axis suppression. Patients with moderate to severe hepatic impairment (Child-Pugh Class B and C respectively) could be at an increased risk of hypercorticism and adrenal axis suppression due to an increased systemic exposure to oral budesonide. Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for increased signs and/or symptoms of hypercorticism in patients with moderate hepatic impairment (Child-Pugh Class B). Risks of immunosuppression: Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients or patients on immunosuppressive doses of corticosteroids. Avoid corticosteroid therapy in patients with active or quiescent tuberculosis infection; untreated fungal, bacterial, systemic viral, or parasitic infections, or ocular herpes simplex. Avoid exposure to active, easily transmitted infections (e.g., chicken pox, measles). Corticosteroid therapy may decrease the immune response to some vaccines. Other corticosteroid effects: TARPEYO is a systemically available corticosteroid and is expected to cause related adverse reactions. Monitor patients with hypertension, prediabetes, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts, or with a family history of diabetes or glaucoma, or with any other condition where corticosteroids may have unwanted effects. Adverse reactions: In clinical studies, the most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients, and ≥2% higher than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight increased (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increased (6%). Drug interactions: Budesonide is a substrate for CYP3A4. Avoid use with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine. Avoid ingestion of grapefruit juice with TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can increase the systemic exposure to budesonide. Use in specific populations Pregnancy: The available data from published case series, epidemiological studies, and reviews with oral budesonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with IgAN. Infants exposed to in-utero corticosteroids, including budesonide, are at risk for hypoadrenalism. Please see Full Prescribing Information . About TARPEYO TARPEYO is an oral 4mg delayed release formulation of budesonide, designed to remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer’s patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1) causing IgA nephropathy. About Primary Immunoglobulin A Nephropathy Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger’s Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose deficient IgA1 is recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney. This deposition in the kidney can lead to progressive kidney damage and potentially a clinical course resulting in end- stage renal disease. IgAN most often develops between late teens and late 30s.

ExpreS2ion to present in spring investor events

By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website . 16 May 2024 | First quarter 2024 financial results webcast, hosted by HC Andersen Capital10:00 CET | VirtualExpreS2ion CEO Bent Frandsen and CFO Keith Alexander will present the 2024 first quarter results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital Events website . 30 May 2024 | The BioStock Global Forum11:00 CET | Lund, SwedenBent Frandsen will present at The Global Forum 2024, an event focusing on international expansion, partnerships, and capital attraction. For those interested in participating, registration is available on the BioStock event website . 4 June 2024 | HC Andersen Capital Life Science SeminarVirtualCEO Bent Frandsen will be participating in the H.C. Andersen Life Science Seminar on June 4[th], which presents a good opportunity for us to engage with the life science community and share our latest developments. Bent will be providing an update on ExpreS2ion, discussing our unique platform and giving insights into our pipeline. More information and registration can be found on the H.C. Andersen Capital Events website . Certified AdviserSvensk Kapitalmarknadsgranskning AB

Eevia Health Plc exhibiting at an essential Nutraceutical tradeshow

This week, Eevia is at the annual Vitafoods Nutraceuticals tradeshow in Geneva. Vitafoods is a key event in the global nutraceutical industry, attracting over 16,000 industry experts from over 130 countries every year. The show has a leading position in the industry by maintaining a strong focus and high quality, including an extensive seminar program adjacent to the tradeshow floor. «Eevia has received strong customer feedback on our recent research article comparing the company’s proprietary Fenoprolic® with the market-leading pine bark extract. The article showed a nearly identical bioactivity profile. The new data resulted in several serious discussions with prospects for the use of Fenoprolic® as an active ingredient in their supplements, and we expect some very nice starting orders at the show or soon after that,” states Anna-Maija Vanhatalo, Eevia’s sales manager for Europe. For further information, please contact: Stein Ulve, CEO, Eevia Health Plc Email: stein.ulve@eeviahealth.com Telephone: +358400 22 5967 INFORMATION ABOUT EEVIA HEALTH PLC Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forestsnearor above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brandsglobally. These global brands utilize the ingredients in their consumer product formulas. Eevia Health is a manufacturer of 100% organically certified plant extracts.Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such asbilberry,lingonberry,chaga-mushroom, and pine bark, are wild-harvested sustainably. Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA . To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn@EeviaHealth.

BoMill announces outcome of the wholly guaranteed Rights Issue

CEO's comment “We are excited by the support and confidence of our existing and new shareholders. Our BoMill InSight™ solution gets strong interest from the industry and it is fantastic to see, through the outcome of this Rights issue, that our owners are convinced, as we are, of its commercial potential.", comments Andreas Jeppsson, CEO. Breakdown of the subscription The ordinary general meeting of BoMill resolved April 12,2024 on the wholly guaranteed Rights Issue of a total number of a maximum of 27 917 442 shares with a maximum issue amount of approximately SEK 16.8 million before transaction costs. The outcome of the Rights Issue shows that 26 962 308 shares were subscribed for with the support of subscription rights, corresponding to approximately 96.6 percent of the Rights Issue, and 8 289 101 shares were subscribed for without the support of subscription rights, corresponding to approximately 29.7 percent of the Rights Issue. In total, 35 251 409 shares were subscribed for with and without support of subscription rights with an issue amount of SEK 21 150 845.40, corresponding to approximately 126.3 percent of the Rights Issue. Thus, the Rights Issue was oversubscribed, and no guarantee undertaking will be utilized. BoMill will receive a total issue amount of approximately SEK 16.8 million before transaction costs through the Rights Issue. Notice of allotment and payment Allotment of shares will be carried out in accordance with the principles set out in the EU growth prospectus published by the Company on April 23, 2024 (the "Prospectus"). Notice of allotment to subscribers that have subscribed for shares without subscription rights is expected to be sent by e-mail on May 17, 2024 as a contract note. Allotted shares shall be paid for in cash in accordance with the instructions on the contract note. Only those who have been allotted shares will be notified. Subscribers who have subscribed for shares through a nominee will receive notification of allotment and payment instructions in accordance with the respective nominee's routines. Change in the number of shares, share capital, and dilution The Rights Issue implies that the number of shares in the Company will increase by 27 917 442 shares to a total of 120 975 582 shares. After registration of the Rights Issue with the Swedish Companies Registration Office (Sw. Bolagsverket), the Company's share capital will increase by SEK 307 091.862 to a total of SEK 1 330 731.402. The dilution from the Rights Issue amounts to approximately 23.1 percent of the total number of shares and votes in the Company. Trading in BTA Trading in paid subscribed shares ("BTA") that are received through subscription in the Rights Issue will take place on Nasdaq First North Growth Market until the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place during week 23, 2024. Thereafter will the BTAs, approximately a week later, be converted to ordinary shares. Issuer agent Nordic Issuing acts as the issuer agent in connection with the Rights Issue.

Does Your House Need Rewiring? - Look Out For These Warning Signs

Electricity is something that most homeowners take for granted, and most don't give much thought to it. However, in some cases, your home may need to be rewired for safety and efficiency. If your home does need to be rewired, you could be putting your home and your family at risk if you don't do something about it. Faulty or old wiring can be dangerous and may lead to shocks or fires. [A person using a drill Description automatically generated] Rewiring your house can be quite a large job, but it’s definitely worth it when you consider the dangers that may come. Homeowners should be aware of the potential warning signs that your home’s wiring needs to be replaced. Below, electrical expert Eric Davis at MyJobQuote.co.uk  has created a list of the four most common signs that your home needs to be rewired. Eric also provides some information on the benefits of rewiring a house, what the job involves, and how long it takes to complete. The Signs That Your House May Need Rewiring Discoloured or Scorched Switches or Sockets If you notice any black or brown marks on your electrical sockets, this may be a result of some tiny fires caused by loose connections within the sockets. These loose connections can create small arcs of electricity and fire. Even if there are no scorch marks present, this doesn't necessarily mean that there are no problems present. The arching may occur within the wiring inside the walls and, therefore, won't be visible from the outside. However, if you notice any discolouration on your sockets or switches, don't ignore them. This may be an issue that becomes a lot more dangerous if it isn't dealt with properly and timely. Fuses blowing Repeatedly If the fuses in your home blow repeatedly, regularly, and randomly, this could signify that your house needs to be rewired. However, it may also be that you have a faulty appliance that is causing these issues. However, if you notice that fuses keep blowing and you can’t identify an appliance that may be causing the issue, it would be worth getting a professional electrician to come out and check out the wiring in your home. If Your House Is Old If you live in a property that is more than 30 years old and you’re not sure if it’s been rewired in the past, you should get a professional electrician to come out and complete an inspection on your home’s wiring to make sure everything is working as it should. Similarly, if you have any old-looking sockets, switches, or fuse boxes, you should get these checked out too. Persistent Smell of Burning If you haven't burned your food recently and there's a burning smell you can't seem to get rid of, this may be a sign that your house needs to be rewired. If there is a burning smell in your home and you can't quite locate the source, turn your home's electrical power off at the circuit and then contact an electrician right away. Electrical burning smells tend to replicate the smell of fish. If you notice anything that doesn't smell quite right, it's not worth taking the risk. Contact a professional electrician who will come and complete an inspection of your home's wiring to ensure there are no issues. What Does a House Rewiring Job Involve? A house rewiring is a process where a single electrician or a team of electricians will remove all of the electrical wiring in every single room of your home. All of the sockets, lights and switches will also be removed so that they can be replaced with new, modern alternatives. The work can be quite disruptive as the walls will need to be cut into so that new wiring can be hidden, and your floorboards will also need to be removed so that cables can be fed between them. With this in mind, it's best to carry out a rewiring job when you're planning on redecorating or remodelling your house anyway. Rewiring your house makes your electrics much safer and more reliable. It also gives you the opportunity to add more sockets, lights, and switches as needed. You can even completely move the location of your sockets and switches, allowing you to customise the room to exactly how you want it. What Are the Benefits of Rewiring a House? Safety The main reason why you should get your home rewired is to improve the safety of your electrics. This ensures that you and your family remain as safe as possible, and it prevents the possibility of any electrical problems. Cheaper Insurance Most home insurers will provide cheaper insurance to those who have a more reliable electrical system. If you get your electrics regularly services too, then you can expect a great deal of savings on your home insurance. Insurers recognise how dangerous old and faulty electrical systems can be. Add Value to the Home Upgrading the electrical system in your home can increase your home’s value by hundreds and even thousands of pounds once it’s been signed off by an inspector. Old electrical systems can instantly put people off wanting to purchase your home whereas new systems are very desirable to potential buyers. Save Money on Bills Old and faulty wirings can often be the cause of high electricity bills. When you have your home rewired, all of the old and faulty wiring will be removed and replaced with modern, efficient wiring. You’ll notice your electricity bills will reduce significantly as soon as your new wiring system is in place. Prevent Malfunctions Faulty wiring around your home can affect your appliances – even some of your bigger appliances. As a homeowner, you will want to ensure that all of your appliances are in good working order. If you leave faulty wiring, it can start to cause disruptions and could end up costing you a lot of money in appliance repairs or replacements. Reduce Chances of Power Cut Power cuts are never fun. Electrical surges are usually the main cause of a power cut, and they can occur for a number of reasons. One of those reasons is faulty electrical wiring. When you have a home rewiring, you eliminate the chances of this occurring because you'll upgrade all of your old and faulty wires for new wiring. How Long Does It Take to Rewire a House? One of the most important things to think about when taking on any kind of house job is the time that the work is going to take. The timescales of your electrical work will have an effect on the cost of labour as the longer the job takes, the longer you will be required to pay for the contractor. There are a number of factors that can affect how long it will take to complete a house rewiring. The main factors include the size of the house, the level of rewiring needed, and whether the electrician runs into any complications during the installation process. On average, you can expect the work to take around 5-9 days to complete. This involves all the steps including removing the old wiring system, replacing the wires, and replacing all of the sockets, light fittings, and switches. Final Thoughts If you're noticing any of the warning signs mentioned above,it's crucial to consult a qualified electrician.They can assess your home's electrical system and recommend the best course of action,whether it's repairs,upgrades,or a full rewire. Remember,ignoring electrical problems can be dangerous and costly.Taking proactive steps now will ensure your home is safe and your electrical system functions efficiently for years to come.So don't hesitate to call in a professional – your peace of mind and safety are worth the investment. MyJobQuote is one of the UK's top trades matching sites that helps individuals find a reputable tradesperson in their local area. MyJobQuote  also has a wide range of experts with extensive knowledge in interior design, cleaning, gardening, property, construction and more. MyJobQuote's experts have been featured in over 700 publications, including Woman and Home, The Times, House Beautiful, BBC News and more. For more information on MyJobQuote's release or comment requests, please email the PR team atContentTeam@ICMEnterprises.co.uk. Copyright © 2024. MyJobQuote.co.uk. All reserved.

Announcement from 24SevenOffice Group AB's annual general meeting

Adoption of the income statement and the balance sheet The AGM resolved to adopt the income statement and the balance sheet in 24SevenOffice and the consolidated income statement and the consolidated balance sheet. Allocation of profit The AGM resolved not to pay any dividend to the shareholders and that the previously accrued profits, including the share premium account and year result would be carried forward. Discharge from liability The board of directors and the CEO were discharged from liability for the financial year 2023. Election of the board of directors, auditor and remuneration The AGM resolved that the board of directors shall consist of four directors. The AGM further resolved that the number of auditors shall be one registered audit firm. It was further resolved that the remuneration to the board of directors is to be SEK 130,000 in total and shall be paid to the board of directors in the following amounts: · SEK 65,000 to the board member Staffan Herbst; and · SEK 65,000 to the board member Karin Lindberg. No other remuneration shall be paid to the board. Remuneration to the auditor shall be paid in accordance with approved invoice. It was resolved to re-elect Staffan Herbst, Karin Lindberg and Staale Risa as directors and to elect Linda Sannesmoen as new director for the period until the end of the next annual general meeting. It was further resolved to elect Staale Risa as chairman of the board for the period until the end of the next annual general meeting, thus Staale Risa leaves his assignment as vice chairman of the board. It is noted that Karl Anders Grønland has declined re-election. It was further resolved to re-elect the registered audit firm RSM Stockholm AB as the Company's auditor for a period up until the end of the next annual general meeting. RSM Stockholm AB has announced that Anneli Richardson will be the main responsible auditor. Establishment of a nomination committee and adoption of principles for the nomination committee The AGM resolved, in accordance with the shareholder R-Venture AS's proposal, to establish a nomination committee and adopt principles for the nomination committee. The following persons were elected as members of the nomination committee until the end of the next annual general meeting: · Stian Rustad, representing the shareholder ICT Group AS; · Hans Arne Flåto, representing the shareholder R-Venture AS; and · Snorre Realfsen, representing the shareholder Ebiz AS. It was resolved that Stian Rustad was appointed as chairman of the nomination committee. The AGM further resolved to adopt the principles for the nomination committee, to apply until further notice. Amendment of the articles of association The AGM resolved, in accordance with the board of directors' proposal, to introduce a new provision in the Company's articles of association which enables the board to resolve that a general meeting may be held digitally. Authorization for the board to resolve on issuances The AGM resolved, in accordance with the board of directors' proposal, to authorize the board of directors during the period up until the next annual general meeting to, on one or more occasions, resolve to issue shares, convertibles and/or warrants, with the right to convert and subscribe for shares, respectively, with or without preferential rights for the shareholders, in the amount not exceeding ten (10) percent of the total number of shares in the Company at the time when the authorization is used the first time, to be paid in cash, in kind and/or by way of set-off. The purpose for the board to resolve on issuances with deviation from the shareholders preferential rights in accordance with the above is primarily for the purpose to raise new capital to increase flexibility of the Company and possibility to advance the development of the Company's business or in connection with acquisitions and to diversify the shareholder base. Issuances of new shares, convertibles or warrants under the authorization shall be made on customary terms and conditions based on current market conditions. If the board of directors finds it suitable in order to enable delivery of shares in connection with a share issuance as set out above it may be made at a subscription price corresponding to the shares quota value. For further details regarding the resolutions set out above, refer to the notice and the annual report available at the Company's website, www.24sevenoffice.com.

A Guide to Using Colour Theory In Your Home For Wellness

Colour is a powerful tool that can influence our mood, energy levels, and even our physical well-being. By understanding colour theory and its psychological effects, you can create a home environment that promotes relaxation, focus, or whatever feeling you desire. [A person and person painting a wall Description automatically generated] Interior design expert Ryan McDonough at MyJobQuote.co.uk  has created this guide on how to use colour theory in your home for wellness. Read on for a deep dive into how to harness the power of colour for a happier, healthier you. Understanding Colour Psychology Colours can be broadly categorised into three categories - warm, cool, and neutral, each with distinct psychological effects that can be leveraged to create specific moods and atmospheres in your home: Warm Colours (Red, Orange, Yellow) These vibrant hues evoke feelings of energy, enthusiasm, and warmth. They can stimulate the appetite, increase heart rate, and encourage conversation. Imagine a kitchen bathed in sunny yellow – it can make you feel more energetic and ready to tackle meal prep. However, too much warmth can be overwhelming. Red, for example, can trigger feelings of urgency or anger if used excessively. Think of a room painted entirely in a bright red shade  – it might feel too intense to relax in after a long day. Cool Colours (Blue, Green, Purple) Associated with calmness, peace, and relaxation. Cool colours have a soothing effect on the nervous system, slowing the heart rate and lowering blood pressure. Blue tones can create a sense of trust and security, perfect for a home office where you need to feel focused and grounded. Greens connect us to nature and promote feelings of growth and renewal. Imagine a serene bathroom painted  in a calming seafoam green – it can feel like a mini escape to a tranquil spa. Darker cool colours like navy blue can feel sophisticated and luxurious, while lighter shades of blue and green inspire tranquillity. Think of a master bedroom painted in a soft lavender – it can lull you into a restful sleep. Neutrals (White, Grey, Beige) These versatile colours provide a sense of balance and can be used effectively anywhere in your home. They act as a canvas for bolder colours or create a minimalist, zen feel. White can make a space feel open and airy, perfect for a small living room. Gray offers a touch of sophistication, ideal for a modern kitchen. Beige creates a warm and inviting atmosphere, well-suited for a cosy family room. Neutrals can also ground bolder accent colours, preventing them from feeling overwhelming. Putting Colour Theory to Work By understanding the psychology of colour, you can create specific moods and atmospheres in different rooms of your home: Living Room This is the heart of your home, a space for socialising, relaxing, or entertaining. Consider calming blues or greens for relaxation or pops of yellow or orange for stimulating conversation and activity. If your living room doesn't get a lot of natural light, opt for lighter and warmer colours like pale yellow or beige to create a sense of spaciousness and energy. You can then add pops of colour with throw pillows or artwork in bolder hues. Bedroom Your bedroom should be a haven of tranquillity, designed to promote restful sleep. Opt for serene blues, lavenders, or light greens to create a calming and peaceful environment. Deeper, cooler tones like a smoky blue or a rich teal can also be effective but avoid overly dark colours like charcoal grey that can feel heavy or gloomy. Experiment with different shades and tints within a cool colour palette to find what works best for you. Bathroom Similar to the bedroom, your bathroom should be a space for relaxation and self-care. Create a spa-like retreat with calming greens, blues, or greys. Lighter colours like pale aqua or sky blue can make a small bathroom feel more spacious, while richer jewel tones like emerald green or sapphire blue can add a touch of luxury. Consider incorporating natural elements like wood or stone accents to complement the calming colour scheme. Home Office Here, the goal is to create a space that promotes focus and productivity. Light blues can boost focus and concentration, while yellows can spark creativity and mental agility. Consider incorporating pops of brighter colours like red or orange for short bursts of energy, but use them sparingly to avoid creating an overwhelming environment. A red accent wall might be too stimulating for long periods of focused work, but a red lampshade or a piece of modern art in red could add a welcome touch of energy. Factors to Consider While colour psychology offers valuable insights, it's important to consider other factors when creating your colour palette: Shades and Tints Don't underestimate the power of variations within a colour family. A soft blue is far more calming than a bright royal blue. Experiment with shades (darker tones) and tints (lighter tones) to achieve the desired mood. For example, a pale lavender can create a feeling of serenity in a bedroom, while a bolder shade of purple can add a touch of drama to a living room. Complimentary Colours Colours opposite each other on the colour wheel, like red and green or blue and orange, can create a vibrant and stimulating energy. Use them in moderation or as accents to add visual interest without overwhelming the space. A throw pillow in a complementary colour can add a pop of personality without being overpowering. Personal Preference While colour psychology offers great insights, your own experiences and associations with colours matter most. Choose colours that make you feel happy and relaxed. Perhaps you have fond childhood memories associated with a particular shade of green, or a certain colour brings back a calming beach vacation. Let your personal connection to colour guide your choices. Consider Lighting The way light interacts with colour can dramatically affect the overall feel of a space. Natural light tends to soften colours, while artificial light can make them appear brighter or cooler. Pay attention to how natural and artificial light affects your chosen colours throughout the day. Trust Your Gut In the end, the most important factor is how the colours make you feel. If a particular colour feels calming and inviting, go for it! Don't be afraid of breaking the rules a little bit and creating a colour scheme that is uniquely you. After all, your home is a reflection of your personality, and your colour choices should reflect that. Ultimately, colour theory is a guide, not a rigid set of rules. The most important aspect is to create a space that feels comfortable and inviting to you. Trust your gut instinct, experiment with different colour combinations, and have fun with the process! After all, there's nothing quite like the feeling of walking into a room that makes you smile, a space that reflects your inner peace and inspires you to live your best life. Final Thoughts By following these tips and embracing the power of colour theory, you can transform your home into a haven of wellness and create a space that promotes relaxation, focus, and overall well-being. Remember, your home is your sanctuary, a place to unwind, recharge, and be yourself. The colours you choose should reflect that. Don't be afraid to experiment, to let your creativity flow, and to create a space that feels uniquely you. RYAN MCDONOUGH:  Ryanis an interior design expert with 15 years worth of experience in the field.Ryanworks closely with clients to make their visions come to life at a price that suits their budget.Ryanalso provides expert interior design commentsfor MyJobQuote and has been featured in a range of top publications. MyJobQuote is one of the UK's top trades matching sites that helps individuals find a reputable tradesperson in their local area. MyJobQuote  also has a wide range of experts with extensive knowledge in interior design, cleaning, gardening, property, construction and more. MyJobQuote's experts have been featured in over 700 publications, including Woman and Home, The Times, House Beautiful, BBC News and more. For more information on MyJobQuote's release or comment requests, please email the PR team atContentTeam@ICMEnterprises.co.uk. Copyright © 2024. MyJobQuote.co.uk. All reserved.

DanCann Pharma A/S: Updated time plan and material terms of the rights issue

As set out in press release published on 30 March 2023, the Company will carry out a rights issue (i.e. an issue of new shares with pre-emptive rights for the Company’s existing shareholders). Below is set out the material terms of the rights issue. Material terms of the rights issue The Offer The Offer is comprised by a maximum of 1,832,907,879 new shares of the Company, each of a nominal value of DKK 0.01, and in the event of full subscription of the rights issue, the share capital of the Company will be increased by nominally DKK 18,329,078.79 (equivalent to a total issue of 1,832,907,879 new shares).The rights issue of new shares is directed at investors in Denmark and Sweden. The new shares are offered to the public with pre-emptive subscription rights for existing shareholders. The New Shares issued in the rights issue will carry the same rights as the existing shares of the Company. Allocation of pre-emptive rightsEach holder of existing shares registered with Euronext Securities on 10 June 2024 (the record date) at 5:59 pm CET as a shareholder in the Company will be allocated eleven (11) pre-emptive rights for each existing share. For each (1) pre-emptive right, the holder is entitled to subscribe for 1 new share at a subscription price of DKK 0.01 per new share. Subscription PriceThe subscription price is DKK 0.01 per new share. Subscription PeriodThe subscription period of the new shares will commence on 11 June 2024 at 9:00 am CET and will close on 24 June 2024 at 5:00 pm CET. Guarantee commitmentsDanCann Pharma has received guarantee commitments (i.e. commitments to subscribe for shares) of approximately DKK 8.959 million, which corresponds to approx. 48.88% of the issue volume, of which (i) approximately DKK 5.5 million consists of bottom-up guarantee commitments, and (ii) approximately DKK 3.459 million consists of top-down guarantee commitments. Any subscription of shares by those having provided bottom-up guarantee commitments will be by way of cash subscription of new shares. Any subscription of shares by those having provided top-down guarantee commitments will be carried out by way of conversion of existing debt in the Company.In addition to the above, an existing lender of the Company (New Growth Opportunities 2) has committed to convert an outstanding loan of an amount of DKK 3,350,000 to shares of the Company at a price of DKK 0.01, provided that the Company receives cash subscriptions of DKK 5.5 million in the rights issue (which the Company has secured) but otherwise regardless of the outcome of the rights issue. Publication of the outcome of the rights issueThe result of the rights issue will be communicated in a company announcement expected to be published through Spotlight no later than three trading days after the expiry of the subscription period, and the result of the rights issue is therefore expected to be announced on 27 June 2024. The proceeds and issue costsIn the event of full subscription of the rights issue, the Company’s gross proceeds will be DKK 18,329,078.79. In the event of full subscription of the rights issue, the Company’s costs in connection with the Offer are estimated at approx. DKK 4.7 million, and hence the net proceeds will in this case be approx. DKK 13.629 million. In the event that the rights issue will not be subscribed for by any other than those having provided guarantee commitments, the costs of the Company in connection with the rights issue are estimated at DKK 3.3 million. Share capital of the CompanyOn the 17 April 2024, an extraordinary general meeting of the Company resolved to complete a reduction of the Company's share capital from 6,248,549.5875 to 1,666,279.89 by transfer of the amount to a special reserve fund (in Danish: henlæggelse til særlig reserve) by way of reduction of the nominal value per share of the Company. The capital reduction will be completed on 16 May 2024 following a 4-week notice period (“proklama”) Therefore, as of the date on which the offer memorandum is published, the nominal value of the Company’s registered share capital is DKK 1,666,279.89 divided into 166,627,989 shares, each having a nominal value of DKK 0.01. The Company’s share capital is not divided into share classes, and all shares carry the same rights. All shares are issued in accordance with the provisions of the Danish Companies Act, fully paid-up and freely transferable. Each Existing Share carries 1 vote.In the event of full subscription of the rights issue, the share capital of the Company will increase from nominally DKK 1,666,279.89 to 19,995,358.68, and the number of outstanding shares will increase from 166,627,989 shares  to 1,999,535,868 shares. Dilution Upon issue of the new shares, existing shareholders’ share of ownership of the Company may be reduced. In the event of full subscription of the rights issue, if an existing shareholder refrains from exercising its pre-emptive rights allocated to the existing shareholder in connection with the rights issue, the existing shareholder's ownership will be diluted by approximately 91.67%. If the existing shareholders elect to partly exercise the pre-emptive rights allocated to them, the rate of dilution will be between 0 to 91.67% depending on the exercise (in the event of full subscription of the rights issue). If the existing shareholders exercise their pre-emptive rights in full, they will not be diluted. Full terms and conditions for the rights issue as well as other information about the Company will be included in the offer memorandum regarding the rights Issue that the Company is expected to publish on 24 May 2024. Updated time plan for the rights issue Date of publication of the memorandum 24 May 2024Last trading day with existing shares 6 June 2024including pre-emptive rightsFirst trading day with existing shares 7 June 2024excluding pre-emptive rightsRecord date for allocation of pre 10 June 2024-emptive rightsPeriod of trading with Pre-Emptive 7 June 2024 at 9:00 am CET -Rights 20 June 2024 at 5:00 pm CETPeriod of trading with temporary Shares 7 June 2024 - 8 July 2024Subscription Period 11 June at 9:00 am CET - 24 June at 5:00 pm CETAnnouncement of the outcome of rights 27 June 2024issueDate of registration of the capital 3 July 2024increase with the Danish BusinessAuthorityFirst day of trading with new shares 9 July 2024 Please note that adjustments may be made to the time plan. Advisors EK Equity AB is acting as a financial advisor to DanCann Pharma.Mazanti-Andersen is acting as the legal adviser of DanCann Pharma. About DanCann Pharma A/S DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm. For more information, visit: www.dancann.com For further information, please contact: Jeppe Krog Rasmussen, CEO E-mail: jkr@dancann.com Forward-looking-statement: Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

ABS Makes Significant Investments for the Digital Future of the Industry

(HOUSTON) Complete with over 100 user requested features, streamlined vessel applications and enhanced user experience, ABS has launched Eagle Unified[TM], an industry-leading structural design verification software tool. The launch is the latest in a series of investments in major new engineering capabilities which have been delivered by ABS in recent weeks.   Eagle Unified[TM] is a single tool that can support multiple vessel types, with containership and LNGC capabilities available at launch, and with future releases to incorporate LPG, ammonia, hydrogen and CO2 carriers. “It’s a new and dynamic technological world, and ABS is investing in our software and services to make sure we remain on the cutting edge, supporting our clients to take advantage of the capabilities and efficiencies that these advanced new ways of working can deliver,” said Christopher J. Wiernicki, ABS Chairman and CEO. “These products are designed to facilitate innovation, modernize processes and drive forward the frontiers of safety, delivering a best-in-class experience for our clients.” Eagle Unified[TM] follows hard on the heels of the launch of an enhanced ABS MyFreedom™ Client Portal that is built on a product life cycle management backbone and features a more modern, responsive, comprehensive and streamlined interface for engineering clients. Built for the future, the upgraded platform is designed to manage data-heavy, next-generation engineering tools such as 3D plans, integrated computer-aided engineering models, simulations, streaming data and other digital assets – ultimately, a fully scalable digital twin system for compliance and safety. The system also features seamless integration of client files for easier collaboration, faster search capabilities, automated reports and comprehensive life-cycle management from concept to operation. In January 2024, ABS delivered the ABS Rule Enhancements program, which enables the safe and rapid adoption of innovation and technology impacting next generation vessel designs and equipment. ABS Marine Vessel Rules now include an extensive set of newly developed functional requirements and a standardized risk-based methodology which provides a path for class approval. “The improvements we are introducing are dramatic and will enhance collaboration and communication across the industry while streamlining our work processes. ABS is pioneering a new way of working that capitalizes on the latest advances in digital technology that supports the design and development of the next generation of vessels, right at a time when the industry needs Class to support the many new vessel designs that are rapidly emerging,” said Patrick Ryan, ABS Senior Vice President and Chief Technology Officer. Further information about Eagle Unified[TM], Rule Enhancements or the ABS MyFreedom Client Portal is available on Eagle.org .

Bulletin from Sivers Semiconductors AB (publ)’s Annual General Meeting on 15 May 2024

Adoption of the annual report and the auditor’s report  The Annual General Meeting resolved to approve the profit and loss statement and the balance sheet regarding the parent Company and the Group, appropriation of the profit in accordance with the Board of Directors proposal and not to distribute any dividends for the financial year 2023, as well as to discharge the CEO and Board members from liability. Election of Board members As members of the Board of Directors it was resolved to re-elect Tomas Duffy, Erik Fällström, Todd Thomson and Bami Bastani, and to elect Karin Thurberg and Keith Halsey as a new member of the Board of Directors. Beth Topolosky has declined re-election. Bami Bastani was re-elected as the Chairman of the Board of Directors and Tomas Duffy was re-elected as the Vice Chairman of the Board of Directors. It was resolved that the total remuneration for the Board of Directors shall amount to SEK 2,700,000 of which SEK 1,050,000 shall be paid to the Chairman of the Board of Directors, SEK 600,000 to the Vice Chairman of the Board of Directors and SEK 350,000 to each of the other members of the Board of Directors except for Todd Thomson who has waived Board remuneration. In addition, remuneration of SEK 100,000 shall be paid annually to the Chairman of the Audit Committee and SEK 50,000 shall be paid annually to the other members. For work on the Investment Committee, remuneration of SEK 60,000 shall be paid annually to the Chairman and SEK 30,000 shall be paid annually to the other members. For work on the Remuneration Committee, remuneration of SEK 50,000 shall be paid annually to the Chairman and SEK 25,000 shall be paid annually to the other members. Election of auditor The Annual General Meeting resolved to re-elect Deloitte AB as auditor with authorised public accountant Alexandros Kouvatsos as auditor-in-charge. The fees shall be paid in accordance with approved invoices. Resolution on approval of allotment of stock options The Annual General Meeting 2023 resolved on an incentive program (“P08”) comprising stock options for the Group’s employees (the “Stock Options”). The Chairman of the Board of Directors, also being Executive Chairman of Sivers Semiconductors Inc., has been allotted 400,000 Stock Options in accordance with the resolution of the Annual General Meeting 2023 on P08. In addition, the Chairman has been allotted 50,000 Stock Options, conditional upon the Annual General Meetings subsequent approval. As a result thereof, the Annual General Meeting resolved to approve the allotment of 50,000 additional stock options to the Chairman within the framework of P08. The performance conditions shall not apply to the Stock Options. Resolution on authorisation for the Board of Directors to resolve on issues of shares and/or convertible bonds The Annual General Meeting resolved to authorise the Board of Directors to, on one or several occasions during the period until the next Annual General Meeting, with or without deviation from the shareholders’ preferential rights, resolve on share issues and/or issues of convertible bonds that involve the issue of or conversion to a maximum of 26,100,000 ordinary shares, corresponding to a dilution of approximately 10.0 percent of the share capital and the voting rights, based on the current number of shares in the Company. Payment for subscribed shares and/or convertible bonds shall be made in cash, in kind or by way of set-off. The purpose of the authorisation and the reason for the deviation from the shareholders’ preferential rights, is to give the Board of Directors flexibility in the work to secure that the Company in a time-efficient and appropriate way can achieve capital for financing of the operation and to enable continued expansion both organically as well as through acquisitions, alternatively to increase the number of shareholders with one or several owners of strategical importance for the Company. The issuance of shares and/or convertible bonds under this authorisation shall be made at a subscription price according to the prevailing market conditions at the time of the issuance of the shares and/or convertible bonds. For more information, please contact:Anders StormCEO, Sivers Semiconductors AB (publ)Email: anders.storm@sivers-semiconductors.comTel: +46 (0)70 262 63 90 Sivers Semiconductors AB (publ) is a leader in SATCOM, 5G, 6G, Photonics and Silicon Photonics that drivers innovation in global communications and sensor technology. Our business units, Photonics and Wireless, supply cutting-edge, integrated chips and modules critical for high-performance gigabit wireless and optical networks. Catering to a broad spectrum of industries from telecommunication to aerospace, we fulfill the increasing demand for computational speed and AI application performance, replacing electric with optical connections for a more sustainable world.Our wireless solutions are forging paths in advanced SATCOM/5G/6G systems, while our photonics expertise is revolutionizing custom semiconductor photonic devices for optical networks and optical sensing, making us a trusted partner to Fortune 100 companies as well as emerging unicorns. With innovation at our core, Sivers Semiconductors is committed to delivering bespoke, high-performance solutions for a better-connected and safer world. The company is listed on Nasdaq Stockholm under SIVE. The head office is located in Kista, Sweden. Discover our passion for perfection at www.sivers-semiconductors.com.

Interim report January – March 2024 Sweco AB (publ)

January–March 2024 · Net sales increased to SEK 7,720 million (7,140) · EBITA amounted to SEK 793 million (849), margin 10.3 per cent (11.9) · EBITA increased 16 per cent year-on-year after adjustment for the significant negative calendar effect in the quarter · EBIT amounted to SEK 778 million (839), margin 10.1 per cent (11.7) · Net debt amounted to SEK 3,118 million (2,916) · Net debt/EBITDA amounted to 1.1x (1.1) · Profit after tax decreased to SEK 558 million (625), corresponding to SEK 1.55 per share (1.75) Comments from President and CEO Åsa Bergman: "A positive start to the year Sweco delivered a good first quarter. Net sales increased 8 per cent and EBITA improved 16 per cent, adjusted for the significant negative calendar effect from Easter. The improvement was mainly driven by continued positive momentum in pricing as well as strong demand within the green transition in energy, transportation, industry and urban development. We are also seeing increasing demand in growth segments such as pharma, defence and data centres. Sweco’s strong market position is reflected in a growing order backlog.  Overall, the demand for Sweco’s services was favourable in most segments, although demand in residential and commercial buildings, as well as traditional industry, remained weaker. A solid quarter with operational improvements Net sales increased to SEK 7,720 million (7,140), with an organic growth of 4 per cent, adjusted for calendar. Nominally, EBITA decreased to SEK 793 million (849) and the margin to 10.3 per cent (11.9), both driven by the large negative calendar effect. Adjusted for calendar effects, EBITA increased 16 per cent or SEK 139 million.  The EBITA improvement was mainly driven by higher average fees, a growing number of employees and contribution from acquisitions, while higher personnel expenses and a lower billing ratio impacted negatively.  Six out of eight business areas reported positive organic growth and EBITA improvements. Sweco Belgium, Denmark and Sweden all reported good organic growth and EBITA improvements, with double-digit margins. Germany and Central Europe continued to improve operational performance with strong organic growth and an increasing EBITA and margin. Finland improved its margin in the quarter, partly driven by the previously communicated redundancy program, and is also taking further improvement actions. The Netherlands reported higher EBITA levels. The weaker performance in Norway is explained by the calendar effect from the early Easter holiday. The repositioning of Sweco’s UK business is progressing and the performance improved significantly compared to the previous quarter. As part of the turnaround, the UK is making further personnel reductions in the first half of 2024. Projects and acquisitions  The projects won in the first quarter highlight Sweco’s multi-disciplinary role in the green transition. In the Netherlands, Sweco won a SEK 1,100 million contract to support energy operator Gasunie in the development of new energy infrastructure for the transportation of hydrogen, carbon dioxide, renewable gas and heat. In Belgium, Sweco has been commissioned to design an open-access rail terminal in Zeebrugge’s back port and in Germany, Sweco will support the City of Bremen in the expansion of its public transportation. In Norway, we will provide architectural design to support a sustainable uplift of an urban area in Oslo.  In early January we closed the first acquisition this year – Econsultancy. With their team of 200 environmental experts, we are strengthening Sweco’s position and offering, both in the Netherlands and across Europe within ecological and environmental services. Priorities going forward Our focus ahead is clear: to capture growth opportunities in the market and deliver continued profitable growth, with improved margins. This requires investments in attractive segments in combination with firm measures to optimise our offering and efficiency. The actions we are taking in the UK, the adjustments of staffing in Finland, Norway and Sweden, and the ongoing organisational review to streamline our operations in all business areas are designed to drive efficiency. A lean, efficient and client-centric organisation has always been and will continue to be our recipe for success." Information meeting Sweco's President and CEO Åsa Bergman and CFO Olof Stålnacke will present the report in a webcast and teleconference on May 16 at 09:00 CET.  · Webcast registration: Click here  · Conference call registration: Click here 

Bioretec Ltd’s business review January–March 2024: Controlled launch in the U.S. progresses

This announcement summarizes Bioretec Ltd’s business review for January–March 2024. The complete business review is attached to this release as a PDF file and available on the company’s website at https://bioretec.com/investors/investors-in-english/releases. January–March 2024 in brief · Net sales amounted to EUR 682 thousand (1–3/2023: EUR 1,071 thousand). · The sales margin was EUR 478 (718) thousand, or 70.1% (67.0%) of net sales. The sales margin of 2024 includes other income of EUR 60 thousand accrued relating to the Business Finland grant. When excluding the grant effect, the sales margin for the current reporting period is EUR 418 thousand, or 61.3%. The main reason for the lower sales margin percentage has been the planned production shutdown due to the ramp-up of new production capacity. · EBITDA was EUR -1,112 (-491) thousand. EBITDA was EUR -1,112 (- 491) thousand. It was burdened by increased personnel costs due to headcount growth and additional fixed costs relating to U.S. commercialization and R&D projects. · The result for the reporting period amounted to EUR -1,097 (-557) thousand. This business review is unaudited. This is Bioretec’s first business review for the first quarter, and comparison period figures have not been published earlier. Key figures +-------------------------------------------+--------+--------+------+---------+|EUR 1,000 unless otherwise noted |1–3/2024|1–3/2023|Change|1–12/2023|+-------------------------------------------+--------+--------+------+---------+|Net sales |682 |1,071 |-36.4%|3,906 |+-------------------------------------------+--------+--------+------+---------+|Sales margin |478 |718 |-33.4%|2,810 |+-------------------------------------------+--------+--------+------+---------+|Sales margin, % of net sales |70.1% |67.0% | |71.9% |+-------------------------------------------+--------+--------+------+---------+|EBITDA |-1,112 |-491 |126.6%|-2,833 |+-------------------------------------------+--------+--------+------+---------+|EBIT |-1,139 |-543 |109.6%|-3,034 |+-------------------------------------------+--------+--------+------+---------+|Profit/-loss for the period (+/-) |-1,097 |-557 |97.0% |-3,789 |+-------------------------------------------+--------+--------+------+---------+|R&D spend on total costs, % |25.9% |24.8% | |25.6% |+-------------------------------------------+--------+--------+------+---------+|Equity ratio, % |74.3% |44.3% | |77.3% |+-------------------------------------------+--------+--------+------+---------+|Cash and cash equivalents at end of period |5,981 |587 |919.3%|6,910 |+-------------------------------------------+--------+--------+------+---------+|Number of personnel at end of period |39 |28 |39.3% |37 |+-------------------------------------------+--------+--------+------+---------+ Key events during the reporting period · European market authorization application for the RemeOsTM trauma screw proceeded to expert panel evaluation. The approval is estimated to be granted during the second quarter of 2024. · Bioretec was granted an FDA Breakthrough Device Designation status for its RemeOs™ Spinal Interbody Cage. · Bioretec’s RemeOs™ biodegradable magnesium alloy composition was granted a patent by the U.S. Patent Office. Timo Lehtonen, CEO of Bioretec Ltd: ” In the first quarter of 2024, our focus was on the production and distribution of our Activa product line as the U.S. market continued to utilize inventories of the RemeOs™ trauma screw from Q4 2023. Net sales this quarter were distinctly marked by contributions from different regions: Europe accounted for 27% of net sales (19% in the comparison period), the U.S. increased from 16% to 24%, while the rest of the world decreased from 65% to 49%. The controlled launch of RemeOs™ trauma screw continued, with an evolving number of surgeries performed utilizing this innovative product. We are actively collecting and analyzing follow-up data from the surgeries to assess the efficacy of the fracture healing treated with our screws. In preparation for continued US sales growth, the need to enhance our production capabilities resulted in a planned production shutdown In January, which is reflected in our profitability numbers for this period. This operational enhancement included the commissioning, qualification, and ramp-up of the new CNC machine dedicated to our trauma screw line and increasing our resource allocation to operational personnel and projects, setting the stage for increased output in subsequent quarters. Looking ahead, we are waiting to receive market authorization for the RemeOs™ trauma screws in Europe during the second quarter of 2024. Our development efforts are ongoing for the next RemeOs™ pipeline products, supported by the new RemeOs™ magnesium alloy patent and the new FDA Breakthrough Device Designation received for the Spinal Interbody Cage. Additionally, we are advancing our plans for the next U.S. market authorization and initiating the RemeOs™ DrillPin clinical study in Austria, waiting for the ethical committee and other regulatory approvals to start the First-in-Human study. As we have concentrated on enhancing our production capabilities in the first quarter, we project that our net sales will be more heavily concentrated in the second half of the year. This strategic growth platform building has been required to expand production capabilities to serve the future anticipated market demand and product portfolio expansions. We are grateful to our investors, customers, and personnel for their continued confidence and support. Your trust encourages our commitment to innovation and excellence as we navigate these exciting opportunities and challenges.” Financial reporting in 2024 In 2024, Bioretec will publish the following financial reports: · half-year report for January–June 2024 on Thursday 15 August 2024 · business review for January–September 2024 on Thursday 14 November 2024 The releases will be available online at Bioretec Ltd’s website at https://bioretec.com/investors/investors-in-english/reports-and-presentations. Tampere, 16 May 2024 Board of Directors Bioretec Ltd Further inquiries: Timo LehtonenJohanna Salko CEOCFO +358 50 433 8493+358 40 754 8172 timo.lehtonen@bioretec.comjohanna.salko@bioretec.com Certified advisor: Nordic Certified Adviser AB, p. +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.  Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark is expected to be received during the second quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment. Better healing – Better life. www.bioretec.com Appendix Bioretec Ltd’s business review January–March 2024 (pdf)

Interim report first quarter 2024: Tobii becomes top-three in automotive interior sensing

First quarter 2024 · Net sales decreased by 4% to SEK 161 million (168), with an organic growth of -9%. · Gross margin was 74% (73%). · Operating result (EBIT) was SEK -75 million (-53). · Profit/loss for the quarter amounted to SEK -89 million (-57). · Earnings per share amounted to SEK -0.84 (-0.55). · Free cash flow amounted to SEK -126 million (46). Significant events during and after the quarter · The acquisition of FotoNation Ltd, including AutoSense, was completed on January 31. · New financial targets were announced on February 1. In 2026, Tobii targets a positive free cash flow and an EBIT margin of around 10% for the full-year, followed by an EBIT margin target of around 20% for 2028. · A rights issue was successfully completed on April 3, and Tobii received total net proceeds of SEK 267 million after the end of the quarter. · A new DMS design win for commercial vehicles was secured on April 9.  CEO Anand Srivatsa comments: “This quarter we completed the acquisition of FotoNation/Autosense establishing our position as a top three player in the automotive interior sensing market. Subsequently, we saw increased interest from automotive OEMs and tier 1 suppliers to engage more deeply with Tobii. I am also pleased that we announced a new design win for driver monitoring system in early April, bringing our total to nine automotive OEM customers so far. In the first week of April, we successfully executed a rights issue, raising SEK 267 million net to finance operational expenses for the acquisition, including the Autosense business segment in 2024 and 2025. Excluding the acquisition, net sales organically decreased by 9 percent in the quarter, mainly attributed to sustained weaker demand for Products & Solutions in Asia. Integrations, on the other hand, delivered a solid performance, achieving organic net sales growth of 23 percent. We continued to see a surge in interest for XR engagements from a broader spectrum of customers. Our new Autosense segment's net sales over the two-month period following the acquisition aligned with our quarterly expectations. We have already realized some synergies through the integration of our expanded Autosense business but anticipate more significant cost synergies as this process continues into the second half of 2024. The integration process is a key focus and is proceeding according to plan. We intend to deliver the market's most comprehensive interior sensing offering, strengthening our competitive outlook and securing new design wins that demonstrate our leading position. We are firm in our commitment to enhancing profitability, leveraging our technology investments, and improving efficiency across all three segments. Building upon the cost-saving initiatives implemented in the fourth quarter of 2024, we will continue to further reduce our expenses throughout the year by optimizing our product portfolio and realizing synergies gained from integrating Autosense. Tobii exits this quarter as a more robust organization as we drive toward profitability, and I am confident that we will deliver a significant improvement in the EBIT result for the full-year 2024.”Q1 presentation today at 9.00 a.m. CET Tobii’s CEO Anand Srivatsa and CFO Magdalena Rodell Andersson will present and comment on the report. After the presentation, there will be time for questions. The presentation will be held in English. Link to the webcast   Please make sure you are connected to the webcast by logging in and registering a few minutes before the presentation begins. It will be possible to ask questions via the chat function or verbally, by selecting participation options. The presentation material will be available at Tobii’s website . The interim report and a recording of the webcast will be available on the same page.For more information, please contact: Carolina Strömlid, Head of Investor Relations, Tobii AB, phone: +46 (0)70 880 71 73, email: carolina.stromlid@tobii.com This information is information that Tobii AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on May 16, 2024, at 7:30 a.m. CEST. About Tobii Tobii is the global leader in eye tracking and pioneer of attention computing. We are on a mission to improve the world with technology that understands human attention and intent. Creating tech for a better future, our technologies and solutions apply to areas such as behavioral studies and research, healthcare, education and training, gaming, extended reality, automotive, and many more. Tobii's eye tracking is used by thousands of enterprises, universities, and research institutes around the globe. Headquartered in Sweden, Tobii is listed on Nasdaq Stockholm (TOBII). For more information: www.tobii.com.

Interim report January - March 2024

January 1 - March 31, 2024 · Net sales increased 9 percent to SEK 4,320 M (3,973). Organic growth was 11 percent. Net sales were positively impacted by 1 percent due to currency effects. · EBIT amounted to SEK 146 M (200) and the EBIT margin to 3.3 percent (4.9). EBIT was negatively impacted by items affecting comparability of SEK -54 M (-) during the quarter. · Adjusted EBIT amounted to SEK 224 M (227) and the adjusted EBIT margin to 5.1 percent (5.6). · Earnings per share, before and after dilution, decreased to SEK 0.92 (1.43). · Cash flow from operating activities increased to SEK 285 M (27). · Net debt in relation to EBITDA decreased to 2.7 (3.3) at the end of the period. · MEKO's Nomination Committee proposes Dominick Zarcone as new Chairman of the Board. · MEKO grows in car glass offering - initiates two-year partnership with ALD Automotive/LeasePlan in Sweden. Significant events after the end of the period: · MEKO optimizes operations in Denmark to strengthen its position. · MEKO automates and streamlines the central warehouse in Finland. · MEKO strengthens its position in Poland through strategic acquisition of Elit Polska. CEO comments: During the year's first quarter, we demonstrated robust growth with stronger cash flow supported by a solid underlying business. In parallel, we are implementing several measures to improve profitability and are now seeing the first effects in the form of lower operating expenses - a concerted effort that is continuing in all of our business areas. Our aim is to be the most comprehensive partner for everyone who repairs, services and maintains cars in northern Europe. We satisfy our customers' needs through a range of well-established brands in eight markets, and I can confirm that the business continued to grow in all markets during the first quarter. The market trend was more favorable in our larger business areas and slightly more challenging in Poland/the Baltics. We can also note that the Easter break with closed branches and workshops fell in March this year, unlike the year-earlier quarter. Despite this calendar effect, net sales increased 9 percent. Strong cash flow and stable adjusted EBITThe favorable sales performance enabled us to strengthen cash flow from operating activities during the quarter. TheSweden/Norway business area performed well, as Sorensen og Balchen in Norway. We could also see a solid underlying trend for the Denmark business area, which is restructuring operations to improve profitability. In Finland, we are taking further measures to achieve the same level of efficiency as in the other business areas and anticipate gradual improvements in 2024, though this has entailed costs. Overall, we reported a stable adjusted EBIT but a lower adjusted EBIT margin year on year. EBIT declined, partly due to planned costs for implementing a new, common business system and an impairment for accounting purposes of the value of our holding in the listed company Omnicar, resulting from the market's revaluation of the company and similar start-up companies. Profitability improvements with positive effectsThese activities are part of a larger plan aimed at improving our profitability. We launched this initiative In November 2023, and have since then implemented measures in all parts of the company. This includes a decision to build a new, automated central warehouse in Norway to raise efficiency and improve service levels for our customers. In addition, we are consolidating our Norwegian distribution network, and in parallel launched a streamlining of operations in Sweden. The restructuring in Denmark involves a new, optimized organization in Denmark to strengthen our logistics and service levels. In Finland, we have decided to automate our central warehouse to raise efficiency, reduce costs and expand our lead as the most accessible partner in the independent auto aftermarket in the country. The first effects of our activities were visible in this quarter. The measures in Sweden made a clear contribution to the profitability improvements in the Sweden/Norway business area. We now expect further improvements as work progresses. Award for our sustainability performanceWe have high ambitions for our sustainability work - MEKO is to be a driving force for increased sustainability across our industry. It is therefore gratifying when our efforts bear fruit. During the quarter, our achievements in sustainability were recognized by EcoVadis, one of the world's leading providers of sustainability ratings. Scoring well-above industry averages across all categories, we are in the top 35 percent of assessed companies. This has inspired us to also continue our focused work in this area. Strategic acquisition in Poland strengthen usContinuously improving our operations is part of our strategy. Equally important is growing through carefully selectedacquisitions. Therefore, I am pleased to announce that on May 10th, we were able to announce that the Polish company Elit Polska is now becoming part of MEKO after reaching an agreement with the seller LKQ Corporation. Elit Polska is a spare parts wholesaler that complements our operations well with its two warehouses, 49 branches, and 485 employees spread across Poland. This makes MEKO the third-largest company in the Polish automotive aftermarket, where we also see opportunities for significant synergies in the future. Pehr OscarsonPresident and CEO This information is such information that MEKO AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above on May 16, 2024 at 07:30 CET. The interim report is published in Swedish and English. The Swedish version is the original version and has been translated into English.

Judges and physicians have very different views about appointing a legal guardian for people with dementia

Dementia often leads to the appointment of a legal guardian for the individual affected, as their legal capacity diminishes as the disease progresses. Conducted in Finland, a recent study explored how physicians and legal experts perceive the association of the need for legal guardianship with the neuropsychiatric and cognitive symptoms of dementia. Cognitive symptoms of dementia include, e.g., memory impairment and language deficits, while neuropsychiatric symptoms include, e.g., impulsivity and sensitivity to stimuli. According to the study, the significance attributed to different symptoms varies greatly when assessing the need for legal guardianship. Significant differences of opinion were found both within and between the professional groups, and similar symptoms may even lead to entirely opposing conclusions, the study found. “The significance attributed to various symptoms is largely based on each professional’s personal views rather than on research evidence. In particular, subjective opinions were prominent in the interview responses of legal experts, which can undermine equality before the law of those who may need legal guardianship,” says Doctoral Researcher Kaisa Näkki of the University of Eastern Finland. According to the study, legal experts regarded memory impairment and dyscalculia as the most evident symptoms necessitating legal guardianship. However, opinions were divided regarding other symptoms. In particular, impulsivity as a neuropsychiatric symptom strongly divided the opinions of legal experts, as some of them regarded impulsivity as an expression of free will rather than as a symptom of progressive neurodegeneration. Physicians, on the other hand, regarded neuropsychiatric symptoms, and especially impulsivity, as the most evident symptom necessitating legal guardianship. Often, neuropsychiatric symptoms were found to necessitate legal guardianship already in the early or mild stages of dementia. Physicians were most consistent in their views of memory impairment being a factor that leads to the need for legal guardianship in the moderate stage of dementia. However, physicians’ perceptions of the significance of other symptoms varied greatly. “Our findings, combined with a lack of previous international research on this topic, indicate that there is an urgent need, both here in Finland and internationally, for a consensus definition of how various symptoms affect legal capacity in dementia. Decisions should not be based on the personal experiences of physicians or judges but on research evidence, which requires systematic data collection. Additionally, there is a need for training for both physicians and legal experts,” says Associate Professor of Clinical Research and Director of Brain Research Unit Eino Solje of the University of Eastern Finland. “Our study is the first to combine the perceptions of both physicians and legal experts on the need for legal guardianship. The fact that both medicine and law are represented in our team creates an interdisciplinary approach that opens up new avenues for research in these fields,” Professor of Law and Ageing Anna Mäki-Petäjä-Leinonen of the University of Eastern Finland says. The findings of the study can be used to improve the consistency of medical and legal assessments, and to ensure equal treatment of those who may need legal guardianship. “This study provides deeper insight into the weaknesses of guardianship assessment. The study is also the first step towards the development of relevant medico-legal criteria as well as towards broader collection of data internationally. Based on international data, it is possible to formulate uniform guidelines on the impact of cognitive and neuropsychiatric symptoms on legal capacity, and on the need for legal guardianship,” Näkki concludes. For further information, please contact: Doctoral Researcher Kaisa Näkki, University of Eastern Finland, Law School, Centre for Law and Welfare, kaisa.nakki@uef.fi, https://uefconnect.uef.fi/en/person/kaisa.nakki/ Professor of Law and Ageing Anna Mäki-Petäjä-Leinonen, University of Eastern Finland, Law School, Centre for Law and Welfare, anna.maki-petaja-leinonen@uef.fi,https://uefconnect.uef.fi/en/person/anna.maki-petaja-leinonen/ Associate Professor of Clinical Research, Director of the UEF Brain Research Unit Eino Solje, University of Eastern Finland, Institute of Clinical Medicine, eino.solje@uef.fi, https://uefconnect.uef.fi/en/person/eino.solje/ Research article: Näkki K, Mäki-Petäjä-Leinonen A, Ervasti K, et al. Diverging medical and legal perceptions of the need for legal guardianship in people with dementia: A qualitative study. Eur J Neurol. 2024;00:e16334https://doi.org/10.1111/ene.16334  10.5.2024

Metacon publishes interim report for Q1 2024

We have successfully secured access to world-leading technology and partners for our efforts to become a leading manufacturer of large-scale, industrial electrolysis plants, comments Christer Wikner, President and CEO. For the full CEO-comment, see the Interim report in its entirety. Quarter 1 January–31 March · Revenues amounted to SEK 8.3 (16.3) million. · Earnings before depreciation and amortization (EBITDA) amounted to SEK -14.5 (-12.7) million. · Operating profit (EBIT) amounted to SEK -17.2 (-15.4) million. · Profit/Loss after financial items amounted to SEK -18.2 (-15.5) million. · Earnings per share amounted to SEK -0,04 (-0.05). Events during and after the quarter · On January 25, 2024, Metacon announces an exclusive license agreement with PERIC for rights to build a "Gigafactory" for the manu-facture of its own electrolysis plants. · On January 25, 2024, the Board of Directors of Metacon announces a rights issue of units of approximately SEK 119 million and announces the terms of the rights issue. · On February 20, 2024, Metacon will announce the final outcome of the rights issue. · On April 10, it is announced that Mattias Jansson has been hired as Chief Financial Officer of Metacon AB (publ) with effect from July 1, 2024, replacing Göran Rasberg who plans to retire. · On May 7, a partnership with Siemens is announced for cooperation in the development of Metacon's technology portfolio and planned factory for the manufacture of large alkaline electrolysers. This information is information that Metacon AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 16 May 2024 at 08:00 CEST. For further information, please contact Christer Wikner, by phone 0707-647389 or e-mail info@metacon.com About  MetaconMetacon AB (publ) develops and manufactures energy systems for the production of fossil-free "green" hydrogen. The products in the Reforming business area are based, among other things, on a patented technology that generates hydrogen through so-called catalytic steam reforming of biogas or other hydrocarbons. The development of Metacon's reforming products is done within the wholly owned subsidiary Metacon S.A in Patras, Greece. The business is focused on catalytic process chemistry and advanced reformers for high-efficiency hydrogen production. Metacon also offers complete electrolysis plants and integrated refueling stations for green hydrogen, a large and globally growing area for the production of green hydrogen. Electrolysis is a process of driving a chemical reaction to split water by adding electricity. If the electricity used is non-fossil, the hydrogen will also be fossil-free and climate-neutral. Green hydrogen can be used in sectors such as transport, basic industry and the real estate sector, with a better environment and climate as a result. www.metacon.com For more information see:www.metacon.com | X: @Metaconab | LinkedIn: www.linkedin.com/company/metaconab

ExpreS2ion announces financial results for the first quarter of 2024

CEO Bent U. Frandsen comments: “We are starting 2024 invigorated by our new strategy with clear objectives, the strong progress of our proprietary pipeline, and a broadly validated platform. The overall conditions for early-stage biotech funding remain challenging and selective. Against this backdrop, we have established our priorities with a focus on advancing the lead proprietary asset, the ES2B-C001 breast cancer program, towards a clinical trial application.” Summary of 2024 first quarter results (January – March 2024) Key income statement figures, SEK ‘000s · Operating income: 1,558 (2,590) · Profit/loss after financial items: -13,839 (-30,282) · Profit/loss for the period: -12,853 (-26,308) Key balance sheet figures, SEK ‘000s · End of period cash balance: 60,203 (71,972) · End of period total assets: 86,145 (103,125) · End of period equity / asset ratio*: 61% (77%) Number of shares · Number of shares at end of the period: 51,404,958 (37,606,796) · Average number of shares: 51,404,958 (37,606,796) · Average number of shares (after dilution): 55,454,958 (39,656,796) Earnings per share, SEK** · Earnings per share for the period based on average number of shares: -0.25 (-0.70) · Diluted earnings per share for the period: -0.23 (-0.66) Figures in parenthesis are the numbers from the same period in 2023.*Equity ratio: Shareholder’s equity divided by total capital.**Earnings per share defined as profit/loss for the period divided with the average number of shares for the period. Webcast presentation of 2024 first quarter year results On 16 May 2024 at 10:00 CET, ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander will present the 2024 first quarter results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital Events website . Significant events during the first quarter · On 8 February 2024, ExpreS2ion announced financial results for the fourth quarter of 2023. · On 21 February 2024, ExpreS2ion announced that AdaptVac ApS (“AdaptVac”) had received 10 million EUR as a result of Bavarian Nordic having completed the clinical Phase III study of the COVID-19 vaccine ABNCoV2. The board of AdaptVac, in line with authority granted through AdaptVac’s articles of association, agreed to resolve on the pay-out of excess capital in AdaptVac to the shareholders of AdaptVac, which are ExpreS2ion (34% share ownership) and NextGen Vaccines Holding ApS (“NextGen”) (66%). ExpreS2ion and NextGen agreed that AdaptVac will retain part of the dividends received to be invested in the Company’s platform technology and pipeline assets. Significant events after the first quarter · On 16 April 2024, ExpreS2ion announced the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. · On 23 April 2024, ExpreS2ion announced that it has been notified by the Board of Directors of its associated company, AdaptVac ApS, of the resolution to pay a dividend of DKK 42.5 million (SEK 66.1 million) to its owners. As a result of ExpreS2ion Biotechnologies ApS holding a 34% stake in AdaptVac ApS, ExpreS2ion received approximately DKK 14.5 million (SEK 22.5 million) after the close of the first quarter. · On 2 May 2024, the Board of Directors of ExpreS2ion Biotech Holding AB had, subject to subsequent approval by the Annual General Meeting to be held on 5 June 2024, resolved on a rights issue of units consisting of shares and warrants of series TO 10 and warrants of series TO 11 ("Units"), with preferential rights for existing shareholders, amounting to approximately SEK 60 million (the "Rights Issue"). The subscription price was set to SEK 1.00 per Unit, corresponding to a subscription price of SEK 1.00 per share. The Company received subscription intentions and guarantee commitments to an approximate amount of SEK 30 million, corresponding to approximately 50 percent of the Rights Issue. Upon full subscription in the Rights Issue, the net proceeds from the Rights Issue will be used for (i) ES2B-C001 clinical phase initiation and progression, (ii) early preclinical development of a cytomegalovirus vaccine candidate, (iii) internal costs related to grant-sponsored projects and (iv) working capital including discovery pipeline and platform development. · On 3 May 2024, the shareholders of ExpreS2ion Biotech Holding AB were given notice to attend the Annual General Meeting to be held on 5 June 2024 at 10.30 (CEST) on Mindpark, Bredgatan 11, Helsingborg, Sweden. The entrance to the meeting and registration will commence at 10.00 (CEST). · On 8 May 2024, ExpreS2ion published the 2023 annual report. Certified AdviserSvensk Kapitalmarknadsgranskning AB

Kenworth showcases its T680 X15N demo truck with Hexagon Agility fuel system

16 May, 2024: Hexagon Agility, the world’s leading provider of (renewable) natural gas (CNG/RNG) fuel systems, announced today its fuel system will be showcased on the Kenworth T680 natural gas truck with the new X15N engine at ACT Expo 2024. Kenworth Truck Company, one of the top three truck OEMs in North America stated in a news release  it will begin production of Kenworth T680 and T880 models specified with the new Cummins X15N natural gas engine in the third quarter of 2024. Customers can select a factory customized truck frame for easy install of Hexagon Agility CNG/RNG fuel systems that can deliver up to a 265-diesel gallon equivalent (DGE). “We are pleased to partner with Hexagon Agility to provide Kenworth customers with a natural-gas engine solution that will reduce emissions in a variety of on-highway and vocational applications,” said Kyle Kimball, Kenworth Director of Marketing. "Over the last two decades, Kenworth has been instrumental in offering clean fuel solutions for heavy-duty truck fleets. Together, we're driving the adoption of economically affordable and environmentally sustainable solutions in trucking," says Eric Bippus, EVP of Sales and Systems, Hexagon Agility. “Our RNG/CNG ProCab (back-of-cab) and ProRail (side-mount) fuel systems are backed by decades of innovation with millions of miles driven by leading fleets that have chosen to partner with us. When combined, ProCab and ProRail enable range of up to 1,300 miles.” Natural gas goes head-to-head with diesel in the heavy-duty sector The Cummins X15N, powered by CNG or RNG, is the industry’s first 15-liter natural gas engine that delivers diesel-like power, range, and performance, making it appealing for short, regional, and long-haul operations. With power ratings up to 500 hp (~370 kW) and torque up to 1850 lb.-ft, (~2500 Nm) the engine allows natural gas to go head-to-head with diesel in the heavy-duty sector. The launch of the Cummins X15N, 15-liter engine is expected to triple the addressable market for heavy-duty natural gas trucks over the next few years*. This is a game-changer for the industry, enabling a powerhouse solution for Class 8 fleets traveling locally and cross country. Kenworth has stated that trucks equipped with the X15N engine will be in serial production in Q3 2024. Kenworth truck at Hexagon Agility booth, ACT Expo 2024 The new Kenworth T680 X15N - equipped with Hexagon Agility’s fuel system will be displayed at the largest clean fuel event in North America, the Advanced Clean Transportation Expo (ACT) in Las Vegas, NV from May 21-23. Join us in booth #3330. For media inquiries, please contact: Jelena Rowe, Director of Marketing and Communications, Hexagon AgilityPhone: +1 310 872-0535Email: jelena.rowe@hexagonagility.com Karen Romer, SVP Communications, Hexagon AgilityPhone: +47 95074950Email: karen.romer@hexagongroup.com About Hexagon Agility Hexagon Agility, a business of Hexagon Composites, is a leading global provider of clean fuel solutions for commercial vehicles and gas transportation. Its product offerings include (renewable) natural gas storage and distribution systems, Type 4 composite natural gas cylinders, and (renewable) natural gas fuel systems. These products transport clean gaseous fuels and enable vehicles to reduce emissions while saving operating costs. Learn more at hexagonagility.com and follow @HexagonAgility on X and LinkedIn. About Kenworth Kenworth Truck Company, founded in 1923, specializes in the design and manufacture of The World’s Best® heavy- and medium-duty trucks. As a leader in the development of advanced diesel powertrains, zero emissions vehicles, connected truck technologies and autonomous driving systems, Kenworth is creating transportation solutions to drive a better world. Kenworth’s Internet home page is at www.kenworth.com. Kenworth is a PACCAR company. *Source: Cummins

Metso launches the first diesel-electric Lokotrack EC range units

Metso’s Lokotrack[®] EC range brings a new diesel-electric power line to the aggregates market. All the process functions of the range are electric, significantly reducing the use of hydraulic oil needed in the crushing operations. All Lokotrack EC range units can be powered with external electricity. In its Lokolaunch event in Tampere, Finland, Metso launched the first two products of the new EC range. Lokotrack LT400J is a 68-ton mobile jaw crusher designed for the primary crushing of hard rock and recycled aggregates. Lokotrack LT350C is a 50-ton mobile cone crusher for secondary and tertiary crushing. To reach high capacity, LT350C is equipped with the new Nordberg[®] HP350e cone crusher, while LT400J counts on the proven Nordberg[®] C120 jaw crusher. Both units can be seamlessly combined with each other as well as with the Lokotrack mobile screens to produce high quality aggregates. “When external electricity is available, the new electric power transmission provides high capacity with minimized operational cost and CO2 emissions. When not available, the onboard diesel gensets allow maximum independent operation time. Also, auxiliary units, such as mobile screens and stackers, can be powered from the same gensets, which will further reduce the needed power to run the complete plant,” says Jarmo Vuorenpää, Director, New Lokotrack Offering at Metso. Lokotrack EC range has been developed using new, modular architecture, which reduces the number of components and provides scalable solutions that can be adapted for different applications and capacities. “The new way to do product development enables a faster and more agile way to meet the changing customer needs. Furthermore, it enables more efficient support for the machines with less parts needed and easier upgrades of new features,” says Renaud Lapointe, Senior Vice President of Metso Products business line in the Aggregates business area. All the components of the new EC range are designed and tested to perform in demanding conditions to reach maximum uptime for the customers. Safety and usability have been given special attention. The design of the LT400J and LT350C fulfills the latest safety standard while being easier to use than ever. With new digital tools, the units can be operated safely from the excavator and be quickly set from transport to operation. About Metso’s Lokotrack[®] range The concept of track-mounted crushers and screens was developed in Finland in 1985 to minimize cost and energy use. Lokotrack units are ideal for processing both natural aggregates and recycled materials. Lokotrack EC is a new diesel-electric range that complements the existing offering. Lokotrack EC range contributes significantly to Metso’s Planet Positive offering with lower CO2 emissions when operated with electric power. It also helps reduce carbon footprint due to the lower need for hydraulic oil. Further information can be found on our website at Lokotrack EC - Metso .  Further information:    Jarmo Vuorenpää, Director, Aggregates, New Lokotrack offering, Metso, tel. +358 20 484 100, email: jarmo.vuorenpaa(at)metso.com     Helena Marjaranta, Vice President, Communications and Brand, Metso Corporation, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com     Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.     Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial  

Kemptron Oy's new CEO has been elected

Kemppi Oy's Board of Directors has elected Petri Suikkanen (51) as the new CEO of Kemptron Oy. He is currently Director, Finance and Operations at the health technology company Adamant Health Oy. Suikkanen will take up his new position on 1 August 2024. Kemptron Oy is a new company that will be established within the Kemppi Group as a result of the partial demerger of Kemppi Oy. Electronics production and contract manufacturing will be transferred to the new sister company, known as Kemptron Oy, on 1 August 2024. During the summer, Petri will be familiarized with his duties at Kemptron in connection with the partial demerger project of Kemppi Oy, starting on 27 May. Prior to his current position, Petri Suikkanen has had an extensive career as CFO in Saimaa Group Oy and Enics AG. “We are very happy to welcome Petri to our new company, Kemptron. Petri brings with him extensive management and business experience and a solid track record of successfully solving and managing financial, commercial and strategic issues. He also has significant experience in international environments, having lived abroad for several years. In addition, he has solid expertise in EMS (Electronics Manufacturing Services), which will be particularly important as we create a new service culture and EMS way of working in our new company," says Teresa Kemppi-Vasama, Chair of the Board of Kemppi Oy. “I am excited to be building a completely new company from scratch. This is a unique opportunity and I will be able to use the EMS expertise I have built up over almost 20 years and my experience of diversifying and growing the business into a successful independent industrial electronics player. Kemptron will focus, among others, on demanding power electronics, a field in which the Kemppi Group has decades of experience. By leveraging these strengths and expertise of the Kemppi Group and Kemppi Oy, and by adding the necessary elements of the EMS business to our operations, we will start to build Kemptron into a specialized EMS player offering its services to industrial OEM customers," says Petri Suikkanen. Additional information: Teresa Kemppi-Vasama, Chair of the Board, Kemppi Oy teresa.kemppi-vasama@kemppi.com Mobile: +358 40 8384202 Distribution: Media

SAS EXPANDS CONNECTIVITIY TO SCANDINAVIAN WINTER DESTINATIONS

These additions will enable more travelers to enjoy the ski resorts, dog sledding, and the opportunity to witness the northern lights during the upcoming winter season. SAS already serves the Scandinavian Mountains Airport (SCR) from Copenhagen and Aalborg during the winter season and will now open two more routes from Aarhus and London Heathrow. Additionally, three new seasonal routes are being introduced: Copenhagen to Finnish Rovaniemi, Copenhagen to Swedish Kiruna and London to Norwegian Tromsø. Connectivity to Northern Scandinavia is further enhanced by additional frequencies to Tromsø, Longyearbyen/Svalbard, Luleå and Åre-Östersund on the existing routes from Copenhagen, Oslo and Stockholm. “We see a significant rise in Europeans traveling to Northern Scandinavia during the winter season and we are very pleased to be able to increase our departures to this part of the world. Our winter program also includes improved connectivity between US and Asia and our Scandinavian as well as European destinations”, says Erik Westman, Chief Revenue Officer at SAS. For Scandinavians seeking warmth during the winter season SAS is adding more flights to warm destinations such as Gran Canaria, Tenerife and Agadir. Bangkok will see a minimum of four weekly flights from Copenhagen throughout the season, increasing to five weekly from late December and daily from late January to early March. The US program is also expanding, featuring daily flights from Copenhagen to Los Angeles and Boston and double daily to New York (JFK and Newark), with improved schedules to facilitate connectivity at JFK. In addition, SAS continues its new route Copenhagen-Atlanta with five weekly frequencies during the winter season. As is customary each winter season, there will also be a focus on European ski destinations like Zürich, Genève, Salzburg, Innsbruck, Milan, and Munich, particularly during the winter holidays. Too book your next trip go here: https://www.flysas.com/en/destinations/

TePe launches its 2023 sustainability report — levelling up its sustainable impact with a dedicated focus on oral health for people

“Julia Lönnegren, Sustainability Manager TePe comments: “Our sustainability journey is about innovative solutions for reduced environmental impact and creating a lasting positive impact through education by inspiring good oral health and well-being globally.” In 2023 TePe continued to use 100 % renewable energy in its state-of-the-art production facility in Malmö, Sweden and investments were made to expand the rooftop solar panel park further. TePe’s journey to phase out virgin fossil-based materials continues, and the launch of a new dental floss made entirely from recycled water bottles was an initiative supporting this journey while contributing to an interdental cleaning range made from renewable or recyclable materials. Meanwhile, TePe’s goal of contributing to 25 million healthy smiles by 2030 is underpinned by the oral health expertise in driving oral health educational initiatives for social sustainable development worldwide.Sanjay Haryana, Dentist at TePe, comments: “Sustainability is more than just bringing down our own emission levels by using renewable energy and plastics from recycled or renewable sources. Good people is about health and well-being for people, the social pillar of sustainability. Not only can good health for people support the overall quality of their life but also have a positive impact on the environment and economy since better oral health means that fewer resources are needed, for example less clinical waste. TePe’s sustainability report emphasizes the importance of working together in partnerships like the alliance with the Swedish Society of Periodontology and Implantology with the aim to inspire good oral health awareness globally. The report also shows TePe actively contributing to the STEPS research programme led by Lund University, a collaborative effort to bring researchers and industrial partners together to work towards a society where plastics are sustainably produced, used, and recycled in a circular economy. Sanjay Haryana says: “Over the years, scientific evidence supporting the connection between oral and general health has grown significantly. Developing products in collaboration with dental professionals with environmental aspects in mind and without compromising on quality, hygiene and safety for patients is the way forward. Conscious choices of raw materials and supporting good oral health for all people is something TePe has focused strongly on ever since the start in 1965.” TePe’s sustainability report is available on https://www.tepe.com/global/sustainability/ For more information, please contact Maria Swartling-Jung, Communications Manager, TePe Oral Hygiene Products AB, +46 40 670 11 00, maria.jung@tepe.com.

ScaffSense in successful pilot test

Yesterday marked the conclusion of the initial pilot test of ScaffSense, the world's first sensor-based stability alarm system for scaffolding. The pilot test went according to plan and with very positive results. ScaffSense AB, a joint venture between Kebni and Solideq Group, is now preparing for additional commercialization tests. Sydställningar AB, one of Sweden's leading scaffolding installers, was the official partner for the pilot test.”Safe scaffolding is Sydställningar’s top priority, so partnering with ScaffSense to facilitate their pilot test was an easy decision. From what we’ve seen, ScaffSense might very well be a game-changer for the entire scaffolding industry. We are proud to be part of the movement and looking forward to continuing our collaboration with ScaffSense.” Says Jonas Möllerbro, CEO at Sydställningar.“From an owner perspective we have now passed an important gateway and are ready for the next step.” Says Torbjörn Saxmo, CEO at Kebni and Chairman of ScaffSense. Tobias Wreje-Larsson, CEO at ScaffSense, adds:“We are thrilled to confirm ScaffSense’s functionality and viability through this successful pilot. We are excited to move forward, getting the product ready to set a new standard for safety in the global scaffolding industry.” Unsafe and collapsing scaffolding is a global problem that causes injuries, fatalities, and billions of dollars in costs for the construction industry every year. ScaffSense is a patent-pending alarm system that uses smart sensors to monitor the stability of the scaffolding in real time, preventing accidents and costly construction stops. Contact:Maya Larsson, Head of Market Communications & IRir@kebni.com / 070-971 00 05About Solideq Group ABSolideq – Safe Access – operates in the scaffolding industry primarily in the Nordic countries but supplies all over the world. Solideq develops, produces, and sells scaffolding and weather protection equipment as well as other related products. We have customers within the fields of oil and gas, construction and shipping, but also sell directly to carpenters and consumers. The Group also conducts e-commerce, through the websites ställning.se, solideq.no, solideq.fi, stegproffsen.se and snickarkläder.se. For more information, visit www.solideq.com .  About Kebni AB (publ)Kebni has a long history and extensive experience in maritime and land-based satellite antenna solutions as well as advanced inertial sensing solutions. The company, headquartered in Stockholm, is a leading supplier of reliable technology, products and solutions for satellite communications, security, positioning, and stabilization. Kebni serves products and solutions to government, military, and commercial customers globally. Kebni’s share (KEBNI B) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission. For more information, visit www.kebni.com.

Bulletin from Annual General Meeting in Everysport Group AB (publ)

The Annual General Meeting in Everysport Group AB (publ) was held on Thursday, May 16. Approval of the financial statementsThe meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet for the financial year 2023. Allocation of profitThe Meeting resolved that no dividend shall be paid for the fiscal year 2023 and that the result shall be carried forward. Discharge from liabilityThe Meeting discharged the members of the Board of Directors and the CEO from liability towards the Company for the financial year 2023. Board of Directors In accordance with the proposal of the Nomination Committee, Michael Hansen, Johan Ejermark, Mernosh Saatchi and Hannes Andersson were re-elected to the Board of Directors. Björn Ulvgården was elected as a new member for the period until the next Annual General Meeting. Michael Hansen was re-elected as Chairman of the Board. The meeting also resolved, in accordance with the proposal of the Nomination Committee, that the remuneration of the Board members for the period until the conclusion of the next Annual General Meeting shall be SEK 170,000 for the Chairman of the Board and SEK 85,000 for each of the other Board members elected by the meeting, with the exception of Johan Ejermark. For committee work, fees of SEK 65,000 shall be paid to the Chairman of the Audit Committee, SEK 50,000 to a member of the Audit Committee, SEK 30,000 to the Chairman of the Remuneration Committee and SEK 10,000 to a member of the Remuneration Committee. The Meeting resolved that the remuneration of the auditors be paid on the basis of approved invoices. Authorization to issue sharesThe Meeting authorized the Board of Directors to decide on one or more occasions during the period until the next Annual General Meeting to issue shares, warrants and/or convertible bonds of the Company. The total number of shares that may be issued under the authorization may not exceed 20 percent of the total number of outstanding shares of the Company at the time of the meeting. The reason why the Board of Directors shall be able to decide on an issue with deviation from the preferential rights of the shareholders and/or with provision for an issue in kind and set-off or otherwise with the above mentioned conditions is that the Company shall be able to issue shares, warrants and/or convertible bonds in connection with the acquisition of companies or businesses. For more information, please contact:Hannes Andersson, CEO, Everysport Group ABPhone: +46 70 736 56 25E-mail: hannes.andersson@everysport.com About Everysport Group (publ)Everysport Group is a leading Swedish company that develops digital platforms and services within sports tech and sports media. The Group's flagship product, Elite Prospects, is a globally leading hockey platform with over 22,000 paying subscribers and 1.5 million unique visitors per week. Everysport Group is headquartered in Stockholm with a local presence in the US. The Group is listed on Spotlight Stock Market with the ticker "EVERY". For more information, please visit www.everysportgroup.com Interested in news and financial information from Everysport Group? Subscribe here 

The Foundation Assar Gabrielsson Prize recipients 2024 awarded

"Anna Wenger is awarded the prize in the category of basic science research for advanced basic science studies on malignant gliomas in children and adults. The studies provide new knowledge about epigenetic differences and cancer stem cells different types of glioma. The results can be of great benefit for the development of better diagnostics and choice of treatment for patients with glioma," says Eva Forssell-Aronsson, professor at the University of Gothenburg and executive member of the Assar Gabrielsson Foundation in the citation. "Sara Bjursten receives the award in the category of clinical research for clinically important and well-conducted research regarding immunotherapy in cancer patients. The studies provide new knowledge about side effects in the central nervous system, especially with regard to T cells and biomarkers in the blood. The results may lead to new strategies for early detection of side effects in these patients," says Professor Eva Forssell-Aronsson. Assar Gabrielsson was one of the founders of Volvo. In accordance with his wishes, a fund was established for clinical research of cancer diseases. The fund has existed since 1962. It primarily supports research projects that are considered promising but have not yet reached the weight that provides funding from major research funds. May 16[th], 2024       Journalists who want further information, please contact: Torbjörn Holmström, Chairman of the Assar Gabrielssons Foundation, 031 66 10 73, or Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation, 070 372 26 26.     For more information, please visit volvogroup.com For frequent updates, follow us on X: @volvogroup  The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2023, net sales amounted to SEK 553 billion (EUR 48 billion). Volvo shares are listed on Nasdaq Stockholm.

Eco Wave Power Announces Q1 Financial Results; Progress with Projects in Israel, United States and Portugal, While Continuing to Present Decrease in Operating Expenses and Plans to Enhance Cash Flow

Management Commentary During the first quarter of 2024, Eco Wave Power continued to demonstrate resilience by decreasing its operating expenses by 3.5% compared to the first quarter of 2023, ending the quarter with $7.96 million in cash and in short term bank deposits. At the same time, we have achieved the following milestones: · In Israel, the EWP-EDF One Project in the Port of Jaffa, has been delivering clean energy from the waves to the Israeli National electrical grid, since its connection to the grid in the end of 2023. An opening ceremony for the project will be held as soon as the Company deems the geopolitical situation in Israel has improved. Eco Wave Power and EDF Renewables IL have started an analysis of the first set of results from January 2024 to April 2024. The results from the project are encouraging, as we can see a month-by-month improvement both in terms of the energy generation results and in terms of significant decrease in down-time for the power station. For example, downtime has decreased from 35% in January 2024, to 26% in February 2024, to 13.4% in March 2024 and to only 3.6% in April 2024. In addition, the Company was able to get closer to its energy generation target for the site by 8%. · At the Port of Los Angeles, in January 2024, we signed a strategic co-investment agreement with a major Energy Company (the full name of the company is disclosed in our annual report on Form 20-F for December 31, 2023), for the implementation of our first U.S-based project while we are also moving forward with the licensing process. We have submitted our comprehensive project engineering plans to the port authorities and have formally requested the final required licenses from both the Port of Los Angeles and the U.S. Army Corps of Engineers. As a response, we have been requested to submit a third-party opinion about the fact that our project site in the Port of Los Angeles, is not a historic site. We have received such a formal opinion on April 29, 2024, and have submitted it to all relevant parties. As soon as we receive the relevant licenses, we expect a very short implementation time of around 6 months for our first U.S. project. In May 2024, the founder and CEO of Eco Wave Power, Inna Braverman, also met with representatives from the U.S. Department of Energy and presented the progress and timeline for the implementation of the project.Due to rising interest and opportunity that we see in the U.S. market, we conducted a comprehensive feasibility study with the same major energy company, aimed at identifying the best locations for commercial onshore wave energy stations along the U.S. coastline and worldwide. The three-month, in-depth feasibility study which now has been completed, has shown favorable conditions for clean energy production in multiple locations in the U.S. and globally. In the study, we pointed out at least 77 sites in the U.S. that may be compatible with the implementation of Eco Wave Power’s technology. · In Portugal, we received the final approval necessary for the commencement of the construction works of our first commercial-size project in Porto (TURH license) from APDL Port Authority. As a result, we have issued a performance bond to APDL, meant to solidify our commitment for the construction of the first commercial wave energy project within a 2-year period. We believe this will be the first wave energy project in the world to show significant energy production from the power of the waves. During Q1, 2024, we have finalized the construction plans for the energy conversion units and held an official project kick-off call on April 22, 2024 with the architect of the implementation site and APDL. The next steps include finalizing detailed construction plans for the full first 1 MW power plant (including the floaters) to be followed by an official site visit by Eco Wave Power’s engineering team and commencing actual construction, which is expected to take up to 24 months. The Portuguese project is expected to be Eco Wave Power’s first MW scale project, which we believe will position Eco Wave Power as a leading wave energy developer and serve as a significant milestone towards the commercialization of wave energy globally. · During the year 2023, Eco Wave Power was able to increase its cash flow and substantially decrease its net loss by providing feasibility studies services and other engineering services to major energy companies and other clients around the globe. In 2024, to increase the Company’s revenue and cash flow, the Company’s management decided to start supplying turnkey wave energy to clients around the world, while progressing with its core projects in Israel, the Port of Los Angeles, and Portugal. · In December 2023, Eco Wave Power submitted an official request to the Financial Supervisory Authority of Sweden (“SFSA”), to receive authorization for the Company’s repurchase of American Depositary Shares representing up to 10 percent of the total number of shares in the Company, which is the maximum amount permitted by Swedish Law. In the meantime, the SFSA recognized that Nasdaq Capital Market is a regulated market for the purpose of such repurchase and has notified the Company that it is examining the prospect of approving such repurchase, based on the shareholder rights attached to the American Depository Shares. Once its examination is completed, the Company hopes that Eco Wave Power will be permitted to exercise such a repurchase and would intend to proceed with the repurchase action as soon as such approval is granted. CEO Commentary: According to an article published by Fidelity International titled “Three reasons clean energy stocks could come back in 2024” on January 26, 2024, high interest rates and a weaker global economy have challenged clean energy equities over the past year, mirroring Eco Wave Power’s stock performance.[1] Despite this, global renewable power installation surged by nearly half in 2023, hinting at optimism for 2024. Clean energy ETFs now outperform those that are tied to oil and gas, reflecting a broader trend according to the article. Our Company’s share price similarly rose during this period, outpacing the MSCI Global Alternative Energy Index by 136.42% in the last three months. We believe that what enabled the growth and rising interest in the Company’s share price is the fact that the Company constantly delivers on its promises, and reaches significant progress during each quarter, while cutting down its operational expenses and boosting revenues. In the first quarter of 2024, we were able to keep the low level of expenses and thus demonstrate our resilience by decreasing our operating expenses by 3.5% compared to the first quarter of 2023, ending the year with $7.96 million USD in cash and in short term bank deposits. There was progress across all projects, including key improvements in the operational results of the EWP-EDF One project at the Port of Jaffa in Israel, submissions of final licensing documents for the installation of the project at the Port of Los Angeles, and moving forward with Eco Wave Power’s first MW-scale project in the city of Porto in Portugal. We have also reinforced our engineering team and are planning on establishing a U.S. based sales and business development team to enable the Company to enter deals for turnkey wave energy projects which we believe will, in turn, significantly boost the Company’s revenues, to be added to the revenues that the Company has been generating from feasibility studies and other related engineering services. The expansion of the engineering team in Israel and the new business development and sales team in the U.S. will require some time. However, we believe that such an enhanced company structure will lead to positive financial results and accelerated project delivery. According to an article published by Reuters titled “Clean energy ETFs start to outperform key oil and gas  ETF” on May 7, 2024, if the momentum seen over the past month is sustained, all major clean power ETFs, may soon register positive returns for the year so far, which will serve to boost sentiment across the clean energy space, and if that sentiment is further boosted by supportive macro-level changes regarding geopolitical tensions and interest rate regimes, additional investor momentum into the broader clean energy ETF space can be expected.[2] I would like to finish by thanking all our existing shareholders, and the new ones that joined us in recent months and reiterate our excitement about the new deal with the major energy company, and the progress with all our projects. Let’s change the world, One Wave at a Time. First Quarter 2024 Financial Overview ●       There were no revenues as of and for the three months ended March 31, 2024 ●       Operating expenses were $659,000, down by 3.5% from the same period last year. · Research and development expenses were $177,000 compared to $210,000 in the same period last year, down by 15.7% on the same period last year. · Sales and marketing expenses were $65,000 compared to $76,000 in the same period last year, down by 14.5% on the same period last year. · General and administrative expenses were $408,000 compared to $397,000 in the same period last year, up by 2.8% on the same period last year. · Other income of $4,000 was generated mainly from management fees in a joint venture. · Share of net loss of a joint venture accounted for using the equity method was $13,000. ●       Operating loss was $659,000 compared to $683,000 in the same period last year, which is down by 3.5%. ●       Net financial income was $132,000 compared to $160,000 in the same period last year. ●       Net loss was $527,000, or $0.01 per basic and diluted share, compared to a net loss of $523,000, or $0.01 per basic and diluted share in the same period last year. ●       The Company ended the period with $7.96 million in cash and cash equivalents and in short term bank deposits. ($7.74 million in cash and cash equivalents and $0.22 million in short-term bank deposits). Conference Call and Webcast Information The Chief Executive Officer of Eco Wave Power, Inna Braverman, will host a conference call to discuss the financial results and outlook on Friday, May 17, 2024, at 9:00 a.m. Eastern time. • The dial-in numbers for the conference call are 888-506-0062 (toll-free) or 973-528-0011 (international).   If requested, please provide participant access code: 193251 • The event will be webcast live, available at: https://www.webcaster4.com/Webcast/Page/2922/50651 A replay will be available by telephone approximately four hours after the call's completion until Friday, May 31, 2024. You may access the replay by dialing 877-481-4010 from the U.S. or 919-882-2331 for international callers, using the Replay ID 50651. The archived webcast will also be available on the investor relations section of the Company’s website. About Eco Wave Power Global AB (publ) Eco Wave Power is a leading onshore wave energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity. Eco Wave Power’s mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves. The Company completed construction of its grid connected project in Israel, with co-investment from the Israeli Energy Ministry, which recognized the Eco Wave Power technology as “Pioneering Technology.” The EWP-EDF One station project marks the first grid-connected wave energy system in Israeli history. Eco Wave Power will soon commence the installation of its newest pilot in AltaSea’s premises in the Port of Los Angeles and its first MW scale wave energy power station in Portugal, Europe. The Company also holds concession agreements for commercial installations in Europe and has a total projects pipeline of 404.7 MW. Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission’s Horizon 2020 framework program. The Company has also received the “Global Climate Action Award” from the United Nations. Eco Wave Power’s American Depositary Shares (WAVE) are traded on the Nasdaq Capital Market. Read more about Eco Wave Power at www.ecowavepower.com Information on, or accessible through, the websites mentioned above does not form part of this press release. For more information, please contact: Inna Braverman, CEO Inna@ecowavepower.com Aharon Yehuda, CFO Aharon@ecowavepower.com +97235094017 Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements in this press release when it discusses the prospective approval of requite licenses for its U.S-based wave energy project at the Port of Los Angeles and expected implementation time should the licenses be granted, the Company’s belief that the wave energy project in Portugal will be the first to show significant wave energy production, the finalization of construction plans and implementation time of the project in Portugal, that the project in Portugal is expected to be the Company’s first MW scale project that may position the Company as a leading wave energy developer, the  pending SFSA decision on whether the Company is permitted to exercise a repurchase of its American Depositary Shares, the Company’s belief that its expansion in its engineering, business development and sales teams may lead to improved financial results, and certain projected positive trends in the green energy market. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will", or variations of such words, and similar references to future periods. These forward-looking statements and their implications are neither historical facts nor assurances of future performance and are based on the current expectations of the management of Eco Wave Power and are subject to a number of factors, uncertainties and changes in circumstances that are difficult to predict and may be outside of Eco Wave Power’s control that could cause actual results to differ materially from those described in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Except as otherwise required by law, Eco Wave Power undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting Eco Wave Power is contained under the heading “Risk Factors” in Eco Wave Power’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024, which is available on the on the SEC’s website, www.sec.gov, and other documents filed or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. References and links to websites have been provided as a convenience and the information contained on such websites is not incorporated by reference into this press release. Eco Wave Power Global AB(publ) CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited) March 31 December 31 2024 2023 In USD thousands AssetsCURRENT ASSETS:Cash and cash equivalents 7,739 4,281Short term bank deposits - 4,102Restricted short-term bank 221 63depositsTrade receivables 20 202Other receivables and prepaid 117 108expensesTOTAL CURRENT ASSETS 8,097 8,756 NON-CURRENT ASSETS:Property and equipment, net 621 636Right-of-use assets, net 66 90Investments in a joint venture 513 527accounted for using the equitymethodTOTAL NON-CURRENT ASSETS 1,200 1,253TOTAL ASSETS 9,297 10,009 Liabilities and equityCURRENT LIABILITIES:Current maturities of long-term 983 974loans from related partyCurrent maturities of other long 64 62-term loanAccounts payable and accruals:Trade 54 50Other 1,017 957Current maturities of lease 63 87liabilitiesTOTAL CURRENT LIABILITIES 2,181 2,130  NON-CURRENT LIABILITIES:Other long-term loan 74 78TOTAL NON-CURRENT LIABILITIES 74 78 TOTAL LIABILITIES 2,255 2,208 EQUITY:Common shares 98 98Share premium 23,121 23,121Foreign currency translation (2,499) (2,275)reserveAccumulated deficit (13,514) (12,994)Capital and reserves attributable 7,206 7,950to parent company shareholdersNon-Controlling interest (164) (149)TOTAL EQUITY 7,042 7,801TOTAL LIABILITIES AND EQUITY 9,297 10,009 Eco Wave Power Global AB(publ) CONDENSED CONSOLIDATED STATEMENTS OF LOSS (Unaudited) Three months ended March 31 2024 2023 In USD thousandsOPERATING EXPENSESResearch and (177) (210)developmentexpensesSales and (65) (76)marketing expensesGeneral and (408) (397)administrativeexpensesOther income 4 5Share of net lossof a joint ventureaccounted for (13) (5)using the equitymethodTOTAL OPERATING (659) (683)EXPENSES OPERATING LOSS (659) (683) Financial expenses (15) (12)Financial income 147 172FINANCIAL INCOME 132 160(EXPENSES) - NET NET LOSS (527) (523) ATTRIBUTABLE TO:The parent company (520) (523)shareholdersNon-controlling (7) -interests (527) (523)                      In USDLOSS PER COMMON (0.01) (0.01)SHARE – BASIC ANDDILUTED WEIGHTED AVERAGENUMBER OF COMMONSHARES USED INCALCULATION OFLOSS      PER COMMON 44,394,844 44,394,844SHARE [1] https://www.fidelityinternational.com/editorial/article/three-reasons-clean-energy-stocks-could-come-back-in-2024-e3b803-en5/ [2] https://www.reuters.com/business/energy/clean-energy-etfs-start-outperform-key-oil-gas-etf-maguire-2024-05-07/

Studsvik visited by Minister for Energy, Business, and Industry and Deputy Prime Minister, Ebba Busch

Alongside CEO Camilla Hoflund and Chairman of the Board Jan Bardell, among others, Ebba Busch discussed Sweden's need for more electricity and Studsvik's contribution to the government's Roadmap for New Nuclear Power in Sweden. Studsvik is a location and a business with opportunities to establish a Swedish and international hub for nuclear research and innovation for new nuclear power. Studsvik may also potentially make land available for new nuclear power plants, with ongoing pre-studies with private stakeholders already in progress. During the visit, the Minister was given a guided tour of Studsvik's fuel testing laboratory. The laboratory is the only one of its kind in the Nordic region and the world's only privately-owned facility, playing a crucial role in meeting the nuclear industry's needs for fuel qualification and investigations into the lifetime extension of nuclear power plants. For further information, please contact: Camilla Hoflund, President and CEO of Studsvik AB, +46 155 22 10 66 Facts about Studsvik Studsvik offers a range of advanced technical services to the global nuclear power industry. Studsvik’s business focus areas are fuel and materials technology, reactor analysis software, decontamination and radiation protection as well as technical platforms for handling, conditioning and volume reduction of radioactive waste. The company has more than 75 years’ experience of nuclear technology and radiological services. Studsvik has 530 employees in 7 countries and the company’s shares are listed on Nasdaq Stockholm. www.studsvik.com

Audientes A/S: Issuer Memorandum related to Rights Issue published

On 14 May 2024 Audientes announced that the Board of Directors had resolved on an issue of shares with pre-emptive rights for existing shareholders. The decision was taken pursuant to existing authorizations in the Company’s articles of association. A summary document for investors will also be published on the website of the Company in connection with the start of the subscription period. Subscription forms for manual subscription of remaining shares will be also made available on the website coinciding with the start of the subscription period. Timetable for the Rights Issue · Last day of trading in shares including the right to receive subscription rights: 16 May 2024. · First day of trading in shares excluding the right to receive subscription rights: 17 May 2024. · Trading in subscription rights: 17 May 2024 – 31 May 2024 (the last day of trading in subscription rights will be announced through a separate press release). · Record date for participation in the Rights Issue: 21 May 2024. · Subscription period: 22 May 2024 – 4 June 2024 · Publication of the final outcome of the Rights Issue: around 10 June 2024 The Rights Issue in brief Summary of the Offer The Company’s nominal share capital will increase by a maximum of DKK 1,387,686 and a maximum of 138,768,644 new shares, each with a nominal value of DKK 0.01. The Rights Issue is conducted with pre-emptive share rights (“Subscription Rights”) for existing shareholders. The net proceeds from the Rights Issue amount to a maximum of approximately DKK 4.1 million assuming that the Rights Issue is fully subscribed. Subscription price The New Shares are offered at the subscription price of DKK 0.035 per new share (excluding fees, if any, from the investor's own custodian bank or brokers). Subscription period The subscription period of the Rights Issue will commence on 22 May 2024 at 9:00 a.m. CEST (Central European Summer Time = local Danish time) and will close on 4 June 2024 at 5:00 p.m. CEST (the “Subscription Period”) Subscription amount Shares are subscribed pro rata, or for as many as Existing shareholders wishes to subscribe. Existing shareholders have the right to subscribe for more than their pro rata right if not subscribed in full by the current shareholders and the general public can subscribe for shares that are not subscribed by the existing shareholders. Allocation of Subscription Rights Each shareholder (as per the Record Date of 21 May 2024) will for every 1 (one) share receive 2 (two) Subscription Rights. 1 (one) Subscription Right give the holder the right to subscribe for 1 (one) New Share (a ratio of 2:1). Subscription and payment Subscription with the support of subscription rights will take place during the subscription period in accordance with the “Terms and conditions” section in the Memorandum. Please note that the subscription rights that the shareholder does not intend to use must be sold no later 31 May 2024, to not expire without value. Pre-subscription- and guarantee commitments Approximately 26 percent of the Rights Issue, corresponding to approximately DKK 1.3 million, is covered by pre-subscription commitments. Dilution As at the Memorandum Date, the Company's registered share capital had a nominal value of DKK 693,843.22 divided into 69,384,322 Existing Shares with a nominal value of DKK 0.01. All Existing Shares are issued and fully paid up, and each Existing Share represents 1 vote. Upon issue of the New Shares, the percentage of ownership of the Existing Shareholders may be reduced. If the Existing Shareholders refrain from exercising Subscription Rights allocated to them in connection with the Offering, each Existing Shareholder's ownership will be diluted by approx. 67 percent. If the Existing Shareholders elect to partly exercise the Subscription Rights allocated to them, the rate of dilution will be between 0 to 67 percent depending on the exercise. If the Existing Shareholders exercise their Subscription Rights in full, they will not be diluted. For more information about the Rights Issue, please contact: Bjørn Wennerlund, Villand Capital Phone: +45 60 13 77 86 or +46730 - 93 96 30 Email: info@villandcapital.com Steen Thygesen,CEO, Audientes A/S Phone: +45 53 17 26 10 Email:st@audientes.com About Audientes A/S Audientes A/S is a Danish hearing health company specializing in smart, self-fitting and affordable hearing aids and advanced hearables. Audientes’ unique hearing aid solution, Ven™ by Audientes, is available for purchase in the Indian and Nepalese markets and will be introduced in other markets in the coming years. Companion by Audientes is an advanced hearable, a consumer electronics product, that is commercially available in Europe and later in 2024 in Japan, China, and other markets. Audientes’ mission is to make high-quality hearing aids and hearables for hearing improvement or hearing enhancement accessible to everyone who needs them globally. Audientes is listed on Spotlight Stock Market Denmark (AUDNTS) and headquartered in Copenhagen, Denmark with subsidiaries in Hyderabad, India and in Tokyo, Japan. For additional information please refer to the company’s websites, www.audientes.com, www.audientes.eu, or www.audientes.in.

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action

The event will feature Gareth J. Thomas, PhD (University Hospital Southampton) and Jonathan Barratt, PhD, FRCP (University of Leicester) with the following program: · Supportive preclinical data and Phase 2 POC trial evaluating setanaxib, the Company's lead candidate from its NOX platform, in patients with squamous cell carcinoma of the head and neck (SCCHN) · The anti-fibrotic effects of Setanaxib in solid tumors and fibrotic diseases · Review of upcoming additional clinical data from the NOX platform · Support for mode of action of TARPEYO (Nefecon) in patients with primary IgA nephropathy (IgAN) The event will include a discussion of positive clinical results and supportive pre-clinical and biomarker data recently announced for both programs, as well as an overview of the Company's pipeline and expected future data readouts. A live question and answer session will follow the formal presentations. Registration information You are required to register in advance for this event by clicking here . Q&A information If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com KOL Biographies Gareth J. Thomas is Professor of Experimental Pathology at the University of Southampton, UK. As a clinical pathologist and tumor biologist, Gareth Thomas’s research is focused how fibroblasts affect cancer progression, characterizing the phenotypes and functions of different fibroblast subpopulations and investigating how fibroblasts interact with immune cells to suppress anti-tumor immunity. The research has a strong translational component aiming to develop new therapies that target fibroblasts to overcome immunotherapy resistance. Jonathan Barratt, PhD, FRCP leads the Renal Research Group within the Col-lege of Life Sciences, University of Leicester. His research is focused on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. Jonathan is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the In-ternational IgA Nephropathy Network. He is Chief Investigator for a number of international randomized controlled Phase 2 and 3 clinical trials in IgA nephropa-thy and was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group.

Hexagon Agility renews master service agreement with UPS and receives new fuel system orders for UPS’ heavy duty renewable natural gas trucks

16 May 2024: Hexagon Agility, a business of Hexagon Composites, signed a 3-year extension of its master services agreement with UPS in February 2024 to supply renewable natural gas (RNG) fuel systems for medium- and heavy-duty trucks. UPS is the world’s premier package delivery company and a leading provider of global supply chain management solutions. Under the extended agreement, Hexagon Agility has received new orders totaling USD 57.7 million (approx. NOK 620 million) for delivery of RNG fuel systems for heavy-duty trucks. The orders include trucks utilizing the new 15-liter (X15N) natural gas engine. “In the past decade Hexagon Agility has supported the deployment of over 100,000 near-zero emission vehicles globally,” said Eric Bippus, EVP of Sales and System Development at Hexagon Agility. “UPS has been a pioneer in sustainable transportation. Once again, they are taking the lead and are among the first companies enhancing their fleet with the game-changing X15N engine and our fuel systems.” RNG in heavy-duty transport results in significant reductions of greenhouse gas (GHG) emissions. In 2023, 6.96 million metric tons of carbon dioxide equivalents were displaced by RNG in the U.S.* This is equal to removing 17 billion miles driven by the average passenger car. In North America, RNG is supported by abundant natural gas pipeline infrastructure which allows for its immediate use today, and for decades to come. Hexagon Agility is enabling adoption of RNG to cost effectively combat climate change. About the market Never before have there been so many natural gas trucks on the road. According to The Transport Project there are more than 175,000 natural gas vehicles on US roads today. In 2023, RNG accounted for 79% of all on-road fuel used in natural gas vehicles in the United States. Meanwhile, fuel providers and RNG producers are rapidly expanding output and availability of RNG at the pump, adding to the 1,500 natural gas fueling stations available across North America today. Timing Deliveries of the new orders are expected to be completed by the end of the fourth quarter of 2024. The bulk of the orders will be completed in the second half of 2024. For more information: Karen Romer, SVP Communications, Hexagon Composites ASATelephone: +47 950 74 950 | karen.romer@hexagongroup.com  Ingrid Aarsnes, VP Investor Relations and ESG, Hexagon Composites ASATelephone: +47 950 38 364 | ingrid.aarsnes@hexagongroup.com *Natural Gas Vehicles for America (NGVAmerica) and Coalition for Renewable Natural Gas (RNG Coalition) About Hexagon Agility Hexagon Agility, a business of Hexagon Composites, is a leading global provider of clean fuel solutions for commercial vehicles and gas transportation solutions. Its product offerings include (renewable) natural gas storage and distribution systems, Type 4 composite natural gas cylinders, propane, and (renewable) natural gas fuel systems. These products transport clean gaseous fuels and enable vehicles to reduce emissions while saving operating costs. Learn more at hexagonagility.com and follow @HexagonAgility on X and LinkedIn. About Hexagon Composites ASA Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications. Learn more at hexagongroup.com and follow @HexagonASA on X and LinkedIn.

Interim report January 1 – March 31, 2024

FIRST QUARTER (JANUARY – MARCH 2024) · Oder intake SEK 238.5 M (206.6) · Net sales SEK 257.2 M (230.2) · Operating profit SEK 45.8 M (23.7) · Profit after tax SEK 36.7 M (17.6) · Earnings per share before/after dilution SEK 1.07 (0.51) · Cash flow SEK 87.9 M (84.5) · Order backlog SEK 1,848.0 M (1,903.3) MSEK at the end of the period SIGNIFICANT EVENTS DURING THE FIRTS QUARTER · RayStation in more than 1,000 radiotherapy centers worldwide. · The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch. · RaySearch acquires the product DrugLog from Pharmacolog. · World leading carbon ion center QST in Chiba, Japan, selects RayStation. SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD · Raigmore Hospital in Scotland selects RayCare. · RaySearch and C-RAD signed collaboration agreement. · RayCare has been certified to be interoperable with Varian TrueBeam. WEBCAST CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for January-March 2024 at a webcast to be held in English on Friday, May 17, 2024 at 10:00 a.m. CET. Link to webcast: RaySearch Q1, 2024  You can also join the webcast by phone: Sverige: +46 (0) 8 505 100 31  UK: +44 (0) 207 107 06 13  US: +1 (1) 631 570 56 13 The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 17, 2024 at. 7:45 a.m. CET.

Experience Iceland's unique nature and recconnect with the elements

Iceland's newest natural, geothermal nature resort, Hvammsvík Hot Springs, merges sustainable modern materials with a rustic, biophilic design to create a unique resort where guests are encouraged to reconnect with nature. Spanning across a 1,200-acre estate in the Icelandic wilderness of the Hvalfjörður, Hvammsvík encompasses eight different-sized, naturally formed hot spring pools, a small bar and bistro, and four rustic, high-end lodges and farmhouses, all of which have nature embedded in every element. Gríma Thorarensen, Creative Director and Co-Owner of Hvammsvík Hot Springs, has been involved in the planning and executing the resort's design development since its inception. Here, she shares her passion and success in creating an atmosphere that is welcoming, relaxed, honest, down to earth, and strongly connected with nature and the surroundings. "We envision Hvammsvík as a never-ending story that will continue to evolve gradually as nature itself. We have been renovating the old farmhouses and barns for several years, always carefully allowing each house to keep its original character and charm. The old original hot spring had been a secret hidden destination for ages; however, during COVID, we decided to evolve and expand it further." At the beginning of the design process, Grima set her sights on a more significant, traditional, high-end spa: "However, after bouncing ideas around, a luxury pretentious resort didn't feel like it belonged in Hvammsvík." In keeping with the extreme elements, magnificent nature, and wildlife, the owners decided to downscale the resort and design it more honestly to make it feel at one with nature. "In the end, simple, understated luxury felt perfectly right and aligned with our ambition of creating a unique destination for our guests. You can't compete with nature," says Grima. Hvammsvík Hot Springs merges sustainable modern materials with a rustic, biophilic design to create a unique resort where guests are encouraged to reconnect with nature. "Firstly and foremost, my inspiration came from the magnificent nature and landscapes that we are so fortunate to enjoy here in Hvammsvík," Grima says. She spent countless hours walking around the property and taking photos throughout the seasons, across all different weather conditions. "The color palette, the materials, the textures, and overall concept all came from the surroundings," she tells us. Mosfellsbær, Iceland, 16.05.2024 - Hvammsvík was taken over by the Allied forces in the Second World War, and the Hot Springs facilities were built on an old barrack foundation. Therefore, history also played a huge part in Greta's inspiration behind the design. "During the Second World War, thousands of soldiers lived in barracks in Hvammsvík, which is where my idea of using an old barrack as guest accommodation came from. To this day, visitors can find remains from the allied forces in Hvammsvík and the Whalfjord at large." All of the houses are unique, with their own characteristics and architecture, because they were built in different eras, from the 1920s until today. "To create synergy between the properties and to fit with the atmosphere of the wider resort, I used a natural color palette of green, blue, white, and grey, alongside the use of natural materials, including reclaimed wood, linen, leather, and stone," Grima explains. All houses provide guests privacy and great views over the mountains and ocean. To encourage relaxation, intimacy, calmness, and peace: "It was hugely important to me to try and choose Icelandic design and craftsmanship where possible, along with opting for sustainable, natural, and local materials. Throughout the resort, there are many examples of how we have successfully done this, with unique and interesting stories behind each that connect us with the local community and the Icelandic culture." The floors of the hot springs have a beautiful, natural terrazzo effect from where the concrete has been mixed with shells, stones, and sand from the beach. "We are so happy with the final outcome and the relationship and combination of the different artwork together. From old and new, materials and colors, refined and rough, light and shadow, depth and contrast, all together, it creates something special and interesting to the eye." This story is a part of the 100 Stories from Iceland . [A unique resort in Iceland where guests are encouraged to reconnect with nature]

Kamux Corporation’s Interim Report for January 1—March 31, 2024: Revenue grew and adjusted operating profit increased significantly, actions in Sweden are progressing

Kamux Corporation, Interim Report, 17.5.2024 at 9:00 Kamux Corporation’s Interim Report for January 1—March 31, 2024: Revenue grew and adjusted operating profit increased significantly, actions in Sweden are progressing This is a summary of Kamux Corporation’s Interim Report for January 1—March 31, 2024. The complete report is attached to this release and is also available at the company website at kamux.com . The figures in parentheses refer to the comparison period, i.e., the same period in the previous year, unless stated otherwise. January–March in brief · Revenue increased by 7.9%, totaling EUR 240.7 million (223.1) · Gross profit increased by 17.4% to EUR 24.4 million (20.7), or 10.1% (9.3) of revenue · Adjusted operating profit (EBIT) increased by 227.0% to EUR 2.7 million (0.8), or 1.1% (0.4) of revenue · Operating profit (EBIT) increased by 285.3% to EUR 2.3 million (0.6), or 1.0% (0.3) of revenue · The number of cars sold increased by 5.3% to 16,137 cars (15,324) · Like-for-like showroom revenue growth was 7.1% (-10.4) · Basic and diluted earnings per share were EUR 0.03 (0.00) Key Figures EUR million 1−3/2024 1−3/2023 Change, % 1−12/2023Revenue 240.7 223.1 7.9% 1,002.1Gross profit 24.4 20.7 17.4% 102.5as percentage of 10.1% 9.3% 10.2%revenue, %Operating profit 2.3 0.6 285.3% 15.8(EBIT)as percentage of 1.0% 0.3% 1.6%revenue, %Adjusted operating 2.7 0.8 227.0% 18.0profit*as percentage of 1.1% 0.4% 1.8%revenue, %Revenue from 13.4 11.5 15.9% 53.0integrated servicesas percentage of 5.5% 5.2% 5.3%revenue, %Number of cars sold 16,137 15,324 5.3% 68,257Gross profit per sold 1,510 1,354 11.5% 1,502car, EURSales growth of like 7.1% -10.4% 2.9%-for-like showrooms, %Net debt 71.0 68.4 3.9% 53.8Inventories 136.2 123.1 10.6% 117.2Inventory turnover, 52.4 56.8 -7.8% 46.9daysCapital expenditures 1.2 0.4 195.7% 1.8Average number of 902 845 6.7% 885employees during theperiodReturn on equity 9.9% 6.1% 8.7%(ROE), %Return on investment 6.9% 4.6% 6.6%(ROI), %Equity ratio, % 49.5% 51.2% 51.9%Earnings per share, 0.03 0.00 N/A 0.24basic and diluted, EUR *) Operating profit adjusted for special items related to strategic planning and consulting, taxes from previous financial years, own real estate operations and other items, totaling EUR 0.4 million for the first quarter of 2024 (1−3/2023: EUR 0.2 million and 1−12/2023: EUR 2.2 million including also special items related to legal processes,). CEO Tapio Pajuharju: "The used car market developed positively in all our operating countries during the first quarter, and the market seems to be returning to normal. At Kamux, the good sales momentum in Finland continued. In addition, in Germany our sales volumes developed favorably. In Sweden, the market was quite strong, but the corrective actions related to previously detected misconduct had a significant impact on the turnover of sales personnel, which is why we were clearly lagging behind the good momentum in the market. We have succeeded very well in recruiting new sales personnel in Sweden, and our sales team is already close to the level of 2023. We have also made significant investments in the onboarding process, and although learning takes time, we believe that we will have a well-performing sales team in Sweden later this year. Other corrective measures were also continued in Sweden during the first quarter, and the full set of corrective actions will be completed gradually towards the end of the year. With the positive development in Finland and Germany, the number of cars sold increased by 5% in the first quarter compared to the first quarter of 2023. However, the almost 8% increase in revenue relied very heavily on Finland, as we implemented a planned change in the car offering in Germany to match the Kamux concept, which led to a lower average revenue per sold car than previously. Gross profit grew in all countries, compared to the comparison period. There are several elements behind the positive development in Finland, and the emphasis on profitability is visible in everything. In Sweden, the positive development of gross profit is a result of the measures implemented last year. In Germany, we continue to improve productivity, e.g. by further developing the centralized processing of cars. Sales and profitability of integrated services developed favorably. The adjusted operating profit for the first quarter was EUR 2.7 million (EUR 0.8 million). Operating cash flow was EUR -16.2 million. In March, we published our updated strategy, which is anchored to placing the customer at the core of all activities and improving operational efficiency. These measures will help us achieve profitable growth. In addition to financial targets, an important indicator of the progress of our strategy is the Net Promoter Score (NPS), measuring the degree of customer referrals, where our long-term target is 60. In the first quarter of the year, our NPS result was 51, which is at a very good level within the car industry. During the past quarter, our strategy implementation progressed according to plan. In Finland, starting from the capital region, we have upgraded some of our showrooms to match our new concept. At the beginning of the second quarter, Finland implemented a merchant model that places the customer at the center of operations, and we separated Kamux Worx, which focuses on utility vehicles, into its own business concept. Our new flagship showroom in Lakalaiva, Tampere, has been finalized in schedule and will have an official opening ceremony at the end of May. The development of sourcing activities continues, and we have opened the first new channels during the spring, focusing especially on international purchasing. In Sweden, after the change in management, we have focused on clarifying processes and roles and responsibilities. In addition, we made decisions regarding updates to our showroom network during the first quarter. During the summer, the showrooms in Sundsvall and Helsingborg will move to bigger premises that are a better fit to Kamux's concept, and the unprofitable Norrköping showroom was closed at the beginning of the second quarter. We will continue the strong development of the control environment in Sweden and strengthen our resourcing, e.g. for internal audit during the second quarter. In Germany, we have focused on changing the car offering to match our concept. The centralized processing of cars has progressed according to plans. We are further expanding our geographical coverage in Germany, and we will open a new showroom in Siershahn during the second quarter. We will also continue to upgrade the existing showrooms to match our concept, as well as to implement the measures aimed at improving productivity. The change in the car trade and the challenges in the sale of new cars have also been partially reflected in the competitive situation during the first quarter. As car manufacturers are tightening their grip on the vendor networks, several dealers focused on representing certain brands have re-evaluated their business models and either decided to invest in selling used cars or to leave the industry altogether. Kamux's omnichannel concept is working well even in this market situation. In Finland, we have strengthened our position as the market leader in used cars, and even though we have lost some of our market share in Sweden, at the European level we are still the third-largest operator focused solely on used cars. Once again, I would like to offer warm thanks to all Kamux employees for the good work during the first quarter of 2024. I would also like to thank all our customers and partners for their trust. We will continue to implement our strategy according to our plans." Outlook for the year 2024 (unchanged) Kamux expects its adjusted operating profit for 2024 to exceed its 2023 adjusted operating profit, which was EUR 18.0 million. Significant events after the reporting period On April 5, 2024, Kamux received a notification pursuant to Chapter 9, Section 5 of the Securities Markets Act (“SMA”), according to which the total holding of funds (Finnish Fund) managed by Danske Bank A/S (Copenhagen, Denmark) in Kamux Corporation shares and votes has decreased below five percent on April 4, 2024, and was 4.95% following the notification. On April 8, 2024, Kamux announced that Juha Saarinen, the Group’s Chief Sourcing Officer and a member of the Group Management Team, had decided to leave Kamux in order to pursue a career opportunity outside of Kamux. Saarinen will continue in his current position until July 8, 2024. On April 16, 2024, Kamux announced that it had completed the share repurchase program as announced on March 20, 2024. During March 21–April 16, 2024, Kamux repurchased in aggregate 135,000 of its own shares at public trading on Nasdaq Helsinki Ltd. for an average price per share of EUR 5.8361. The total purchase price paid for the shares was EUR 787,875.71. The share repurchases were based on the authorization given by the Annual General Meeting of 2023 for the Board of Directors, and the shares are intended to be used as part of the reward payments of the long-term incentive plan for the Group’s key persons for 2024–2026 and the Green Lions matching share plan for the Group’s key employees. Following the purchases, the Company held a total of 144,053 of its own shares, which represent approximately 0.36 percent of all shares. Kamux Corporation’s financial reporting in 2024 Publication schedule for Kamux Corporation’s financial reporting in 2024 is as follows: · Half-Year Report for January—June 2024                                  August 16, 2024 · Interim Report for January—September 2024                         November 8, 2024 News conference News conference for investors, analysts and media will be held today, Friday, May 17, 2024, at Sanomatalo, Flik Studio Eliel, 1st floor, Töölönlahdenkatu 2, Helsinki at 11:00 EEST in English. CEO Tapio Pajuharju and CFO Jukka Havia will present the Interim Report. The conference can be followed as a live webcast at https://kamux.videosync.fi/q1-2024 Participation by conference call: You can access the teleconference by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. If you wish to ask a question, please dial *5 on your telephone keypad to enter the queue. https://palvelu.flik.fi/teleconference/?id=50049835   For more information, please contact:CEO Tapio Pajuharju, tel. +358 50 577 4200CFO Jukka Havia, tel. +358 50 355 3757Head of Communications & IR Katariina Hietaranta, tel. +358 50 557 6765 Kamux CorporationCommunications Kamux is a retail chain specialized in preowned cars and related integrated services that has grown rapidly. Kamux combines online shopping with an extensive showroom network to provide its customers with a great service experience anytime, anywhere. In addition to digital channels, the company has a total of 77 car showrooms in Finland, Sweden and Germany. Since its founding in Hämeenlinna, Finland, in 2003 the company has sold over 500,000 used cars, 68,257 of which were sold in 2023. Kamux’s revenue in 2023 was EUR 1,002 million and its average number of employees was 885 in terms of full-time equivalent employees. Kamux Corporation is listed on Nasdaq Helsinki Ltd. For more information, please visit www.kamux.com 

Volvo Group and Daimler Truck intend to form a joint venture for a software-defined vehicle platform to amplify digital transformation

As two leading companies in the commercial vehicle industry, Volvo Group and Daimler Truck share the ambition to lead the digital transformation to software-defined heavy-duty commercial vehicles. To amplify their efforts, both companies have reached a preliminary agreement to establish a joint venture to develop a common software-defined vehicle platform and dedicated truck operating system, providing the basis for future software-defined commercial vehicles. The intention is to make the new joint venture a leading developer of standardized hardware and software. This technical basis will then enable Volvo Group and Daimler Truck and potentially other partners to provide differentiating digital vehicle features for its products ultimately enhancing customer efficiency and experience. Volvo Group and Daimler Truck intend to be 50/50 partners in the joint venture, which will operate as an independent entity, with Volvo Group and Daimler Truck continuing to be competitors in all other areas of business. In the context of the already heavy-investments into the transformation towards CO2-neutral drive technologies, cooperation on digital technology development has become even more vital to best meet development objectives and customer expectations within a feasible timeframe. Martin Lundstedt, Volvo Group President and CEO adds: “Volvo Group and Daimler Truck are two individually great companies. Now we are combining our forces to accelerate the customer benefits that a software-defined truck platform will bring. Given the rapid transformation of our industry, it makes sense to collaborate to accelerate development, increase volumes and share cost. Software-defined heavy-duty trucks represent a paradigm shift in the transformation of our industry. Making the truck a programmable device with standardized hardware and operating system for fast product updates will give both companies the opportunity to create value for our customers and their customers though differentiating digital services and solutions. Partnership is truly the new leadership.” Martin Daum, CEO of Daimler Truck comments: “Just as important as the transformation towards CO2-neutral drive technologies is the digitalization in the vehicle. Developing a common software-defined vehicle platform with Volvo Group will enable us to turn our vehicles into a programmable device. It will allow us to build differentiating digital vehicle features with significantly greater speed and efficiency for our truck and bus customers around the globe. Together with the Volvo Group we can develop a benchmark truck operating system and set an industry standard.”  The joint venture is set to be headquartered in Gothenburg, Sweden, incorporating existing assets and resources of both companies into the new organization. The goal of both shareholders is to set the industry standard for a truck operating system and offer its products to other OEMs as well. To that end the joint venture will provide a common developer platform as a service, on top of which its customers can build differentiating software layers. Volvo Group and Daimler Truck therefore will remain fierce competitors and continue to differentiate their complete product and services offerings, including their respective digital solutions. Both companies will provide their own end-user applications on top of the platform to offer differentiating digital vehicle features to their respective customers. The now signed preliminary agreement is non-binding. A final agreement is expected within this year, with the goal to close the final transaction in Q1 2025, subject to necessary examination and approvals by the respective authorities.       May 17[th], 2024       Contact Volvo Group:Claes Eliasson, Volvo Group, +46 76 553 72 29, press@volvo.com Contact Daimler Truck:Paul Mandaiker, +49,176 30999267, paul.mandaiker@daimlertruck.com    For more information, please visit volvogroup.com For frequent updates, follow us on X: @volvogroup  The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2023, net sales amounted to SEK 553 billion (EUR 48 billion). Volvo shares are listed on Nasdaq Stockholm.

Successful case studies with EndoDrill GI continue in Norway and Sweden

"The continued evaluation of EndoDrill[®] GI in Norway and Sweden has provided a consistent picture of a user-friendly biopsy instrument that safely obtains high quality core tissue biopsies. We notice that the interest in EndoDrill[®] GI is gradually increasing as we initiate evaluations at new hospitals and participate in congresses," says Dr. Charles Walther, CMO at BiBB. BiBB's team has recently been on site introducing EndoDrill[®] GI in Norway and Sweden. Dr. Khanh Do-Cong Pham at Haukeland University Hospital in Bergen became the first user to evaluate EndoDrill[®] GI in Norway. Dr. Pham himself writes about his impression of EndoDrill[®] GI on LinkedIn* and he has also posted a video, in which Dr. Pham describes that he managed to obtain a core biopsy of a recurrent gastric cancer to demonstrate deeper infiltration. He further explains that the instrument did not cause any bleeding and can be considered atraumatic (gentle). The evaluation in Bergen will now continue. During the week, several patient cases were performed at Örebro University Hospital. Dr. Robert Glavas, who previously participated in a pilot study with EndoDrill[®] GI, was well acquainted with the instrument. It was the first time BiBB used the new industrialized motor unit, which is significantly more compact than its predecessor. The cases were varied and challenging, involving pancreatic tumors, lymph nodes, and the gastric wall. Sampling with EndoDrill[®] GI provided a series of true core biopsies. The evaluation at Örebro University Hospital will now continue. * https://www.linkedin.com/feed/update/urn:li:activity:7195553432508764160/ About EndoDrill[®] GIEndoDrill[®] GI is the world's first market-cleared electric-driven biopsy instrument for endoscopic ultrasound (EUS). The instrument is used for EUS-guided tissue sampling for all indications in the gastrointestinal tract, e.g. pancreas, stomach, oesophagus, lymph nodes, and liver. EndoDrill[®] GI received FDA 510(k) clearance in the US in 2023 and CE approval in Europe in early 2024. The product is being evaluated clinically in the US and Scandinavia with a planned launch in Sweden later in 2024. This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails. For more information about BiBB, please contact:Fredrik Lindblad, CEOE-mail: fredrik.lindblad@bibbinstruments.comPhone: +46 70 899 94 86www.bibbinstruments.com About BiBB The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill[®], a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill[®] instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill[®] GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill[®] URO. Thus EndoDrill[®] is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill[®] system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.

CFO and Deputy CEO Seppo Parvi leaves Stora Enso during the fourth quarter of 2024

Stora Enso's Chief Financial Officer and Deputy CEO, Seppo Parvi, has decided to leave Stora Enso to assume a role with a company outside of the forest industry. He will leave Stora Enso during the fourth quarter of 2024.“Since joining in 2014, Seppo Parvi has, in his role as CFO and member of Stora Enso’s Group Leadership Team, been integral in transforming Stora Enso to ‘The renewable materials company’. He has also played an important role as Stora Enso’s Country Manager Finland, and in developing the forest industry more broadly. On behalf of Stora Enso, I want to express our sincere gratitude for Seppo’s significant contributions to Stora Enso and wish him the very best in his future endeavours,” says Hans Sohlström, President and CEO of Stora Enso.Stora Enso will immediately begin the search for Seppo Parvi’s successor.Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors   STORA ENSO OYJ

K-Prefab has signed an agreement for a complete framework contract at Årstaberg in Stockholm

K-Prefab AB, a subsidiary of K-Fast Holding AB (“K-Fastigheter”), has signed an agreement with Noccon AB regarding a full service concrete frame for the construction of new apartments, commercial premises and parking garage in Årstaberg in Stockholm municipality. Noccon’s end customer is Wallenstam AB. K-Prefab is to carry out a complete contract (ABT-U) with K-Prefabs concrete frame system in full including casted and painted facades. In total, the Årstaberg project in Stockholm comprises around 400 apartments, commercial premises, and a parking garage with two levels. The project will be certified with Miljöbyggnad Silver version 4.0. ”This is K-Prefabs largest single order in history and I am both happy and proud that we have been selected to deliver a complete frame solution for a project of this size. It is another testament of our strong product and our competitiveness as a frame contractor” says Stefan Paulsson, CEO of K-Prefab. Production of the prefabricated concrete elements and construction will be carried out in phases, with construction of the first main phase starting in Q1 2025. The order value amounts to about SEK 200 million. For more information, please contact:Stefan Paulsson, CEO of K-Prefabe-post: stefan.paulsson@k-prefab.se, telephone: +46 10-161 83 49Johan Hammarqvist, Head of Investor Relations and Communicationse-mail: johan.hammarqvist@k-fastigheter.se, telephone: +46 10 167 60 99 K-Fastigheter is much more than a property company. Through an integrated process, we build our business in the two business segments Construction and Property Management. In business segment Construction the objective is to deliver completed housing units based on the Group’s concept houses, developed in-house, as well as high-quality frame solutions. Our prefab operations is organized in the subsidiary K-Prefab. To enhance cost efficiency and cut construction times, K-Fastigheter has chosen to work with three concept houses for housing, developed in-house. Business segment Property Management manages the Groups property portfolio with focus on housing. K-Fastigheter offers more than 5,000 homes from Copenhagen in the south to Gävle in the north and is continuously assessing new markets. K-Fastigheter strive to create attractive homes with a high comfort factor. The Group’s property portfolio has a book value SEK 15,3 billion. Annual rental value in invest properties under management amounts to SEK 686 million. Since November 2019, the company’s Class B shares have been traded on Nasdaq Stockholm (under the ticker: KFAST B). Read more at k-fastigheter.com

Notice to the Extraordinary General Meeting of Eevia Health Abp

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 5 June 2024 at 12:00 (Finnish time GMT +3) at the main office of Eevia Health Abp in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 11:00. A. Matters on the agenda of the Extraordinary General Meeting At the Extraordinary General Meeting, the following matters will be handled: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise the counting of votes 4. Recording legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Authorizing the Board of Directors to decide on issuance of shares, options, and other special rights The Board of Directors proposes that the Extraordinary General Meeting resolves to authorize the Board of Directors to decide, in one or more transactions, on the issuance of shares and the issuance of options and other special rights entitling to shares referred to in Chapter 10 Section 1 of the Companies Act as follows: The number of shares to be issued based on the authorization may in total amount to a maximum of 70,000,000 shares. The Board of Directors decides on all other terms and conditions of the issuances of shares and of options and other special rights entitling to shares. The issuance of shares and of options and other special rights entitling to shares may be carried out in deviation from the shareholders’ pre-emptive rights (directed issue), if there is a weighty financial reason for the company. The authorization is valid until 30 June 2025. 7. Closing of the meeting B. Documents of the General Meeting This notice including all the proposals relating to the agenda of the General Meeting is available on Eevia Health Abp’s website at www.eeviahealth.com. The documents mentioned above are also available at the meeting. Minutes of the General Meeting are available on the above-mentioned website. C. Instructions for the participants 1. Shareholder registered in the shareholders’ register Each shareholder who is registered on 27 May 2024 in the shareholders’ register of the company held by Euroclear Finland Ltd., has the right to participate in the General Meeting. A shareholder, whose shares are registered on his/her/its personal Finnish book-entry account, is registered in the shareholders’ register of the company. A shareholder, who wants to participate in the General Meeting, shall register for the meeting no later than 31 May 2024 at 16:00 (Finnish time), by which time the registration shall be received. The registration may take place: a)      by e-mail to address info@eeviahealth.com; b)      by mail to Eevia Health Abp, General Meeting, Koulukatu 14, 60100 Seinäjoki, Finland. Requested information shall be given in connection with the registration such as name, personal identification number, address, email address and the name of a possible assistant or proxy representative, and the personal identification number of a proxy representative. The personal data given to Eevia Health Abp is used only in connection with the General Meeting and the processing of related necessary registrations and for shareholder communication. Shareholder, his/her/its representative or proxy representative shall, when necessary, be able to prove his/her/its identity and/or right of representation. 2. Holder of nominee-registered shares A holder of nominee-registered shares has the right to participate in the General Meeting by virtue of shares based on which he/she/it on the record date of the meeting, i.e. on 27 May 2024, would be entitled to be registered in the shareholders’ register of the company held by Euroclear Finland Ltd. The right to participate in the General Meeting requires, in addition, that the shareholder has on the basis of such shares been registered into the temporary shareholders’ register of the company held by Euroclear Finland Ltd. at the latest on 30 May 2024 by 10:00 (Finnish time). As regards nominee-registered shares this constitutes a due registration for the General Meeting. A holder of nominee-registered shares is advised without delay to request necessary instructions regarding the registration in the temporary shareholder’s register of the company, the issuing of proxy documents and registration for the General Meeting from his/her/its custodian bank. The account management organization of the custodian bank must register a holder of nominee-registered shares, who wants to participate in the General Meeting, into the temporary shareholders’ register of the company at the latest on the date and time mentioned above. 3. Shares registered at Euroclear Sweden AB Shareholder whose shares are registered in the securities system of Euroclear Sweden AB and who wants to participate in the General Meeting and use his/her/its voting right, shall be registered at the shareholder’s register held by Euroclear Sweden AB on 28 May 2024 at the latest. To be entitled to request for temporary registration in the shareholder’s register of Eevia Health Abp held by Euroclear Finland Ltd., a shareholder of nominee-registered shares shall request that his/her/its shares are temporarily registered under his/her/its own name in the shareholder’s register held by Euroclear Sweden AB and to ensure that the custodian bank will send the above-mentioned request for temporary registration to Euroclear Sweden AB. The registration shall be made on 3 June 2024 at the latest, and therefore a shareholder shall give the request to his/her/its custodian bank in good time prior to the above date. Shareholder, whose shares are registered in the securities system of Euroclear Sweden AB and who intends to participate in the General Meeting and use his/her/its voting right, shall request for a temporary registration of his/her shares to the shareholder’s register of Eevia Health Abp held by Euroclear Finland Ltd. The request to Eevia Health Abp shall be made in written at the latest on 3 June 2024 at 10:00 (Swedish time). The temporary registration through Eevia Health Abp constitutes a due registration to the General Meeting. 4. Proxy representative and powers of attorney A shareholder may participate in the General Meeting and exercise his/her/its rights at the meeting by way of proxy representation. A proxy representative shall produce a dated proxy document or otherwise provide reliable evidence of the right to represent the shareholder. The authorization applies to one meeting, unless otherwise stated. When a shareholder participates in the General Meeting by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the General Meeting. Possible proxy documents should be delivered via email to info@eeviahealth.com or by mail to Eevia Health Abp, General Meeting, Koulukatu 14, 60100 Seinäjoki, Finland before the end of the registration period. 5. Other instructions and information Pursuant to Chapter 5 Section 25 of the Finnish Companies Act, a shareholder who is present at the General Meeting has the right to request information with respect to the matters to be handled at the meeting. On the date of the notice to the General Meeting, 17 May 2024, the total number of shares in Eevia Health Abp is 35,713,884. Each share carries one vote at General Meeting. In Seinäjoki, 17 May 2024 EEVIA HEALTH ABP Board of Directors For more information: Stein Ulve, CEO, Eevia Health Abp Email: stein.ulve@eeviahealth.com Telephone: +358 400 22 5967 About Eevia Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas. Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.

Telia Company announces upcoming change to the Group Executive Management team

Telia Company today announces that Dr. Rainer Deutschmann, Senior Vice President, Group Chief Operating Officer, will leave his position on May 31, 2024, to pursue opportunities outside the company. Rainer has been a member of the Group Executive Management team since September 2020. In this capacity, he was responsible for the company’s common Products, Networks, IT and Services, as well as responsible for driving the company’s digital transformation to become more agile with simplified operations, focused on growth, and with improved customer experience. Patrik Hofbauer, Telia Company President and CEO, says: “Rainer has been vital in driving Telia’s digital transformation over the last four years. This work has simplified and reduced the company’s legacy products and platforms, standardized, scaled and modernized our network and IT assets, and returned the business to growth. As Rainer is now leaving Telia, I wish him all the best in his future endeavors.” As of June 1, 2024, Hein Müskens, Group Chief Information Officer since March 1, 2023, will, in addition to his current role, temporarily take on the position as acting Group Chief Operating Officer until a permanent replacement is announced. NOTES TO EDITORS For more information, contact Telia Company’s press office on +46 (0)771 77 58 30 , visit our newsroom  and follow us on LinkedIn  and X . To download our logo, high-resolution images of Telia leaders, offices and solutions or B-roll footage for editorial use, visit our media bank . ABOUT TELIA Telia Company (STO: TELIA) is a Nordic and Baltic telecommunications leader and Nordic media house, serving consumers, businesses and public sector customers with essential digital infrastructure, ICT services and entertainment. Our 18,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. We’re the hub in the digital ecosystem, providing 25 million mobile, broadband and TV subscriptions that empower people, companies and societies to stay in touch with everything that matters 24/7/365. Learn more at www.teliacompany.com

CS MEDICA A/S announces financial results for the first half of the financial year 2023/24

PERFORMANCE HIGHLIGHTS Following growth in Q1, we see continued development in Q2 2023/2024, delivering 76,000 units to new and existing customers. All sales were within the EU, with a new market launch in Switzerland, strengthening our presence in the DACH region. With existing customers built over the last two years, recurring sales were driven by Italy, Spain, Sweden, Germany, and Slovenia. Sales exceeded targets by 18%, reaching mDKK 2.45, marking our best result in five quarters. Notably, 82% of sales were recurring, demonstrating our improved market position through our partners and their sales channels. Own-label products accounted for 86% of sales, improving cash flow and volume. Order intake is mainly from the EU, MENA, and APAC regions. Own-label products cover 11% of the order intake, with the majority for the CANNASEN® brand. Reducing Delays in Revenue BreakthroughWe continue to face delays due to limited financial capacity, a challenge expected to persist into 2nd half of 2023/2024. Our supply chain needs further optimization, and we are streamlining our primary and secondary packaging to improve efficiency and control extended lead times. Enhancing our financial capacity is critical to reducing these delays and speeding up deliveries in the upcoming quarters. Financial highlights for Q2 2023/2024 (October 2023 – March 2024) · In the second quarter of 2023/2024 (January– March 2024), CS MEDICA sustained its growth trajectory and exceeded the Net Sales targets by 18%, reaching a net sales of mDKK 2.45 (251). This accumulated to a revenue of mDKK 4.13 in the first half of 2023/2024 (Oct-Mar), and an order intake backlog of mDKK 10.6 in the first half year. · Operating loss in the second quarter was reduced by 47%, from mDKK 4.23 last year to mDKK 2.23 current quarter, surpassing the cumulative reduction of 30% for the first half of 2023/2024. This quarterly enhancement stems not only from increased net sales but also from a significant reduction in administration costs by 77% to mDKK 0.49 together with a 59% reduction in sales and distribution expenses. · Credit bank/Cash and Cash equivalents at the end of the Q2 quarter closed at mDKK -2.04 (30), which subsequently has been reduced to mDKK 1,2 in alignment with the credit line at Danske Bank. To bolster CS MEDICA’s liquidity, the focus remains on upfront payments, short-term sales, and the factoring agreement with Svea. Simultaneously, we continue to explore various options for funding transfer in collaboration with our investor, RongShi. However, due to delays and our current going concern, we no longer solely depend on this funding. We now view the funding from RongShi as having long-term potential, hence, we intensely investigate alternative funding solutions to ensure financial stability. · At the end of the Q2 period, CS MEDICA’s equity/asset ratio was 15% (70%). Live streamed conference following the H1 2023/2024 ReportOn Thursday 23 May 2023 at 15:00 CET, CS MEDICA will host a H1 2023/2024 web conference. The web conference will start with a presentation from the management team commenting on the H1 2023/2024 report, followed by a Q&A session where the management team will answer questions from investors. The Q&A is already open, meaning that you can now submit your questions and vote for the best questions submitted by other investors. You will afterward be able to find all answers in the uploaded recording and transcript. The web conference will be held in English. Please register, submit questions now or during the live presentation and vote for the best questions at the following link >> . Date and timeThursday 25[th] of May, 2024, from 15:00 – 15:30 PM CET Sign up for conferenceLive conference sign-up link >>.  

Terclara is the market leader in Sweden

One and a half months after starting consumer marketing, Terclara[®] has reached a market leading position, both in value and units, with a 36% market share in value and 31% market share in units in April. Additionally, the introduction of Terclara[®] has led to a 52% growth in the total market compared to the same period last year.[1]  Terclara[®] has been available on Swedish pharmacy shelves since February this year. In parallel with the pharmacies filling up the shelves, work was ongoing in February and March to inform physicians and pharmacists about the unique benefits of Terclara[®]. Subsequently, the focus shifted to the end consumer, including digital marketing from mid-March and TV advertising starting April 1. Significant emphasis has also been placed on positioning and marketing in pharmacies. "I am very pleased with the launch together with our partner Allderma. Terclara[®] is now available for those who want to begin the journey towards attractive, fungus-free nails before sandal season and summer vacation. It is an achievement to quickly reach a market-leading position, and the team in Allderma once again demonstrates that they are an excellent partner in our home market." says Anna Ljung, CEO of Moberg Pharma. Allderma is led by the key individuals responsible for the launch of Moberg Pharma's first generation nail fungus product, Nalox[®], in the Nordic region. For additional information, please contact:Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se About this informationThe information was submitted for publication, through the agency of the contact person set out above, on May 20[th], 2024, at 8.00 am CEST. About MOB-015 and OnychomycosisApproximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015 to be in the range of USD 250-500 million. MOB-015 is an in-house developed topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage. MOB-015 has been granted marketing authorization in 13 countries and is launched during spring 2024 in Sweden under the brand name Terclara[®.] The approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions. About Moberg Pharma, www.mobergpharma.comMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries. MOB-015 is available in Sweden under the brand name Terclara[®]. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB). [1] Source: IQVIA MIDAS, Pharmacy Sell-Out data, April 2024

Crunchfish signs gesture agreement with OPPO

[A person with a beard and a hat Description automatically generated] OPPO signed an agreement in November 2022 at a value of US$500,000 for the use of Crunchfish’s gesture control software for pose detection in their devices. This new agreement marks the completion of this Crunchfish product, which has been installed and shipped with millions of mobile devices by Oppo. “I am happy to wrap up the current collaboration with Oppo and the use of our pose detection software in their mobile devices in a positive way on favorable terms. We welcome new opportunities to work with Oppo again within our focus area, XR technology, in the future.”, says Patrik Lindeberg, COO at Crunchfish AB. For more information, please contact:Joachim Samuelsson, CEO of Crunchfish AB+46 708 46 47 88joachim.samuelsson@crunchfish.com This information is such information as Crunchfish AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:30CET on May 20th, 2024. Västra Hamnen Corporate Finance AB is the Certified Adviser. Email: ca@vhcorp.se. Telephone +46 40 200250. About Crunchfish – crunchfish.com  Crunchfish is a deep tech company developing a device-agnostic generic trusted client application platform for offline payments, tokenized card payments as well as other mobile client / server systems. Crunchfish has been listed on Nasdaq First North Growth Market since 2016, with headquarters in Malmö, Sweden and with a subsidiary in India.

Inside information: Alan Donze has been appointed as Bioretec's new CEO

Bioretec Ltd is pleased to announce that Mr. Alan Donze has been appointed CEO of Bioretec as of today, 20 May 2024. He will start in this position immediately. With a distinguished career spanning the banking and medical device industries, Mr. Donze brings a wealth of experience and expertise to the Bioretec organization. Mr. Donze began his career journey in the banking industry, serving as the Vice President of Commercial Lending and Leveraged Finance for a regional predecessor to Chase bank. He left banking to begin his medical device career as a Regional Sales Representative for Stryker Endoscopy in 1991. Over his 13 years at Stryker, Mr. Donze’s responsibilities increased to various senior management positions, including Vice President General Manager of Stryker Endoscopic Service and Vice President General Manager of Stryker Communications, a division he was given the tremendous opportunity to create and build from the ground up. Mr. Donze has also held senior leadership positions for a number of other medical device and technology companies including Smith+Nephew, Bioventus, and Lima Corporate and venture-led startups such as Isotis Orthobiologics, Aerobiotix and Rx.Health. Mr. Donze received his Bachelor of Science in Finance from Louisiana State University. "We are excited to announce the appointment of Alan Donze as our new Chief Executive Officer. With his proven track record of leadership and vision, we are confident that Alan will lead our company to new heights of commercial success. Alan brings with him 30 years of sales and marketing leadership experience in medical devices, where he has demonstrated a deep understanding of market dynamics and a relentless drive for excellence. His strategic insights and passion for Bioretec's mission make him the ideal leader to guide us into the future," says Tomi Numminen, Bioretec's Chairman of the Board. "I am honored to be given the opportunity to lead Bioretec to the next level and deeply appreciate the confidence placed in me by the Board of Directors. Bioretec’s groundbreaking work in developing alternatives to traditional metal implants represents a significant advancement in the medical field. Our products have the potential to reduce the need for invasive surgeries and improve patient outcomes, aligning with a critical need within the healthcare community.I am eager to contribute to Bioretec’s mission by expanding our efforts to introduce these transformative solutions to the benefit of many more patients. I look forward to the journey ahead and to our continued growth and success,” says Alan Donze. Timo Lehtonen, Bioretec's CEO since 2019, will transfer to the position of Chief Technology Officer (CTO) and continue to lead the development of Bioretec’s future product pipeline. "It has been a privilege to lead Bioretec since 2019 and support its remarkable growth through interesting, challenging times. I am excited to focus my efforts on advancing the RemeOs™product pipeline. Together with Alan, I am confident we will continue to strengthen our growth and transform bone fracture care. In my forthcoming role as CTO, I will leverage my extensive experience in innovation, product development, and regulatory expertise to support the management team and our skilled personnel. Our goal is to achieve the best possible outcomes in redefining bone fracture treatment and improving patients' quality of life," says Timo Lehtonen. "I would like to thank Timo Lehtonen for his passionate and dedicated leadership as our CEO over the past five years. Under his guidance, Bioretec has grown strongly and strengthened its position as a leading innovator in biodegradable technologies. With its biodegradable metal implants, the company has significantly modernized the surgical treatment of bone fractures, which significantly increases the quality of the lives of the patients. Our mutual and succesful path with Timo continues while he assumes the role of CTO in which role he continues to provide important support for the future development of our product pipeline," says Chairman of the Board Tomi Numminen. Further enquiries Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132 Certified advisor Nordic Certified Adviser AB, +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.  Bioretec isdevelopingthe new RemeOs™product linebased on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing onvalue for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE-mark is expected to be received during the second quarter of 2024. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical bone fracture treatment. Better healing – Better life. www.bioretec.com

Repurchases of shares by EQT AB during week 20, 2024

The repurchases form part of the repurchase program of a maximum of 2,154,000 own ordinary shares for a total maximum amount of SEK 1,000,000,000 that EQT announced on 22 April 2024. The repurchase program, which runs between 23 April 2024 and 24 May 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052. EQT ordinary shares have been repurchased as follows: Date: Aggregated daily Weighted average Total daily volume (number of share price per day transaction value shares): (SEK): (SEK):13 May 2024 93,897 325.5542 30,568,562.7214 May 2024 85,726 334.5773 28,681,973.6215 May 2024 101,127 340.4761 34,431,326.5716 May 2024 108,624 347.3181 37,727,081.2917 May 2024 115,054 340.6818 39,196,803.82Total 504,428 338.2163 170,605,748.01accumulatedoverweek20/2024Total 1,589,234 314.0822 499,150,095.37accumulatedduring therepurchaseprogram All acquisitions have been carried out on Nasdaq Stockholm by Skandinaviska Enskilda Banken AB on behalf of EQT. Following the above acquisitions and as of 17 May 2024, the number of shares in EQT, including EQT’s holding of own shares is set out in the table below. [][] Ordinary shares Class C shares[1] TotalNumber of issued 1,245,048,412 881,555 1,245,929,967sharesNumber of shares 62,064,063 - 62,064,063owned by EQTAB[2]Number of 1,182,984,349 881,555 1,183,865,904outstandingshares 1) Carry one tenth (1/10) of a vote.2) EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders’ meetings. A full breakdown of the transactions is attached to this announcement. ContactOlof Svensson, Head of Shareholder Relations, +46 72 989 09 15 EQT Press Office, press@eqtpartners.com, +46 8 506 55 334